In Vivo Near-Infrared Fluorescence Imaging: Advanced Protocols for Biomedical Research and Drug Development

Abstract

This article provides a comprehensive guide to in vivo near-infrared (NIR) fluorescence imaging, a powerful non-invasive technique for real-time visualization of biological processes. Tailored for researchers and drug development professionals, it covers foundational principles, from the advantages of the NIR optical windows (NIR-I to NIR-III) that minimize autofluorescence and enhance tissue penetration, to the latest high-contrast probes like those operating in the 1880-2080 nm range. Detailed methodological protocols for applications in oncology, neurology, and sentinel lymph node mapping are presented, alongside essential troubleshooting for optimizing signal-to-background ratio and minimizing phototoxicity. The guide concludes with rigorous validation frameworks and comparative analyses with other imaging modalities, offering a complete resource for advancing preclinical research and accelerating clinical translation.

Principles and Probes: Mastering the Fundamentals of NIR Light and Contrast Agents

The efficacy of in vivo near-infrared (NIR) fluorescence imaging is fundamentally governed by how light interacts with biological tissues. These interactions—primarily absorption, scattering, and autofluorescence—collectively determine the signal-to-background ratio (SBR), penetration depth, and spatial resolution achievable in preclinical and clinical imaging. NIR fluorescence imaging leverages the unique optical transparency window of biological tissues in the 700-1700 nm spectrum, where the combined effects of absorption and scattering are minimized compared to visible wavelengths [1]. Understanding these phenomena is crucial for optimizing imaging protocols, selecting appropriate fluorophores, and interpreting experimental data accurately in drug development research.

The migration from conventional NIR-I imaging (700-900 nm) toward emerging NIR-II techniques (1000-1700 nm) represents a paradigm shift in fluorescence-guided procedures, driven by superior performance characteristics in longer wavelength windows. This transition is underpinned by fundamental principles of light-tissue interactions: photon scattering decreases significantly at longer wavelengths, following a λ⁻⁴ relationship in some tissues, while tissue autofluorescence diminishes substantially in the NIR-II region [2] [3]. Even within the NIR spectrum, different sub-windows (NIR-Ia, NIR-Ib, NIR-II) present distinct advantages and limitations based on the interplay between absorption from biological chromophores like hemoglobin and water, and scattering from cellular and extracellular structures [4]. This application note provides a comprehensive framework for researchers to understand, quantify, and leverage these principles in developing robust NIR fluorescence imaging protocols.

Fundamental Principles of Light-Tissue Interactions

Absorption by Tissue Components

The absorption of light in biological tissues is dominated by specific chromophores with distinct spectral characteristics. In the NIR window, the primary absorbers include hemoglobin (in both oxygenated and deoxygenated forms), water, and lipids [1]. In typical non-pigmented tissues with an 8% blood volume and 29% lipid content, hemoglobin accounts for 39-64% of total absorbance across NIR wavelengths, establishing it as the dominant absorber [1]. Water, while relatively transparent in the standard NIR-I window, exhibits significantly increased absorption in the NIR-Ib (900-1000 nm) and NIR-II regions, with a prominent peak centered at 970 nm [4] [5]. This absorption profile directly influences the selection of optimal imaging wavelengths for specific applications and tissue types.

The strategic selection of NIR imaging windows is fundamentally guided by minimizing combined absorption from all tissue components. The conventional NIR-I window (700-900 nm) benefits from relatively low hemoglobin and water absorption, while the emerging NIR-II window (1000-1700 nm) leverages significantly reduced scattering despite increased water absorption at longer wavelengths [3] [5]. Research has demonstrated that despite theoretical concerns about water absorption, the NIR-Ib window (900-1000 nm) can provide superior image contrast for certain applications due to an optimal balance between reduced scattering and manageable water absorption [4]. This counterintuitive finding highlights the importance of considering absorption in concert with other optical phenomena rather than in isolation.

Scattering Phenomena

Scattering represents the deviation of photons from their original trajectory due to interactions with tissue microstructures and inhomogeneities. The magnitude and angular dependence of scattering are quantitatively described by the scattering coefficient (μₛ) and anisotropy factor (g), respectively [1]. Scattering in tissues can arise from both Rayleigh scattering (when tissue inhomogeneity is small relative to wavelength) and Mie scattering (when inhomogeneity is roughly equal to wavelength). Empirical measurements reveal strong tissue-dependent wavelength relationships, with the reduced scattering coefficient proportional to λ⁻².⁴ in rat skin (suggesting Rayleigh dominance) but only proportional to λ⁻⁰.⁶ in post-menopausal human breast (suggesting Mie dominance) [1].

The significant reduction in scattering at longer wavelengths represents a primary motivation for NIR-II imaging. Since scattering is proportional to λ⁻⁴ in many tissues, moving from 800 nm (NIR-I) to 1300 nm (NIR-II) theoretically reduces scattering by approximately 85% [2]. This reduction directly translates to enhanced spatial resolution and improved penetration depth,

as fewer photons are diverted from their original path. For example, while NIR-I light typically penetrates 2-3 mm in skin, NIR-II imaging can achieve penetration depths of 5-10 mm or more, enabling visualization of deeper structures [2] [3]. The decreased scattering in longer wavelength windows also minimizes the "blooming effect" around bright sources, allowing for more precise delineation of fine anatomical features like capillary networks and tumor margins [3].

Autofluorescence Background

Tissue autofluorescence refers to the inherent fluorescence emission from endogenous biomolecules when excited by light, creating a background signal that can obscure specific contrast agent fluorescence. In visible light imaging (400-700 nm), autofluorescence from compounds like collagen, elastin, flavins, and porphyrins generates substantial background, severely limiting achievable SBR [1]. This phenomenon is readily observable in comparative imaging studies, where "green" autofluorescence of skin and viscera—particularly the gallbladder, small intestine, and bladder—appears "astoundingly high" when excited with blue light [1].

The transition to NIR excitation and emission dramatically reduces autofluorescence interference, representing a key advantage of NIR fluorescence imaging. As demonstrated in Figure 1, while green light excitation produces significant gallbladder and intestinal autofluorescence, and red light excitation reduces but does not eliminate this background, NIR excitation essentially eliminates autofluorescence [1]. This reduction occurs because few endogenous biomolecules possess electronic transitions corresponding to NIR excitation and emission. The autofluorescence advantage extends further into the NIR-II window, where background signals become negligible, contributing to the significantly enhanced SBR observed in NIR-II compared to NIR-I imaging [2] [3]. For researchers designing imaging studies, this autofluorescence reduction translates directly to improved detection sensitivity and more accurate quantification.

Diagram 1: Fundamental light-tissue interactions in fluorescence imaging and optimization through NIR window selection.

Quantitative Comparison of NIR Imaging Windows

Performance Metrics Across Wavelengths

The evolution of NIR fluorescence imaging has identified distinct spectral windows with unique performance characteristics. While conventional NIR-I imaging (700-900 nm) remains widely utilized, emerging research demonstrates significant advantages in longer wavelength windows, particularly NIR-Ib (900-1000 nm) and NIR-II (1000-1700 nm). Systematic comparisons of these windows reveal differential impacts of absorption, scattering, and autofluorescence on key imaging metrics [4] [2]. These performance differences inform optimal window selection for specific applications in biomedical research and drug development.

Table 1: Quantitative Performance Comparison of NIR Imaging Windows

Imaging Parameter	NIR-I (700-900 nm)	NIR-Ib (900-1000 nm)	NIR-II (1000-1700 nm)
Tissue Penetration Depth	2-3 mm [2]	3-5 mm [4]	5-10+ mm [2] [3]
Spatial Resolution	Limited by scattering	Improved [4]	High (∼μm) [3]
Signal-to-Background Ratio	Moderate	Enhanced [4]	Significantly enhanced [2] [3]
Tissue Autofluorescence	Low	Very low [4]	Negligible [2] [3]
Water Absorption	Low	Moderate (peak at 970 nm) [4]	Increasing with wavelength [5]
Photon Scattering	Significant	Reduced [4]	Minimal (λ⁻⁴ relationship) [2]

Experimental Evidence for Window Selection

Comparative studies provide compelling evidence for window-specific advantages. In one systematic investigation, heptamethine dyes with emissions in both NIR-Ia and NIR-Ib windows were evaluated across multiple models. Surprisingly, NIR-Ib imaging yielded superior results for leaf venation visualization, anthracnose infection detection, sentinel lymph node mapping, and tumor delineation despite theoretical concerns about water absorption [4]. The enhanced performance was attributed to markedly reduced autofluorescence, scattering, and light absorption by biological tissues at longer wavelengths, which collectively outweighed the impact of water absorption [4].

In clinical sample evaluations, the comparative advantage appears context-dependent. A 2024 study comparing NIR and shortwave-infrared (SWIR) imaging of clinical tumor samples from penile squamous cell carcinoma (PSCC) and head and neck squamous cell carcinoma (HNSCC) found that SWIR performance varied by tissue type [2]. While SWIR (NIR-II) imaging performed similarly to NIR in PSCC samples, it underperformed in HNSCC due to background fluorescence overwhelming the off-peak SWIR fluorescence signal [2]. This finding highlights that theoretical advantages of longer wavelengths may be modulated by tissue-specific characteristics, including disease pathology and endogenous fluorophore content. For drug development researchers, these results emphasize the importance of validating window selection in disease-relevant models.

Experimental Protocols for Characterizing Light-Tissue Interactions

Protocol 1: Quantitative Assessment of Fluorophore Performance Across NIR Windows

Purpose: To systematically evaluate and compare the performance of NIR fluorophores across different imaging windows (NIR-I, NIR-Ib, NIR-II) through characterization of optical properties and in vivo imaging performance.

Materials and Reagents:

• NIR fluorophores (e.g., heptamethine dyes: IR-775, IR-780, IR-783, IR-797, IR-806, IR-808) [4]
• Reference fluorophore with known quantum yield (e.g., IR-26 dye, QY=0.5%) [4]
• UV/vis spectrophotometer (e.g., PerkinElmer Lambda 25) [4]
• Fluorescence spectrometer with extended NIR detection (e.g., Edinburgh F920 with R928P and G8605-23 photodetectors) [4]
• NIR-I imaging system (silicon CCD camera, 350-900 nm detection range) [4]
• NIR-Ib/NIR-II imaging system (InGaAs camera, 900-1700 nm detection range) [4]
• Animal or plant models for in vivo validation [4]

Procedure:

• Spectroscopic Characterization:
  • Prepare fluorophore solutions in appropriate solvents at concentrations yielding optical densities between 0.1-1.0 at λmax.
  • Record absorption spectra from 400-1300 nm using UV/vis spectrophotometer.
  • Measure fluorescence emission spectra using fluorescence spectrometer with appropriate excitation wavelengths and detector configurations for each NIR window.
  • Determine fluorescence quantum yield (Φ) using reference fluorophore method according to: Φx(λ) = Φst(λ) × (Fx/Fst) × [(1-10⁻ODst(λ))/(1-10⁻ODx(λ))] [4].

• In Vitro Tissue Phantom Studies:

  • Prepare tissue homogenates (5% w/v in buffer) from relevant tissues (e.g., liver, muscle, tumor) [4].
  • Embed fluorophore-containing cuvettes within tissue homogenates to simulate in vivo conditions.
  • Acquire fluorescence spectra in both NIR-I and NIR-II windows using appropriate detection systems.
  • Perform spectral unmixing to distinguish specific fluorescence from background signals [4].

• In Vivo Performance Evaluation:

  • Administer fluorophores to animal models via appropriate routes (e.g., intravenous injection for systemic distribution, topical application for surface imaging).
  • Acquire sequential images in NIR-I and NIR-II windows using respective imaging systems.
  • Quantify signal-to-background ratios (SBR) for specific anatomical features (e.g., vasculature, tumors, lymph nodes) in each window.
  • Compare spatial resolution by measuring line profiles across sharp anatomical boundaries.

• Data Analysis:

  • Calculate and compare performance metrics (SBR, resolution, penetration depth) across imaging windows.
  • Perform statistical analysis to determine significant differences (typically p<0.05, n≥3).
  • Correlate in vivo performance with spectroscopic properties to establish structure-activity relationships.

Diagram 2: Experimental workflow for comprehensive characterization of NIR fluorophores across imaging windows.

Protocol 2: Quantification of Tissue Optical Properties for Imaging Optimization

Purpose: To systematically measure tissue-specific absorption, scattering, and autofluorescence properties to inform optimal imaging window selection and protocol design.

Materials and Reagents:

• Fresh tissue samples of interest (normal and pathological if applicable)
• Tissue homogenization equipment (e.g., Dounce homogenizer, surgical scissors)
• UV/vis/NIR spectrophotometer with integrating sphere attachment
• Fluorescence spectrometer with NIR capability
• NIR fluorophores relevant to intended applications (e.g., ICG, IRDye800CW)
• Buffer solutions (e.g., Tris-HCl, sucrose, pH 7.4) [4]

Procedure:

• Sample Preparation:
  • Collect fresh tissue samples and immediately place in ice-cold buffer.
  • Remove excess blood and connective tissue if necessary.
  • Prepare tissue homogenates (5-10% w/v in appropriate buffer) using mechanical homogenization [4].
  • For intact tissue measurements, prepare thin sections (100-500 μm) using vibratome or cryostat.

• Absorption Spectroscopy:

  • Measure absorption spectra of tissue homogenates from 400-1300 nm using spectrophotometer.
  • For intact tissue sections, use integrating sphere attachment to capture both absorption and reduced scattering coefficients.
  • Identify wavelength-specific absorption peaks attributable to hemoglobin (∼540 nm, ∼575 nm, ∼760 nm), water (∼970 nm, ∼1200 nm), and lipids (∼930 nm, ∼1040 nm).

• Scattering Characterization:

  • Calculate reduced scattering coefficient (μs') using integrating sphere measurements and inverse adding-doubling algorithm.
  • Determine wavelength dependence of scattering by fitting μs' = a × λ⁻ᵇ, where b represents scattering power.
  • Classify tissues as primarily Rayleigh (b > 2) or Mie (b < 1.5) scatterers based on fitted parameters [1].

• Autofluorescence Assessment:

  • Measure autofluorescence emission spectra of tissues using excitation wavelengths across UV, visible, and NIR ranges.
  • Quantify autofluorescence intensity relative to proposed fluorophore signals at intended imaging concentrations.
  • Calculate theoretical SBR based on measured autofluorescence and fluorophore brightness.

• Data Integration and Imaging Parameter Optimization:

  • Compile wavelength-dependent absorption, scattering, and autofluorescence data.
  • Identify optimal imaging windows by maximizing μs'/(μa + μs' + autofluorescence) ratio.
  • Validate predictions with phantom studies using tissue-simulating materials.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 2: Key Research Reagents and Materials for NIR Fluorescence Imaging Studies

Category	Specific Examples	Function/Application	Key Characteristics
NIR-I Fluorophores	ICG (Indocyanine Green) [6] [1]	Clinical perfusion imaging, lymphatic mapping	FDA-approved, 805/830 nm excitation/emission, di-sulfonated
	IRDye800CW [2]	Targeted molecular imaging	Tetra-sulfonated, 774/789 nm excitation/emission, conjugatable
NIR-Ib Fluorophores	Heptamethine dyes (IR-808, IR-806, IR-780) [4]	Multispectral imaging, NIR-Ib exploration	700-900 nm absorption, 900-1000 nm emission, tumor-targeting properties
NIR-II Fluorophores	Organic fluorophores (D-A conjugated molecules) [7]	Deep-tissue imaging, high-resolution vasculature	1000-1700 nm emission, tunable properties, high biocompatibility
	Carbon nanotubes [3]	Preclinical NIR-II imaging	1000-1400 nm emission, high photostability, complex functionalization
	Quantum dots [1] [3]	Multiplexed imaging, surgical navigation	Broad absorption, narrow emission, size-tunable wavelengths
Imaging Systems	Silicon CCD cameras [4]	NIR-I detection	350-900 nm range, high sensitivity, widely available
	InGaAs cameras [4] [2]	NIR-Ib/NIR-II detection	900-1700 nm range, improving availability, essential for SWIR
Reference Standards	IR-26 dye [4]	Quantum yield reference	Φ = 0.5% in organic solvent, NIR-II standard

The science of light propagation through biological tissues provides the fundamental framework for optimizing in vivo NIR fluorescence imaging protocols. The interplay between absorption, scattering, and autofluorescence varies significantly across the NIR spectrum, creating distinct advantages for specific wavelength windows in different applications. While NIR-I imaging (700-900 nm) remains the clinical standard with established fluorophores like ICG, emerging evidence demonstrates clear advantages for NIR-Ib (900-1000 nm) and NIR-II (1000-1700 nm) windows in terms of reduced scattering, minimal autofluorescence, and enhanced spatial resolution [4] [2] [3].

For researchers in drug development and biomedical imaging, systematic characterization of tissue-specific optical properties and fluorophore performance across multiple NIR windows is essential for protocol optimization. The experimental frameworks presented herein enable evidence-based selection of imaging parameters to maximize SBR, resolution, and penetration depth for specific research applications. As fluorophore chemistry and detection technologies continue to advance, leveraging these fundamental principles of light-tissue interactions will remain crucial for pushing the boundaries of in vivo imaging sensitivity and specificity.

Near-infrared (NIR) fluorescence imaging has emerged as a cornerstone technique in biomedical research, enabling non-invasive visualization of biological processes in living subjects. This technology leverages the unique properties of light in the near-infrared spectrum to achieve deeper tissue penetration and higher signal-to-noise ratios compared to traditional visible light imaging. The NIR spectrum is strategically divided into distinct windows—NIR-I (700-900 nm), NIR-II (1000-1700 nm), and NIR-III (2080-2340 nm)—based on the significant reduction of light scattering and absorption by biological tissues within these ranges [8]. The development of this imaging modality is particularly crucial for drug development, where real-time monitoring of drug distribution, target engagement, and therapeutic efficacy can significantly accelerate the preclinical research pipeline.

The fundamental principle underlying NIR fluorescence imaging is the utilization of the "biological transparency windows." In these spectral regions, the primary absorbers in tissues—such as hemoglobin, melanin, and water—exhibit minimal absorption, while scattering effects are substantially reduced [8]. This combination allows NIR light to penetrate biological tissues more effectively, facilitating high-resolution imaging at greater depths. For drug development professionals, this capability translates to unprecedented opportunities for monitoring drug delivery, pharmacokinetics, and pharmacodynamics in real time within live animal models, providing critical data that bridges in vitro assays and clinical outcomes.

The Optical Fundamentals: Biological Transparency Windows

The effectiveness of in vivo fluorescence imaging is governed by how light interacts with biological tissues. Understanding these interactions is essential for selecting appropriate imaging windows and designing effective experiments. The following table summarizes the key characteristics of the primary biological transparency windows:

Table 1: Characteristics of Biological Transparency Windows for In Vivo Imaging

Window	Wavelength Range	Penetration Depth	Primary Absorbers	Advantages
NIR-I	650-950 nm	Moderate	Hemoglobin, Melanin	Established technology, High quantum yield probes
NIR-II	1000-1350 nm	Deep	Water (increasing)	Reduced scattering, Minimal autofluorescence
NIR-III	1550-1870 nm	Very deep	Water (peak)	Lowest scattering, High clarity
NIR-IIb	1500-1700 nm	Exceptional	Water (strong)	Ultimate image clarity, Lowest tissue scattering

The superior performance of NIR-II and NIR-III windows stems from significantly reduced scattering phenomena. As wavelength increases, light scattering decreases following a λ^(-α) relationship (where α typically ranges from 0.2 to 4 for biological tissues, depending on the structural composition) [8]. This reduction in scattering directly translates to improved penetration depth and spatial resolution. Additionally, autofluorescence from endogenous fluorophores such as flavins and collagen is negligible in the NIR-II and NIR-III regions, resulting in dramatically improved signal-to-background ratios compared to the NIR-I window [8].

It is worth noting that the regions between these windows (950-1000 nm and 1350-1550 nm) should generally be avoided for in vivo imaging. In the 950-1000 nm range, water absorption creates significant interference, while the 1350-1550 nm region experiences considerable light scattering, diminishing image quality [8]. Therefore, optimal probe design and imaging system configuration should focus on the central regions of each recognized window to maximize performance.

NIR Fluorophores: From Molecular Design to Performance

The development of advanced fluorophores is critical for harnessing the full potential of each NIR window. Different classes of fluorescent materials offer distinct advantages and limitations for specific research applications.

Table 2: Comparison of NIR Fluorophores Across Spectral Windows

Fluorophore Type	Spectral Range	Quantum Yield	Advantages	Limitations
Organic Dyes (Indocyanine Green)	NIR-I (780-850 nm)	Moderate (1-5%)	Clinical approval, Well-characterized	Rapid clearance, Moderate brightness
Carbazole-based Probes	NIR-I to NIR-II	Varies with structure	Tunable emission, AIE properties	Requires structural optimization
Chair-shaped Indoline Donors [9]	NIR-I to NIR-II	High for NIR	Bright molecular & aggregated state emission	Novel, undergoing validation
Rare-earth Nanocrystals [10]	NIR-IIb (1500-1700 nm)	Low to Moderate	Photostability, Sharp emissions	Complex synthesis, Potential toxicity concerns
Fluorinated Conjugated Polymers [11]	NIR-II	2.73% (QY), 67.3% (PCE)	Combined imaging & therapy	Potential biocompatibility challenges

Recent innovations in molecular engineering have produced remarkable advances in NIR fluorophore performance. A breakthrough study demonstrated a novel "chair-shaped" indoline donor configuration that enables bright emission in both molecular and aggregated states [9]. This design features a unique hybrid planar-twisted conformation that achieves two critical advantages: (1) localized π-electrons with super electron-donating capability that enhances light absorption and reduces the HOMO-LUMO gap, and (2) a non-planar "chair" structure that effectively suppresses concentration-dependent non-radiative energy dissipation [9]. The resulting NIR fluorophores display superior performance in molar absorption coefficient, absorption/emission wavelength, aggregation-induced emission characteristics, radiative decay rate, and fluorescence quantum yield compared to reference dyes.

Similarly, fluorination strategies for conjugated polymers have shown promise in simultaneously improving fluorescence quantum yield (QY) and photothermal conversion efficiency (PCE)—parameters that typically represent a trade-off in photothermal agent design [11]. One recently reported fluorinated polymeric photothermal agent achieved an exceptional NIR-II QY of 2.73% alongside a PCE of 67.3% [11]. This dual enhancement is accomplished through fluorination-mediated modulation of intramolecular donor-acceptor interactions and intermolecular stacking states, leading to increased recombination energy and non-radiative transitions.

Experimental Protocols for In Vivo NIR Fluorescence Imaging

General Protocol for In Vivo Fluorescence Imaging

The following protocol outlines the standard procedure for conducting in vivo NIR fluorescence imaging studies in small animal models, adaptable across NIR spectral windows:

Materials & Reagents:

• NIR fluorescent probe (dissolved in appropriate solvent)
• Animal model (e.g., tumor-bearing mice)
• NIR fluorescence imaging system (e.g., FOBI imaging system)
• Anesthesia system (isoflurane vaporizer with induction chamber)
• Depilatory cream for hair removal
• Sterile saline for injection
• Dissection tools for tissue collection

Procedure:

• Animal Preparation: Anesthetize mice using isoflurane (3% for induction, 1.5% for maintenance in 100% oxygen). Apply depilatory cream to remove hair from the imaging area to minimize light scattering and absorption. Ensure body temperature is maintained throughout the procedure using a heating pad.

• Baseline Imaging: Acquire pre-injection images using the same parameters that will be used for post-injection imaging. This provides a baseline for autofluorescence subtraction and background correction.

• Probe Administration: Intravenously inject the NIR fluorescent probe via the tail vein. Typical injection volumes range from 100-200 μL for mice, with probe concentrations dependent on the specific fluorophore's brightness and toxicity profile.

• Time-point Imaging: Image animals at predetermined time points (e.g., 1, 4, 24 hours post-injection) using consistent imaging parameters (exposure time, lamp intensity, binning, and field of view). For NIR-II imaging, ensure the system is equipped with appropriate lasers and detectors (e.g., InGaAs cameras) [12].

• Image Analysis: Quantify fluorescence intensities using image analysis software (e.g., ImageJ, National Institutes of Health). Define regions of interest (ROIs) for target tissues and background areas. Calculate signal-to-background ratios for quantitative comparison.

• Ex Vivo Validation: At terminal time points, euthanize animals and collect tissues of interest (tumor, heart, lungs, liver, spleen, kidneys, etc.) for ex vivo imaging. This validates in vivo findings and provides information on biodistribution [12].

Synthesis Protocol for Chair-shaped Indoline-based NIR Fluorophores

Based on recent literature, below is a generalized synthesis protocol for advanced NIR fluorophores with chair-shaped indoline donors:

Materials:

• Indoline precursor compounds
• Electron-accepting moieties (e.g., 2-(2-decyltetradecyl)-6,7-dimethyl-2H-[1,2,3]triazolo[4,5-g]quinoxaline)
• Anhydrous solvents (tetrahydrofuran, dimethylformamide)
• Catalysts (palladium catalysts for coupling reactions)
• Purification materials (silica gel, chromatography columns)

Procedure:

• Donor Synthesis: Prepare the chair-shaped indoline donor unit through multi-step synthesis involving cyclization and conformational locking steps. Confirm the unique hybrid planar-twisted conformation using nuclear magnetic resonance (NMR) spectroscopy.

• Donor-Acceptor Coupling: React the indoline donor with selected electron-accepting moieties via palladium-catalyzed cross-coupling reactions under inert atmosphere.

• π-Conjugation Extension: Systematically extend the π-conjugation system through additional coupling reactions to achieve emission wavelengths spanning from NIR-I (650-1000 nm) to NIR-II (1000-1700 nm) regions [9].

• Purification and Characterization: Purify the resulting fluorophores using column chromatography and characterize using techniques including mass spectrometry, NMR, and high-performance liquid chromatography. Evaluate photophysical properties including absorption/emission spectra, fluorescence quantum yield, and photostability.

• Nanoparticle Formulation: For in vivo applications, formulate hydrophobic fluorophores into water-dispersible nanoparticles using nanoprecipitation methods with amphiphilic polymers or lipids as encapsulating agents.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Research Reagent Solutions for NIR Fluorescence Imaging

Reagent/Material	Function	Application Examples	Considerations
Indocyanine Green (ICG)	Clinical NIR-I dye	Vascular imaging, Liver function assessment	Rapid plasma binding, FDA-approved
Carbazole-based Probes [13]	Tunable NIR fluorophore	Organelle labeling, Molecular sensing	Requires structural optimization for AIE
Chair-shaped Indoline Donors [9]	High-performance NIR donor	NIR-I/II imaging, STED microscopy	Novel design, patent considerations
Rare-earth Nanocrystals [10]	NIR-IIb contrast agents	Deep-tumor imaging, Image-guided surgery	Requires surface functionalization
Fluorinated Conjugated Polymers [11]	Theranostic agents (imaging + therapy)	NIR-II imaging, Photothermal therapy	Biocompatibility assessment needed
Gold Nanorods	Photothermal agents	Tumor ablation, Photoacoustic imaging	Size-dependent plasmon resonance
Surface-functionalized Quantum Dots	Bright NIR probes	Multiplexed imaging, Lymph node mapping	Potential heavy metal toxicity

Workflow and Signaling Pathways in NIR Imaging Applications

The following diagrams illustrate key experimental workflows and biological processes that can be investigated using NIR fluorescence imaging.

Workflow for In Vivo NIR Fluorescence Imaging Study

Mechanism of Tumor Targeting and Imaging with NIR Probes

Advanced Applications in Drug Development

NIR fluorescence imaging has become indispensable in modern drug development pipelines, offering solutions to critical challenges in preclinical research. In the realm of nanoparticle drug delivery, NIR imaging enables real-time tracking of nanocarrier distribution, accumulation at target sites, and release kinetics. Recent studies using advanced NIR-II probes have revealed alternative transport mechanisms beyond the traditional enhanced permeability and retention (EPR) effect, including immune cell-mediated nanoparticle transport and trans-endothelial pathways [14]. These insights are crucial for designing more effective nanomedicines.

For therapeutic monitoring, NIR imaging provides non-invasive assessment of treatment efficacy. The integration of fluorescence imaging with photothermal therapy, as demonstrated by fluorinated conjugated polymers, enables simultaneous treatment and monitoring of therapeutic response [11]. This theranostic approach achieved 100% tumor ablation by the 4th day of treatment with no recurrence over 21 days post-treatment in preclinical models [11].

In gene therapy development, NIR probes combined with CRISPR/Cas systems allow real-time monitoring of gene editing processes and quantitative analysis of delivery efficiency [14]. However, challenges remain in improving delivery efficiency, endosomal escape, and reducing off-target effects, areas where NIR imaging provides critical feedback for vector optimization.

The navigation through NIR spectral windows from NIR-I to NIR-II and beyond represents a paradigm shift in biomedical imaging capabilities. Each window offers distinct advantages, with the NIR-II and particularly the NIR-IIb windows providing exceptional image clarity due to significantly reduced scattering effects [8] [10]. Recent innovations in fluorophore design, including chair-shaped indoline donors [9] and fluorination strategies for conjugated polymers [11], have dramatically improved fluorescence quantum yields and photothermal conversion efficiencies, expanding the applications of NIR imaging into theranostics.

Future developments will likely focus on improving the biocompatibility and targeting specificity of NIR probes, enhancing quantitative imaging capabilities, and integrating artificial intelligence for image analysis and interpretation [14] [15]. The continued collaboration between chemists developing novel fluorophores, biologists identifying relevant targets, and drug developers applying these tools to therapeutic challenges will ensure that NIR fluorescence imaging remains at the forefront of biomedical innovation, ultimately accelerating the translation of promising therapies from bench to bedside.

The established paradigm in near-infrared (NIR) bioimaging has long prioritized the minimization of light absorption by biological tissues, operating under the assumption that both absorption and scattering universally degrade image quality. This conventional approach has largely excluded spectral regions featuring strong water absorption peaks, particularly around 1450 nm and 1930 nm, from consideration as viable imaging windows. However, a transformative reassessment of the fundamental physics of light-tissue interaction is now underway. Emerging research demonstrates that strategic exploitation of these high-absorption regions can dramatically enhance imaging contrast by preferentially attenuating multiply scattered photons, which constitute the background signal, thereby increasing the signal-to-background ratio (SBR) [16]. This application note details the protocols and theoretical underpinnings for leveraging two key high-contrast imaging windows—NIR-IIx (1400-1500 nm) and the newly proposed 1880-2080 nm window—for superior in vivo fluorescence imaging.

Theoretical Foundation: Re-evaluating Light-Tissue Interaction

The propagation of light through biological media is governed by absorption and scattering events. While scattering deflects photons, blurring the image, absorption attenuates photon intensity. The critical insight is that the path length of multiply scattered photons is substantially longer than that of ballistic (direct-path) photons. Consequently, in spectral regions with significant absorption, the scattered background signal experiences greater attenuation, while the informative ballistic signal is better preserved [16]. This mechanism underlies the enhanced contrast observed in high-absorption windows.

Water, as the dominant component in biological tissues, dictates the absorption profile. Its spectrum features primary peaks at approximately 1450 nm and 1930 nm [16]. The NIR-IIx window (1400-1500 nm) flanks the first peak, and recent work has proven its exceptional imaging potential. Similarly, the region from 1880-2080 nm, surrounding the second peak, was historically avoided but is now recognized as a high-performance window when sufficiently bright fluorophores are employed [16].

Table 1: Characteristics of High-Contrast NIR Imaging Windows

Imaging Window	Spectral Range (nm)	Governing Absorption Feature	Primary Contrast Mechanism	Simulated SBR (Relative Performance)	Simulated SSIM (Relative Performance)
NIR-IIa	1300-1400	Low Water Absorption	Reduced Scattering	Low	Low
NIR-IIx	1400-1500	~1450 nm Water Peak	High Absorption & Scattering Suppression	High	High
NIR-IIb	1500-1700	Moderate Water Absorption	Reduced Scattering	Medium	Medium
NIR-IIc	1700-1880	Rising Water Absorption	Scattering Suppression	Medium	Medium
New Window	1880-2080	~1930 nm Water Peak	Highest Absorption & Scattering Suppression	Very High	Very High

Table 2: Optical Properties and Optimal Use Cases

Imaging Window	Photon Scattering	Water Absorption	Recommended Tissue Type	Key Application Example
NIR-IIa	Moderate	Low	General Tissue	Superficial Vasculature Imaging
NIR-IIx	Low	High	Hydrated Tissues	Deep-Tissue High-Contrast Angiography
NIR-IIb	Low	Medium	General Tissue	Tumor Margin Delineation
NIR-IIc	Very Low	High	Adipose-Rich Regions	Sentinel Lymph Node Mapping in Fat
New Window	Very Low	Very High	Hydrated & Deep Tissues	High-Contrast Imaging Over Liver Background

The following conceptual diagram illustrates the photon propagation dynamics that enable superior contrast in high-absorption windows.

Experimental Protocols for High-Contrast NIR Imaging

In Vivo Fluorescence Imaging in the 1880-2080 nm Window

Principle: This protocol utilizes the intense water absorption in the 1880-2080 nm window to suppress scattered photons. The bright fluorescence from PbS/CdS quantum dots overcomes the inherent signal attenuation, yielding exceptional image contrast [16].

Materials:

• Animal Model: Anesthetized mouse (e.g., BALB/c or nude mouse).
• Fluorophore: PEGylated PbS/CdS core-shell quantum dots (QDs) with emission peaks within the 1880-2080 nm window [16].
• Imaging System: NIR-II fluorescence imaging system equipped with an InGaAs camera detector sensitive beyond 1500 nm and capable of gating to the 1880-2080 nm range.
• Excitation Source: 808 nm or 980 nm laser, adjusted for optimal QD excitation.

Procedure:

• Fluorophore Administration: Intravenously inject a solution of PbS/CdS QDs (e.g., 100-200 µL at 1-10 µM concentration) via the tail vein.
• System Setup: Position the animal under the imaging system. Set the excitation laser power to a safe level (e.g., 100 mW/cm²) to avoid tissue damage.
• Spectral Gating: Configure the emission filters or spectrometer to isolate the 1880-2080 nm signal.
• Image Acquisition:
  • Acquire a background image prior to QD injection.
  • Post-injection, acquire time-series images with exposure times between 50-500 ms to monitor QD biodistribution and circulation.
  • For vascular imaging, acquire a rapid sequence immediately after injection.
• Image Processing:
  • Subtract the pre-injection background image from all subsequent images.
  • Calculate the Signal-to-Background Ratio (SBR) by selecting a region of interest (ROI) over the target (e.g., vessel) and an adjacent background ROI.
  • Apply false-coloring to the fluorescence intensity for visualization.

Multi-Window Comparative Imaging Analysis

Principle: This protocol directly compares the performance of the novel 1880-2080 nm window against established NIR sub-windows (e.g., NIR-IIa, NIR-IIx, NIR-IIb) in the same animal, quantifying metrics like SBR and Structural Similarity Index Measure (SSIM) [16].

Materials:

• Same animal model and fluorophore as in Protocol 3.1.
• An advanced NIR fluorescence imaging system capable of sequential or simultaneous acquisition across multiple spectral bands (e.g., 1300-1400 nm, 1400-1500 nm, 1500-1700 nm, 1700-1880 nm, 1880-2080 nm).

Procedure:

• Animal Preparation and Injection: Follow Steps 1 and 2 from Protocol 3.1.
• Sequential Multi-Window Acquisition: After QD injection, acquire a set of coregistered images of the same anatomical region (e.g., brain vasculature or area above the liver) by rapidly switching emission filters or adjusting the detection spectrometer to each target window.
  • Ensure all acquisition parameters (laser power, camera gain, exposure time) are kept constant across all windows for a valid comparison. Note: Absolute signal intensity will vary; the key metric is the SBR.
• Data Analysis:
  • For each imaging window, calculate the SBR as described in Protocol 3.1.
  • Compute the SSIM for each image relative a high-resolution reference standard to quantify structural fidelity.
  • Plot the SBR and SSIM values for each window to visualize performance differences.

The experimental workflow for a comprehensive multi-window study is outlined below.

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful implementation of high-contrast imaging in high-absorption windows is contingent upon the use of specialized reagents and equipment.

Table 3: Essential Research Reagents and Materials

Item Name	Specifications / Key Properties	Critical Function in Protocol
PbS/CdS Core-Shell Quantum Dots	Bright emission in 1500-2080 nm range; PEGylated for water solubility and biocompatibility [16].	Serves as the bright fluorescent probe whose signal can overcome high water absorption attenuation.
ICG-HSA Conjugate	Indocyanine Green adsorbed to Human Serum Albumin; emission ~800-850 nm; used for NIR-I mapping [17].	Validated clinical-grade tracer for control experiments and sentinel lymph node mapping studies.
NIR-II Fluorescence Imaging System	InGaAs camera; wavelength-tunable emission filters (900-2080 nm); 808/980 nm laser excitation [16].	Enables detection of faint fluorescence signals in the NIR-II and beyond, including high-absorption windows.
NIR-Optimized Endoscope	High transmission efficiency at NIR wavelengths (e.g., >40% at 760 nm) [18].	Facilitates minimally invasive fluorescence-guided surgery and imaging in deep tissues.
Standardized Phantom	Tissue-simulating materials with calibrated optical properties (scattering, absorption).	Provides a controlled environment for system calibration and validation before in vivo studies.

Data Analysis and Reporting Standards

Quantitative Analysis: The primary quantitative metrics for evaluating image quality in these windows are the Signal-to-Background Ratio (SBR) and the Structural Similarity Index Measure (SSIM). Monte Carlo simulations predict and experimental data confirm that both SBR and SSIM are significantly higher in the NIR-IIx and 1880-2080 nm windows compared to other NIR-II sub-windows [16].

Reporting Guidelines (REFLECT Framework): To ensure reproducibility and comparability between studies, adherence to community-driven reporting guidelines is crucial. Key items to report include [19]:

• Imaging Agent: Detailed characterization of the fluorescent probe (e.g., QDs), including absorption/emission spectra, quantum yield, and degree of labeling for conjugates.
• Imaging Device: Full specifications of the camera, light source, and filters used.
• Imaging Protocol: Administration route, dose (report in moles or moles/body weight for accurate comparison), and timing [19].
• Image Analysis: Detailed description of background subtraction methods, ROI selection, and calculations for SBR and other metrics.

Application Scenarios and Future Perspectives

The exceptional contrast of these windows is particularly beneficial in challenging imaging scenarios:

• Differentiating Superficial Vasculature from Deep Background: When imaging skin vessels over an organ with high background signal (e.g., the liver), the 1880-2080 nm and NIR-IIx windows can distinguish the target vessels with clarity that other windows cannot achieve [16].
• Imaging in Adipose Tissue: Simulations and experiments show that for adipose tissue, which has unique absorption properties, the optimal window expands to 1700-2080 nm, leveraging low scattering and moderate absorption for the best quality [16].
• Multi-Channel Bioimaging: The distinct optical properties of these windows allow them to be used in parallel with other spectral channels (e.g., NIR-IIx and 1880-2080 nm) for multi-analyte imaging.

Future development will focus on the clinical translation of these techniques, which hinges on the development of safe, bright, and target-specific fluorophores for these long-wavelength windows and the wider availability of cost-effective, sensitive detectors. The recent community push for standardized reporting, as encapsulated in the REFLECT guidelines, will be instrumental in this translational effort [19].

In vivo near-infrared (NIR) fluorescence imaging has emerged as a cornerstone technique in preclinical research and drug development, enabling non-invasive, real-time visualization of biological processes with high sensitivity and spatial resolution. The efficacy of this modality is fundamentally governed by the photophysical and pharmacokinetic properties of the fluorophores employed. This application note provides a detailed technical overview of three principal fluorophore classes: established organic dyes (ICG and heptamethine cyanines), inorganic probes (quantum dots), and the emerging generation of NIR-II emitters. Framed within the context of standardized in vivo imaging protocols, we present quantitative performance comparisons, detailed experimental methodologies for key applications, and a visual guide to fluorophore selection and evaluation workflows to accelerate research in oncology and molecular imaging.

Performance Comparison of Major Fluorophore Classes

The selection of an appropriate fluorophore requires careful consideration of its optical properties, biodistribution, and biocompatibility. The data below summarize the key characteristics of the major classes discussed in this note.

Table 1: Comparative Analysis of Organic and Inorganic NIR Fluorophores

Fluorophore Class	Example(s)	Excitation/Emission (nm)	Key Advantages	Documented Limitations
Heptamethine Cyanine Dyes	ICG ( [20])	~780 / ~820	FDA-approved; rapid clinical translation	Poor stability in aqueous solution; rapid plasma clearance; non-specific liver/kidney accumulation ( [20])
Heptamethine Cyanine Dyes	DZ-1 ( [20])	NIR (specific peaks not provided)	Superior tumor specificity; NIRF intensity one order of magnitude stronger than ICG; longer tumor retention (>24h) ( [20])	Water solubility challenges in earlier analogs (e.g., IR-783) ( [20])
Quantum Dots (NIR-I)	QD800-RGD ( [21])	~800	High photostability; narrow, tunable emission; high quantum yield; suitable for surface functionalization (e.g., with RGD peptides) ( [22] [21])	Potential heavy metal toxicity (Cd, Pb); large hydrodynamic diameter can affect clearance ( [22] [21])
NIR-II Organic Dyes	C5T-Pco ( [23])	763 / 796 (NIR-I), with tail emission >1000 nm (NIR-II)	Excitation-wavelength selective NIR-II imaging and photodynamic therapy; counterion engineering controls aggregation ( [23])	Susceptible to aggregation-caused quenching (ACQ) without molecular engineering ( [23])
NIR-II Small Molecules	D-A-D & Cyanine Dyes ( [24])	1000-1700	Deeper tissue penetration; reduced scattering/autofluorescence; higher resolution in vivo ( [24])	Relatively limited library of clinically translatable probes; complex synthesis and modification ( [24])

Table 2: Quantitative In Vivo Performance of Selected Fluorophores in Tumor Models

Fluorophore	Model	Dose	Key Metric	Result	Citation
ICG	Nude mouse, HCC	10 μmol/kg	Peak T/B Ratio	~2.5 (at 12h)	[20]
DZ-1	Nude mouse, HCC	0.5 μmol/kg	Peak T/B Ratio	~5.0 (at 24h)	[20]
QD800-RGD	Nude mouse, U87MG tumor	200 pmol	Tumor Uptake (%ID/g)	10.7 ± 1.5 %ID/g	[21]
QD800-RAD (Control)	Nude mouse, U87MG tumor	200 pmol	Tumor Uptake (%ID/g)	4.0 ± 0.5 %ID/g	[21]
Folate-ZW800-1 Forte	Mouse, Skov-3 tumor	Not specified	Tumor Contrast	Highest vs. other folate conjugates	[25]

Detailed Experimental Protocols

Protocol 1: Evaluating Tumor Targeting and Pharmacokinetics of a Novel Heptamethine Cyanine Dye (DZ-1)

This protocol is adapted from a study comparing the novel dye DZ-1 with the FDA-approved ICG in hepatocellular carcinoma (HCC) models [20].

1. Reagent Preparation:

• DZ-1 Dye: The anionic heptamethine cyanine dye DZ-1 was synthesized as described [20]. Prepare a stock solution in saline for intravenous injection. The typical dose for in vivo studies is 0.5 μmol/kg.
• ICG Control: Prepare an ICG (e.g., Diagnostic Green GmbH) solution in saline. The typical comparative dose is 10 μmol/kg [20].
• Cell Line: Use human HCC cell line Hep3B2.1-7 (Hep3B), engineered to express luciferase (Hep3B-Luc) for co-registered bioluminescence imaging.

2. In Vitro Cell Uptake and Specificity Assay:

• Seed Hep3B cells in a multi-well plate or petri dish and culture for 24 hours.
• Co-incubate cells with DZ-1 or ICG at a concentration of 20 μM in culture medium for 30 minutes at 37°C.
• Wash cells thoroughly with PBS to remove unbound dye.
• Image cells at successive time points (e.g., 1, 3, 12, 24 h) using a NIR fluorescence microscope. The fluorescence intensity of DZ-1 is expected to be significantly stronger and more persistent than ICG at 24 hours [20].
• For organelle co-localization, incubate cells with MitoTracker (200 nM) or LysoTracker (75 nM) for 30 min prior to adding the NIRF dye.

3. In Vivo Subcutaneous Xenograft Model Imaging:

• Tumor Inoculation: Subcutaneously inoculate nude mice with 1x10^6 to 9x10^6 Hep3B-Luc cells in the front flank. Proceed with imaging once tumors reach a volume of 200-500 mm³ (approximately 2-3 weeks).
• Dye Administration: Inject mice intravenously via the tail vein with either DZ-1 (0.5 μmol/kg) or ICG (10 μmol/kg).
• Longitudinal Imaging: At defined time points post-injection (e.g., 0.5, 1, 4, 6, 16, 24, 48 h), anesthetize mice and acquire both NIRF and bioluminescence images using a co-registered optical imaging system (e.g., IVIS Spectrum).
• Data Analysis: Quantify the fluorescence intensity within the tumor region (T) and a contralateral background region (B). Plot the T/B ratio over time. DZ-1 should show a gradually increasing T/B ratio, peaking at around 24 hours, whereas ICG peaks rapidly and declines [20].

4. Ex Vivo Biodistribution Analysis:

• At terminal time points (e.g., 24 h and 48 h post-injection), sacrifice the mice and harvest the tumors and major organs (heart, liver, spleen, lung, kidney).
• Place tissues on an imaging plate and acquire ex vivo NIRF images.
• Quantify the fluorescence intensity per cm² for each organ. DZ-1 is expected to show high specificity for tumor tissue, while ICG will show significant accumulation in the liver and kidneys [20].

Protocol 2: Surface Functionalization and Application of NIR Quantum Dots for Tumor Vasculature Targeting

This protocol details the PEGylation and peptide conjugation of non-cadmium QDs for targeted imaging of integrin αvβ3, a key marker of tumor angiogenesis [21].

1. Reagent Preparation:

• QD800 Core: Synthesize InAs/InP/ZnSe core/shell/shell QDs with an emission maximum at ~800 nm as previously described [21].
• Phospholipid-PEG Conjugate: Use DSPE-PEG2000-amine (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]).
• Peptides: Obtain thiolated RGD peptide (c(RGDy(ε-acetylthiol)K), RGD-SH) for active targeting and a thiolated RAD peptide (c(RADy(ε-acetylthiol)K), RAD-SH) as a scrambled control.

2. PEG Coating of QDs (QD800-PEG):

• Mix 10 nmol of as-synthesized QD800 and ~1.8 μmol of DSPE-PEG2000-amine in 200 μL of chloroform.
• Allow the chloroform to evaporate slowly at room temperature in a fume hood.
• Place the dry film under vacuum for 4 hours to remove residual solvent.
• Re-disperse the film in pure water by gentle sonication to form QD800-PEG micelles.
• Purify the QD800-PEG by centrifugation using a 100 kDa molecular weight cut-off filter at 4000 rpm for 20 min to remove excess DSPE-PEG2000-amine. Resuspend the final product in PBS buffer (pH 7.4) to a concentration of ~10 μM.

3. Conjugation with Targeting Peptide (QD800-RGD):

• Activate QD800-PEG (1 nmol) by reacting with 4-maleimidobutyric acid N-succinimidyl ester (1 μmol) in borate buffer (pH ~8.5) for 2 hours at room temperature with gentle shaking.
• Purify the maleimide-activated QDs using a NAP-10 size-exclusion column.
• Immediately add the thiolated RGD peptide (1 μmol) to the activated QDs and allow the reaction to proceed for 2 hours at room temperature.
• Purify the final QD800-RGD conjugate using a NAP-10 column and store in PBS at 4°C. Follow the same procedure with the RAD peptide to produce the control conjugate QD800-RAD.

4. In Vivo Imaging and Validation:

• Animal Model: Establish subcutaneous U87MG human glioblastoma tumors in nude mice.
• Systemic Administration: Inject ~200 pmol of QD800-RGD, QD800-RAD, or QD800-PEG intravenously into tumor-bearing mice.
• Image Acquisition: Image mice at multiple time points (0.5 to 24 h) using an NIR imaging system with appropriate filters (e.g., excitation 605-665 nm, emission 800-875 nm).
• Ex Vivo Validation: Harvest tumors and major organs at 4-24 h post-injection for ex vivo imaging. The tumor uptake of QD800-RGD is expected to be significantly higher (~10.7 %ID/g) than the control groups [21].
• Immunofluorescence Staining: Confirm the specific localization of QD800-RGD on tumor vasculature by co-staining tumor sections with an anti-CD31 antibody (endothelial cell marker) and visualizing under a fluorescence microscope.

Workflow and Signaling Pathways

The following diagrams outline the logical workflow for fluorophore evaluation and the strategic design of a novel NIR-II fluorophore, integrating key concepts from the cited literature.

Diagram 1: Decision Workflow for Selecting and Evaluating Fluorophores for In Vivo NIR Imaging. This flowchart guides researchers through critical decision points, from initial fluorophore class selection to the evaluation of key performance metrics, culminating in an optimized imaging protocol. Property checks are informed by comparative data from the literature [20] [22] [21].

Diagram 2: Strategic Design of a NIR-II Fluorophore for Theranostics. This diagram outlines the problem-solving approach used to develop the C5T-Pco fluorophore, where counterion engineering was employed to overcome the inherent aggregation-caused quenching (ACQ) of the anionic cyanine dye C5T, enabling its use in excitation-wavelength-selective NIR-II imaging and photodynamic therapy (PDT) [23].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Reagents and Materials for Fluorophore Synthesis and Evaluation

Item Name	Function/Application	Example/Catalog
Heptamethine Cyanine Dye DZ-1	Novel, high-specificity NIR dye for tumor targeting and imaging.	Research synthesis as detailed in [20].
IRDye 800CW NHS Ester	Commercially available NIR dye for conjugating to targeting ligands (antibodies, peptides).	LI-COR Biosciences [25].
Non-Cadmium QDs (InAs/InP/ZnSe)	Biocompatible quantum dot core for NIR-I imaging with minimal heavy metal toxicity.	Synthesized as per [21].
DSPE-PEG2000-Amine	Amphiphilic polymer for encapsulating hydrophobic nanoparticles, conferring water solubility and a functional group for bioconjugation.	Avanti Polar Lipids, Inc. [21].
RGD-SH Peptide	Targeting ligand for functionalizing probes to target integrin αvβ3 on tumor vasculature.	c(RGDy(ε-acetylthiol)K) [21].
ICG-OSu	NHS-ester derivative of ICG for controlled conjugation to biomolecules.	AAT Bioquest [25].
ZW800-1 Forte NHS Ester	Commercial NIR dye with optimized pharmacokinetics for high contrast imaging.	Curadel LLC [25].
IVIS Spectrum Imaging System	Preclinical in vivo imaging system for longitudinal bioluminescence and fluorescence imaging.	PerkinElmer Inc. [20] [25].

The efficacy of in vivo Near-Infrared (NIR) fluorescence imaging is fundamentally governed by the photophysical and biological properties of the fluorescent probes utilized. For researchers and drug development professionals aiming to visualize biological processes, diagnose diseases, or guide surgical interventions, a rigorous understanding of four core characteristics—quantum yield, extinction coefficient, photostability, and biocompatibility—is non-negotiable. These parameters collectively determine a probe's brightness, longevity during imaging, and suitability for use in living systems. Probes with emissions in the near-infrared windows (NIR-I: 650–950 nm; NIR-II: 1000–1400 nm) are particularly advantageous due to reduced light scattering, minimal tissue autofluorescence, and deeper tissue penetration compared to visible-light probes [22] [26] [27]. This document provides a detailed framework for the quantitative evaluation and practical application of fluorescent probes within the context of in vivo NIR fluorescence imaging protocols.

Quantitative Foundations of Probe Performance

Defining the Core Characteristics

The performance of a fluorescent probe is quantifiable through several key photophysical parameters. Their definitions and interrelationships are foundational to probe selection and experimental design.

• Extinction Coefficient (ε): This parameter, typically measured in M⁻¹cm⁻¹, indicates the probability that a fluorophore will absorb a photon at a specific wavelength. A higher extinction coefficient means the probe is more efficient at capturing excitation light, which is the first step in generating a fluorescent signal [28] [29].
• Quantum Yield (QY or Φ): The fluorescence quantum yield is the ratio of the number of photons emitted to the number of photons absorbed. It is a direct measure of the efficiency with which the absorbed light is converted into emitted light. A quantum yield of 1.0 (or 100%) signifies that every absorbed photon results in an emitted photon [28] [22].
• Photostability: This refers to a fluorophore's ability to resist permanent photochemical degradation (photobleaching) under prolonged or intense illumination. Photostable probes are essential for longitudinal studies and techniques requiring high laser power, such as confocal microscopy or super-resolution imaging [27] [29].
• Biocompatibility: This broad characteristic encompasses low cytotoxicity, minimal non-specific interaction with biological components (non-specific binding), predictable pharmacokinetics, and safe metabolism and excretion from the organism. For clinical translation, this is a paramount concern [22] [27].

The following workflow illustrates the logical relationship between these core characteristics and the overall process of developing an effective probe for in vivo imaging.

The Interplay of Parameters: Defining Brightness

A probe's practical brightness is not a standalone property but the direct product of its extinction coefficient and its quantum yield (Brightness ∝ ε × QY) [29]. A probe must be both an efficient absorber and an efficient emitter to be truly bright. For example, a probe with a very high extinction coefficient but a low quantum yield will absorb much light but emit very little, resulting in a weak signal. Conversely, a probe with a perfect quantum yield (Φ=1) but a very low extinction coefficient has limited potential for brightness as it cannot absorb much light to begin with. Therefore, both parameters must be optimized and considered together when selecting a probe for sensitive detection applications.

Experimental Protocols for Characterizing Probe Properties

Protocol 1: Determining Extinction Coefficient and Quantum Yield

Objective: To quantitatively measure the extinction coefficient (ε) and fluorescence quantum yield (Φ) of a novel NIR probe in solution.

Materials:

• Spectrophotometer (UV-Vis-NIR capable)
• Fluorometer (NIR-sensitive)
• Quartz cuvettes (for both absorption and fluorescence)
• Solvent of choice (e.g., phosphate-buffered saline (PBS) for biocompatibility studies)
• Standard reference dye with known quantum yield in the NIR region (e.g., IR-26 for NIR-II)

Methodology:

• Sample Preparation: Prepare a dilution series of the probe (e.g., 5-6 concentrations) in the desired solvent. Ensure the absorbance values at the excitation wavelength are below 0.1 to avoid inner-filter effects in fluorescence measurements.
• Extinction Coefficient Measurement:
  • Using the spectrophotometer, record the absorption spectrum for each concentration.
  • Plot the absorbance at the wavelength of maximum absorption (λ_abs-max) against the known concentration for each sample.
  • Perform a linear regression analysis. The slope of the resulting line (from the Beer-Lambert law, A = εcl) is the extinction coefficient (ε).
• Quantum Yield Measurement (Comparative Method):
  • Select a reference standard with a known quantum yield (Φref) that has an absorption maximum and fluorescence profile similar to the sample.
  • Measure the absorption and fluorescence spectra of both the sample and the reference standard at the same excitation wavelength.
  • Ensure the absorbance of both the sample and reference at the excitation wavelength are matched and low (<0.05).
  • Integrate the area under the fluorescence emission curve for both the sample (F) and the reference (Fref).
  • Calculate the quantum yield using the formula: Φ = Φref × (F / Fref) × (Aref / A) × (η² / ηref²) Where:
    • F = Integrated fluorescence intensity of the sample
    • Fref = Integrated fluorescence intensity of the reference
    • A = Absorbance of the sample at the excitation wavelength
    • Aref = Absorbance of the reference at the excitation wavelength
    • η = Refractive index of the sample solvent
    • η_ref = Refractive index of the reference solvent

Protocol 2: Evaluating Photostability

Objective: To assess the resistance of the probe to photobleaching under continuous illumination.

Materials:

• Fluorescence microscope or plate reader with a stable light source
• Timer and data recording software
• Glass slides or multi-well plates

Methodology:

• Sample Preparation: Prepare a solution of the probe at a standard working concentration and load it into a well or onto a slide. Include a control probe (e.g., a commonly used dye like Cy5) for comparison.
• Illumination and Data Acquisition:
  • Expose the sample to a constant and high-intensity light at the excitation wavelength.
  • Acquire fluorescence images or read fluorescence intensity at regular, short intervals (e.g., every 10-30 seconds) over a prolonged period (e.g., 30-60 minutes).
• Data Analysis:
  • Plot the normalized fluorescence intensity (I/I₀, where I₀ is the initial intensity) against time.
  • Calculate the photobleaching half-life (t₁/₂), which is the time taken for the fluorescence intensity to decay to half of its initial value.
  • A probe with a longer t₁/₂ is considered more photostable and is preferable for long-duration imaging sessions.

Protocol 3: Assessing Biocompatibility and Targeting

Objective: To evaluate probe cytotoxicity and confirm specific binding to the molecular target in a biological context.

Materials:

• Relevant cell lines (e.g., those expressing and not expressing the target antigen)
• Cell culture reagents and equipment
• Cell viability assay kit (e.g., MTT, CellTiter-Glo)
• Flow cytometer or confocal microscope

Methodology:

• Cytotoxicity Assay:
  • Seed cells in a multi-well plate and allow them to adhere.
  • Treat cells with a range of probe concentrations for a defined period (e.g., 24-48 hours).
  • Perform a cell viability assay according to the manufacturer's instructions.
  • Calculate the percentage viability relative to untreated control cells and determine the half-maximal inhibitory concentration (IC₅₀) if necessary.
• Specificity and Binding Validation:
  • Incubate target-positive and target-negative cell lines with the probe under physiological conditions.
  • For flow cytometry: Harvest, wash, and resuspend cells. Analyze fluorescence intensity in the appropriate channel. A significant signal shift should be observed only in the target-positive population.
  • For microscopy: Image cells after staining and washing. Specific binding will show clear localization to the intended cellular compartment (e.g., membrane, organelles). Use control groups (e.g., cells pre-treated with a blocking antibody) to confirm that binding is specific.

Comparative Analysis of Fluorophore Classes

The choice of fluorophore class imposes inherent trade-offs between the core characteristics. The table below summarizes the performance of common classes relevant to NIR imaging.

Table 1: Comparative Analysis of NIR Fluorophore Classes and Their Key Characteristics

Fluorophore Class	Extinction Coefficient (ε)	Quantum Yield (QY)	Photostability	Biocompatibility / Key Considerations
Quantum Dots (QDs) [28] [22]	Very High (∼10⁵-10⁶ M⁻¹cm⁻¹)	High (Up to 95% core/shell; 45% in water)	Excellent	Concerns regarding heavy metal (Cd, Pb) toxicity; relatively large size can affect pharmacokinetics.
Cyanine Dyes (e.g., Cy5, Cy7) [26] [29]	High (∼2.5×10⁵ M⁻¹cm⁻¹)	Moderate to High	Moderate; can be improved via chemical modification.	Can be prone to non-specific binding; pharmacokinetics dominated by the dye moiety when conjugated.
Rhodamine Derivatives [29]	High	High (>0.7)	Excellent	Relatively high cost; some derivatives exhibit excellent metabolic stability for long-term imaging.
NIR-II Organic Small Molecules [30]	Varies by design (Generally High)	Moderate in aqueous media; challenging to achieve high NIR-II QY.	Good	Excellent potential for clinical translation due to predictable metabolism and biocompatibility.
Alexa Fluor Dyes [29]	High	High (>0.8)	Excellent	Engineered for superior performance and pH insensitivity; often patented and more expensive.

The Scientist's Toolkit: Essential Reagents and Materials

Successful in vivo imaging relies on a suite of specialized reagents and tools. The following table details essential components for a typical study.

Table 2: Essential Research Reagent Solutions for In Vivo NIR Imaging Studies

Item	Function / Application	Key Considerations
NIR Fluorescent Probe	The core imaging agent that provides contrast by binding to a biological target or responding to a specific microenvironment.	Must be selected based on target specificity, excitation/emission profile, and the core characteristics outlined in this document.
Animal Model	Provides the in vivo context for studying disease biology and testing probe efficacy.	The biology and kinetics of the model must be well-understood to time probe injection and imaging correctly [31].
Reference Standard Dye (e.g., IR-26)	A dye with a known quantum yield, used for the accurate determination of the QY of novel probes.	Should have spectral overlap with the sample and be soluble in the same solvent.
Cell Viability Assay Kit	To quantitatively assess the cytotoxicity of the probe in vitro before proceeding to animal studies.	Kits like MTT or CellTiter-Glo provide a colorimetric or luminescent readout of metabolic activity.
Blocking Antibody	An antibody that binds the same epitope as the targeting probe. Used to confirm binding specificity in control experiments.	Pre-incubation with a blocking antibody should significantly reduce probe signal if binding is specific.
NIR Fluorescence Imager	A device equipped with NIR-excitation lasers and sensitive NIR-detection cameras (e.g., CCD, InGaAs).	Capabilities should match the probe's spectral range (NIR-I vs. NIR-II). Integration with other modalities (e.g., MRI, CT) is advantageous.

The rigorous characterization of quantum yield, extinction coefficient, photostability, and biocompatibility is not merely a preliminary step but a continuous requirement in the development and application of NIR fluorescent probes. These parameters are deeply interconnected, dictating the signal strength, duration, and biological safety of imaging experiments. As the field advances towards more complex applications like multiplexed imaging, super-resolution microscopy, and fluorescence-guided surgery, a fundamental understanding of these core characteristics will empower researchers to select optimal probes, design robust protocols, and generate reliable, interpretable data for drug development and translational research.

From Lab to Life: Step-by-Step Protocols for Preclinical and Translational Imaging

Near-infrared (NIR) fluorescence imaging has become an indispensable tool for preclinical research, enabling non-invasive, real-time visualization of biological processes in live animal models. This protocol details the setup for in vivo NIR fluorescence imaging, framed within a broader thesis on standardizing these techniques for drug development. The methodology is structured into three core components: instrumentation, animal preparation, and fluorophore administration, providing researchers and drug development professionals with a standardized framework for obtaining reproducible, high-quality data. Adherence to community-driven reporting guidelines, such as the REFLECT framework, is emphasized throughout to enhance the quality, transparency, and reproducibility of study results [19].

Instrumentation Setup

The choice of imaging system is critical and depends on the specific research objectives, particularly the desired balance between tissue penetration depth and spatial resolution.

Imaging System Selection and Comparison

NIR imaging is typically divided into two spectral windows. The first near-infrared window (NIR-I, 700-950 nm) utilizes established dyes like Indocyanine Green (ICG) and is supported by widely available clinical imaging systems [32] [2]. The second near-infrared window (NIR-II, 1000-1700 nm) offers reduced tissue scattering and autofluorescence, leading to superior tissue penetration and spatial resolution, but requires specialized Indium Gallium Arsenide (InGaAs) detectors [32] [3].

Table 1: Comparison of Near-Infrared Fluorescence Imaging Systems

System Feature	NIR-I Imaging Systems	Preclinical NIR-II Systems (e.g., IR VIVO)	Clinical/Ambient Light NIR-II Systems (e.g., LightIR)
Spectral Range	700 - 950 nm	1000 - 1700 nm (SWIR)	1000 - 1700 nm (SWIR)
Detector Type	Silicon-based	InGaAs	InGaAs
Spatial Resolution	Lower than NIR-II	High (~125 µm)	Moderate (~250 µm)
Tissue Penetration	~2.2 mm [2]	Deeper than NIR-I	≥4 mm (demonstrated with ICG) [32]
Operating Environment	Clinical/Preclinical	Controlled, enclosed Preclinical	Ambient light, suitable for intraoperative use [32]
Key Advantage	Clinical availability of agents and systems	High resolution for preclinical research	Practical for real-time surgical guidance without blackout enclosures [32]

For NIR-II imaging, systems like the IR VIVO provide high-resolution data in a controlled, enclosed environment ideal for preclinical research [32]. In contrast, systems like the LightIR are designed for clinical translation, offering the capability for robust NIR-II imaging under ambient lighting conditions, which is crucial for intraoperative or back-table assessment [32].

System Calibration and Performance Validation

Prior to animal imaging, validate system performance using tissue-mimicking phantoms.

• QUEL Phantoms: Use standardized phantoms containing known concentrations of fluorophores (e.g., ICG, IR-1048) to quantitatively assess imaging sensitivity, spatial resolution, and depth penetration [32].
• Agar-based Phantoms: Custom phantoms can be created to mimic specific tissue optical properties for a more tailored validation [32].

Animal Preparation

Animal Models

The selection of an appropriate animal model is fundamental to the research question. Common models include:

• Subcutaneous Xenograft Models: Generated by injecting human cancer cells (e.g., SGC-7901 gastric cancer cells) into the flanks of immunocompromised mice. This model is straightforward and allows for easy tumor monitoring [33].
• Orthotopic Xenograft Models: Established by implanting cancer cells into the corresponding organ of origin in the mouse (e.g., liver for hepatic cancer). These models better recapitulate the tumor microenvironment and are more clinically relevant [33].

All animal experiments must be approved by the Institutional Animal Care and Use Committee (IACUC). This study follows the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) to ensure comprehensive reporting [33].

Anesthesia and Stabilization

• Anesthesia: Induce and maintain anesthesia using an inhaled isoflurane/oxygen mixture (e.g., 2-3% for induction, 1-2% for maintenance). This provides stable sedation and rapid recovery.
• Physiological Monitoring: Monitor the animal's body temperature and respiratory rate throughout the imaging procedure.
• Stabilization: Securely position the animal in the imaging chamber to prevent motion artifacts during image acquisition.

Fluorophore Administration

The administration of the fluorescent contrast agent must be meticulously controlled and reported.

Fluorophore Selection and Properties

Researchers can choose from a range of non-targeted and targeted agents.

Table 2: Research Reagent Solutions for NIR Fluorescence Imaging

Reagent Name	Category / Target	Key Function in Experiment	Ex/Emm (nm)
Indocyanine Green (ICG)	Non-targeted perfusion agent	Angiography, lymph node mapping, assessing tissue perfusion [6]	~780/~820 [32]
IR-780	Tumor-targeting dye [33]	Selective accumulation in tumor cells for intraoperative detection [33]	~760/~780 [33]
ESS65-Cl	Normal stomach tissue-targeting dye [33]	Identification of normal gastric tissue; used in dual-channel imaging with IR-780 [33]	~630/~700 [33]
Cetuximab-IRDye800CW	Targeted agent (EGFR) [2]	Visualization of EGFR-positive tumors (e.g., HNSCC, PSCC) for margin assessment [2]	~774/~789 [2]
Pafolacianine (Cytalux)	Targeted agent (Folate Receptor) [34] [19]	FDA-approved for highlighting ovarian and lung cancer lesions during surgery [19]	NIR-I

For novel fluorophores, a detailed characterization must be reported, including: chemical structure, excitation/emission spectra, molecular extinction coefficient, quantum yield, and purity [19]. The Degree of Labeling (DoL)—the average number of dye molecules per targeting molecule—must be calculated and reported for each batch of a conjugated agent, as it impacts brightness and pharmacokinetics [19].

Administration Protocol

• Dosage and Formulation: Administer the fluorophore via intravenous injection (e.g., tail vein in mice). The dose should be reported in molar units (e.g., nmol) or nmol per body weight to standardize comparisons, as fluorescence signal correlates with molar concentration [19].
  • Example: 200 nmol of ESS65-Cl or 100 nmol of IR-780 in 100 µL of saline containing 10% bovine serum albumin (BSA) has been used in mouse models [33].
• Injection Formulation: Specify the exact composition and volume of the solution used to solubilize the agent (e.g., saline, with or without BSA) and details of any post-injection flush [19].
• Timing of Imaging: The optimal time window for imaging is fluorophore-specific and depends on its pharmacokinetics. For example, ESS65-Cl achieved a stomach signal-to-background ratio of 3.3 by 48 hours, while IR-780 exhibited a tumor-to-background ratio of 4.0 in xenograft models [33].

Experimental Workflow and Data Analysis

The following diagram outlines the comprehensive experimental workflow for an in vivo NIR fluorescence imaging study, integrating the components of instrumentation, animal preparation, and fluorophore administration.

Quantitative Data Analysis

After image acquisition, quantitative analysis is essential for objective assessment.

• Signal-to-Background Ratio (SBR): Measures the fluorescence intensity of the target structure relative to the surrounding background tissue [33].
• Tumor-to-Background Ratio (TBR): A specific application of SBR for oncology studies, critical for evaluating the efficacy of targeted agents [2].
• Adapted Contrast-to-Noise Ratio (aCNR): An advanced metric that evaluates the visibility of a target (e.g., a tumor margin) by considering both the contrast and the noise in the image. It is particularly useful for assessing image quality in clinical samples [2].

This application note provides a detailed protocol for setting up instrumentation, preparing animal models, and administering fluorophores for in vivo NIR fluorescence imaging. By following this standardized methodology and adhering to rigorous reporting guidelines like REFLECT [19], researchers can generate reliable, reproducible, and quantitatively robust data to advance drug development and molecular imaging research.

Targeted molecular imaging represents a paradigm shift in biomedical science, enabling the non-invasive visualization of cellular and molecular processes in living organisms. Framed within a broader thesis on in vivo near-infrared (NIR) fluorescence imaging, this document provides detailed application notes and protocols for visualizing three critical biological targets: protease activity, hydroxyapatite deposition, and steroid hormone receptors. These protocols leverage the advantages of NIR optical imaging—including deep tissue penetration, minimal autofluorescence, and high spatial resolution—to provide researchers with robust tools for investigating disease mechanisms, tracking treatment efficacy, and advancing drug development [35] [36].

Experimental Principles and NIR Imaging Windows

Near-Infrared Fluorescence Imaging Fundamentals

Near-infrared fluorescence imaging operates primarily within two biological windows: NIR-I (700-900 nm) and NIR-II (1000-1700 nm). The NIR-II window, particularly the 1000-1350 nm range, offers superior performance due to significantly reduced tissue scattering and autofluorescence, enabling deeper tissue penetration (up to several centimeters) and micron-level resolution [36] [30]. Recent investigations have explored wavelengths beyond 1880 nm, discovering that controlled water absorption can preferentially deplete background signals from scattered photons, further enhancing image contrast [37].

Molecular Design Strategies for NIR Probes

Advanced NIR probes are engineered through strategic molecular design:

• Donor-Acceptor-Donor (D-A-D) architectures feature an electron-accepting core (e.g., benzobisthiadiazole) symmetrically connected to electron-donating units, enabling precise tuning of absorption/emission profiles through HOMO-LUMO gap manipulation [30].
• Cyanine derivatives utilize polymethine chains with heterocyclic termini; their optical properties can be red-shifted by vinylene bond elongation [35].
• Activity-based probes (ABPs) covalently bind to enzyme active sites, enabling precise localization of enzymatic activity [38] [39].
• Activatable "smart" probes employ fluorescence resonance energy transfer (FRET) mechanisms, where protease cleavage separates fluorophore-quencher pairs, generating a detectable signal only at the disease site [39].

Protocol 1: Imaging Hydroxyapatite Deposition in Cardiovascular Tissues

Background and Principle

Cardiovascular calcification involves the pathological deposition of hydroxyapatite (HA), a crystalline calcium phosphate compound, in vascular tissues. This protocol utilizes Cy-HABP-19, a near-infrared optical molecular imaging contrast dye derived from an osteocalcin-mimetic peptide that specifically targets hydroxyapatite with high selectivity over other calcium salts [40].

Reagents and Equipment

Table 1: Key Reagents for Hydroxyapatite Imaging

Reagent/Equipment	Specification/Source	Function/Application
Cy-HABP-19 probe	Cy5.5-labeled HABP-19 peptide (10 μM stock)	Selective hydroxyapatite binding
Control probes	FITC, cHABP	Specificity controls
Human aortic VSMCs	Genlantis	In vitro calcification model
Osteogenic medium	SMCGM + 50 μg/ml AA + 7.5 mM β-GP + 10 nM LPC	Induces mineralization
Nanoshuttle-PL	n3D Biosciences	Magnetic suspension culture
Alizarin Red S	Sigma-Aldrich	Histological calcium detection
Fluorescence microscope	With NIR-capable camera	Imaging and analysis

Detailed Experimental Workflow

Step 1: Induction of Mineralization in VSMCs

• Culture human aortic vascular smooth muscle cells (VSMCs) at 1.5 × 10⁴ cells per cm² in smooth muscle cell growth medium (SMCGM).
• For experimental groups, replace medium with osteogenic stimulating medium (SMCGM supplemented with 50 μg/ml ascorbic acid, 7.5 mM β-glycerophosphate, and 10 nM L-α-lyso-phosphatidylcholine).
• For advanced 3D culture models, treat cells with Nanoshuttle-PL for 8 hours, then apply magnetic levitation using a magnetic drive. Culture in control or stimulating media for 4 days.
• Replace culture medium with fresh medium every 2 days.
• Define the first day of culture in stimulating media as day 0.

Step 2: Staining and Detection

• Wash cell monolayers with PBS and fix in formalin.
• For quantitative assessment of mineralization, perform Alizarin Red S (ARS) staining (pH 4.2) followed by extraction with 10% acetic acid and neutralization with ammonium hydroxide. Measure absorbance at 405 nm.
• For hydroxyapatite-specific detection, incubate samples with 2 nmol of Cy-HABP-19 probe at room temperature for 60 minutes.
• Include control groups stained with FITC-labeled HABP-19, cHABP (control peptide), and FITC dye alone.
• Wash extensively with PBS to remove unincorporated probes.

Step 3: Imaging and Analysis

• Image samples using a NIR fluorescence microscope with appropriate filter sets for Cy5.5 (excitation/emission maxima ~675/694 nm).
• For ex vivo tissue imaging (carotid endarterectomy samples, resected aortic valves), follow the same staining and washing procedure.
• Quantify fluorescence intensity using image analysis software (e.g., ImageJ) and correlate with ARS staining data.

Key Technical Considerations

• The Cy-HABP-19 probe demonstrates high binding affinity for hydroxyapatite with minimal binding to other calcium salts (calcium carbonate, calcium oxalate, calcium phosphate, calcium pyrophosphate).
• Magnetic suspension culture enhances osteogenic differentiation and more accurately mimics the 3D microenvironment of vascular tissues.
• This protocol enables detection of early-stage hydroxyapatite deposition before macroscopic calcification becomes apparent, providing a sensitive tool for studying initial pathophysiological changes in cardiovascular diseases [40].

Protocol 2: Visualizing Protease Activity in Cancer Models

Background and Principle

Proteases, including cathepsins and matrix metalloproteinases (MMPs), are overexpressed in the tumor microenvironment and facilitate invasion and metastasis. This protocol employs quenched activity-based probes (qABPs) that become fluorescent upon covalent modification by active proteases, enabling real-time visualization of protease activity in live cells and animal models [38] [39].

Reagents and Equipment

Table 2: Essential Reagents for Protease Activity Imaging

Reagent/Equipment	Specification	Function/Application
qABP library	Various fluorophore-warhead combinations	Broad-spectrum protease detection
Cathepsin-specific qABPs	BMV109-based probes	Specific cysteine cathepsin imaging
NIRF fluorophores	Cy5.5, IR-783 derivatives	In vivo compatible detection
Tumor cell lines	HT-1080, MCF-7, MDA-MB-231	Cancer models
Fluorescence microscope	With live-cell capability	Dynamic imaging
In vivo imaging system	NIR-II capable	Whole-body imaging

Detailed Experimental Workflow

Step 1: Probe Design and Selection

• Select appropriate warhead based on protease class: epoxides for cysteine proteases, phosphonates for serine proteases.
• Conjugate to NIR fluorophore (e.g., Cy5.5) via flexible linker.
• Incorporate quencher on leaving group for quenched ABPs (qABPs).
• Validate probe specificity against recombinant proteases in vitro.

Step 2: In Vitro Imaging in Live Cells

• Culture tumor cells (e.g., HT-1080 fibrosarcoma, MCF-7 breast cancer) in appropriate medium.
• Incubate cells with 1-5 μM qABP in serum-free medium for 1-2 hours at 37°C.
• Wash cells with PBS to remove excess probe.
• Image immediately using fluorescence microscopy or flow cytometry.
• For time-course studies, image cells at regular intervals over 24 hours.

Step 3: In Vivo Imaging in Tumor Models

• Establish subcutaneous or orthotopic tumor models in immunocompromised mice.
• Administer NIRF-labeled qABP intravenously (2-5 nmol in 100-200 μL PBS) when tumors reach 5-8 mm diameter.
• Perform serial imaging at 0, 4, 24, and 48 hours post-injection using NIR-II imaging systems.
• For optimal NIR-II imaging, use spectral unmasking techniques to separate specific signal from background.
• After terminal imaging, excise tumors and process for histological validation.

Step 4: Image Analysis and Validation

• Quantify fluorescence intensity in regions of interest (tumor vs. background).
• Calculate signal-to-background ratios across time points.
• Correlate fluorescence with immunohistochemical staining for specific proteases.
• Use fluorescence-mediated tomography (FMT) for three-dimensional reconstruction of protease activity distribution.

Key Technical Considerations

• qABPs provide "always-on" fluorescence upon protease binding, enabling precise localization but requiring thorough washing to reduce background signal.
• The modular design allows customization for different protease families by varying the warhead chemistry.
• NIR-II imaging (1000-1700 nm) significantly improves signal-to-background ratio compared to NIR-I for deep-tumor imaging [39] [30].
• These probes can be used to monitor treatment response to protease inhibitors in preclinical models.

Protocol 3: Detection of Estrogen and Progesterone Receptors in Breast Cancer

Background and Principle

Estrogen receptor (ER) and progesterone receptor (PR) status are critical biomarkers in breast cancer management, determining eligibility for endocrine therapies. This protocol utilizes a genetically encoded reporter system where ER/PR binding to engineered response elements drives expression of near-infrared fluorescent proteins, enabling non-invasive detection of functional steroid receptor status [41].

Reagents and Equipment

Table 3: Key Components for ER/PR Reporter System

Component	Specification	Function/Application
p(ERE)2-(PRE)2-iRFP713	Plasmid with double response elements	ER/PR-activated NIR reporter
pGL3-Promoter vector	Backbone for construct	Contains SV40 promoter
iRFP713 protein	Far-red/NIR fluorescent protein	Reporter with 713 nm emission
Cationic polymer	In vivo-jetPEI	Non-viral delivery vector
Breast cancer cells	MCF-7, BT-474, ZR-75-1 (ER/PR+); MDA-MB-231 (ER/PR-)	Validation models
NIR imaging system	iRFP713-compatible	In vivo detection

Detailed Experimental Workflow

Step 1: Reporter Construct Preparation

• Engineer the p(ERE)2-(PRE)2-iRFP713 plasmid by inserting double estrogen response elements (ERE) and double progesterone response elements (PRE) with auxiliary sequences into the pGL3-Promoter vector upstream of the iRFP713 gene.
• Verify construct sequence by restriction digest and sequencing.
• Prepare endotoxin-free plasmid DNA using maxiprep kits.

Step 2: In Vitro Validation and Imaging

• Culture ER/PR-positive (MCF-7, BT-474, ZR-75-1) and ER/PR-negative (MDA-MB-231) breast cancer cells in appropriate medium.
• Transfect cells with p(ERE)2-(PRE)2-iRFP713 using Lipofectamine 2000 according to manufacturer's protocol.
• Include control groups transfected with empty vector and single response element constructs.
• After 48 hours incubation, image cells using a NIR fluorescence microscope with appropriate filter sets for iRFP713.
• Quantify fluorescence intensity using image analysis software.

Step 3: In Vivo Imaging in Murine Models

• Establish subcutaneous tumor xenografts using ER/PR-positive and negative cell lines in immunocompromised mice.
• When tumors reach 5-7 mm diameter, prepare transfection complex by mixing 10 μg p(ERE)2-(PRE)2-iRFP713 plasmid with in vivo-jetPEI cationic polymer according to manufacturer's instructions.
• Administer transfection complex via direct intratumoral injection (50 μL total volume).
• Perform NIR fluorescence imaging at 24, 48, 72, and 96 hours post-transfection using an in vivo imaging system.
• Quantify tumor-associated fluorescence intensity and compare between ER/PR-positive and negative models.

Step 4: Validation and Analysis

• After terminal imaging, excise tumors and process for histology.
• Perform immunohistochemical staining for ERα and PR on consecutive sections.
• Correlate fluorescence intensity with ER/PR protein expression levels.
• Confirm specificity by comparing with bioluminescence imaging using luciferase reporter constructs.

Key Technical Considerations

• The double response element design ((ERE)2-(PRE)2) demonstrates significantly higher sensitivity than single elements, with 2.22-12.2-fold increased signal depending on cell type [41].
• Direct intratumoral delivery of the reporter system avoids potential biosafety concerns associated with viral vectors.
• The iRFP713 reporter (emission ~713 nm) provides deeper tissue penetration compared to visible fluorescent proteins while minimizing autofluorescence.
• This system reports functional receptor activity rather than mere protein presence, potentially providing more clinically relevant information.

The Scientist's Toolkit: Essential Research Reagents

Table 4: Core Reagent Solutions for Targeted Molecular Imaging

Reagent Category	Specific Examples	Key Function	Application Notes
Hydroxyapatite Binders	Cy-HABP-19, FITC-HABP-19	Selective hydroxyapatite detection in calcified tissues	Distinguishes HA from other calcium salts; enables early calcification detection [40]
Activity-Based Protease Probes	qABPs with Cy5.5, BMV109 derivatives	Covalent labeling of active proteases	Warhead determines protease specificity; quencher provides activation mechanism [38] [39]
NIR-II Organic Fluorophores	D-A-D scaffolds, cyanine derivatives, BODIPY analogs	Deep-tissue imaging with high resolution	Emission 1000-1350 nm optimal; D-A-D design enables spectral tuning [30]
Molecular Reporter Systems	p(ERE)2-(PRE)2-iRFP713, pGL3-Promoter	Detection of functional transcription factor activity	Double response elements enhance sensitivity; iRFP713 enables deep-tissue imaging [41]
Contrast Agents for Advanced Windows	PbS/CdS quantum dots, IR-783 derivatives	Imaging in 1880-2080 nm window	Bright probes overcome water absorption; enable high-contrast imaging [37]

The protocols detailed herein provide robust methodologies for visualizing critical molecular targets in disease processes, with particular emphasis on NIR fluorescence imaging approaches. As the field advances, several emerging trends warrant attention: the continued development of NIR-II and beyond imaging windows (1700-2080 nm) offers unprecedented contrast for deep-tissue imaging [36] [37]; multifunctional theranostic probes that combine imaging with therapeutic payloads represent a promising frontier for personalized medicine; and the integration of optical imaging with other modalities (MRI, PET, CT) through multimodal probes will provide complementary anatomical and functional information.

These targeted molecular imaging protocols not only facilitate basic research into disease mechanisms but also accelerate drug development by enabling non-invasive monitoring of treatment response and disease progression. As probe design evolves toward greater specificity and sensitivity, these techniques will increasingly bridge the gap between preclinical research and clinical application, ultimately improving patient care through precision medicine approaches.

In vivo near-infrared (NIR) fluorescence imaging has emerged as a powerful modality for real-time investigation of biological processes, offering significant advantages for preclinical research in vascular biology, tissue perfusion, and central nervous system (CNS) drug discovery [42] [43]. This non-invasive technique provides high spatial and temporal resolution, enabling researchers to visualize dynamic physiological events with exceptional clarity. The technology operates on the principle that light in the near-infrared spectrum (700-1700 nm) experiences reduced scattering and absorption by biological tissues compared to visible light, allowing for deeper tissue penetration and enhanced image clarity [43]. The recent expansion into the second near-infrared window (NIR-II, 1000-1700 nm) has been particularly transformative, offering superior performance for deep-tissue imaging with minimal autofluorescence background [16] [43].

Fluorescence imaging relies on exogenous contrast agents that accumulate in target tissues and emit light upon excitation. These fluorophores can be designed to circulate within the vasculature, extravasate into specific tissues, or target molecular biomarkers, making them exceptionally versatile for various research applications [43] [30]. The ongoing development of novel NIR fluorophores with improved brightness, stability, and biocompatibility continues to expand the potential applications of this technology in drug discovery and development pipelines [42] [30].

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful implementation of NIR fluorescence imaging protocols requires specific reagents and equipment. The table below outlines the core components of a complete NIR imaging workflow.

Table 1: Essential Research Reagents and Equipment for NIR Fluorescence Imaging

Category	Specific Examples	Function and Application Notes
NIR-I Fluorophores	Indocyanine Green (ICG), 5-aminolevulinic acid metabolites	FDA-approved agents for clinical and preclinical angiography, tissue perfusion, and tumor delineation [19] [43].
NIR-II Fluorophores	LZ-1105 (organic dye), PbS/CdS Quantum Dots, single-walled carbon nanotubes (SWNTs)	High-resolution vascular and anatomical imaging; offers superior spatial resolution and deeper tissue penetration than NIR-I [44] [16] [45].
Targeted Molecular Probes	Antibody- or peptide-conjugated fluorophores (e.g., Erbitux@IR-FGP)	Enable visualization of specific molecular targets (e.g., EGFR) for precision imaging of tumor biomarkers [3] [30].
Imaging Instrumentation	InGaAs cameras, FOBI imaging system	Specialized detectors sensitive to NIR-II light; essential for capturing emitted fluorescence signals [44] [12].
Optical Filters	Long-pass emission filters (e.g., 1300 nm, 1400 nm LP)	Isolate specific emission bands (e.g., NIR-IIa, NIR-IIb) to optimize signal-to-background ratio [44] [45].
Analysis Software	ImageJ, custom PCA algorithms	For quantification of fluorescence intensity, signal-to-background ratio (SBR), and vascular dynamics [12] [45].

NIR Imaging Windows: Characteristics and Applications

The choice of imaging window is critical for experimental design, as it directly impacts penetration depth, spatial resolution, and image contrast. The following table compares the key properties of different spectral windows used in fluorescence bioimaging.

Table 2: Comparison of Optical Imaging Windows for In Vivo Fluorescence Imaging

Imaging Window	Wavelength Range	Key Characteristics	Ideal Applications
NIR-I	700-900 nm	Moderate scattering and autofluorescence; limited penetration depth (< 1 cm) [43] [30].	Clinical image-guided surgery using FDA-approved dyes like ICG [43].
NIR-II	1000-1700 nm	Reduced scattering, minimal autofluorescence; deeper penetration and higher resolution than NIR-I [43] [3].	High-resolution anatomical and dynamic vascular imaging [44] [45].
NIR-IIa	1300-1400 nm	A sub-window of NIR-II with favorable balance of scattering and water absorption [16].	Deep-tissue imaging of vasculature and organs [16].
NIR-IIb	1500-1700 nm	Very low scattering and virtually no autofluorescence; offers exceptional spatial resolution [44] [43].	Microvascular imaging with sub-10 µm resolution [44].
NIR-IIx	1400-1500 nm	Region near water absorption peak; high contrast due to preferential absorption of scattered photons [16].	High-contrast imaging in scenarios with significant background interference [16].
1880-2080 nm	1880-2080 nm	High water absorption leveraged for contrast; requires very bright probes [16].	Experimental high-contrast imaging, particularly in adipose tissue [16].

Workflow for NIR Fluorescence Imaging Experiment

The following diagram illustrates the generalized workflow for conducting an in vivo NIR fluorescence imaging experiment, from probe preparation to data analysis.

Protocol 1: High-Resolution Vascular Imaging and Hemodynamic Analysis

This protocol details the procedure for non-invasive, real-time imaging of vascular architecture and blood flow dynamics in murine models using NIR-II fluorophores.

Materials and Reagents

• Fluorophore: LZ-1105 organic dye (5 mg/kg) or PbS/CdS quantum dots (5 mg/mL, 200 μL) [44] [45]
• Animals: Healthy nude mice or ICR mice (for brain/limb imaging)
• Imaging System: NIR-II imaging setup with InGaAs camera and 1064 nm laser excitation
• Optical Filters: 1400 nm long-pass filter for LZ-1105 [45]
• Analysis Software: ImageJ for intensity measurements; custom PCA algorithms for artery-vein separation [12] [45]

Step-by-Step Procedure

• Animal Preparation: Anesthetize mouse using approved anesthetic (e.g., isoflurane). Secure animal in supine position on heated imaging stage to maintain body temperature during procedure.
• System Setup: Configure NIR-II imaging system with appropriate filter (1400 nm LP for LZ-1105). Set camera acquisition parameters (frame rate: 50-100 ms for dynamic imaging) [45].
• Baseline Imaging: Acquate pre-injection background image using identical acquisition parameters.
• Fluorophore Administration: Administer LZ-1105 (5 mg/kg) or PbS/CdS QDs via tail vein injection using 30-gauge needle [44] [45].
• Image Acquisition: Initiate continuous video acquisition immediately after injection. For cerebral vasculature, position animal for dorsal head imaging. For hindlimb vasculature, position for lateral limb imaging.
• Time-Series Imaging: Capture static images at defined intervals post-injection (1 min, 5 min, 30 min, 1 h, 2 h, 4 h) to assess circulation longevity [45].
• Data Processing:
  • Subtract background fluorescence from all images.

• Calculate signal-to-background ratio (SBR) as: SBR = (Signal_Region - Background_Region) / Background_Region [45].
• Measure vessel diameter using Gaussian-fitted full width at half maximum (FWHM) of cross-sectional fluorescence intensity profiles [44].
• Apply principal component analysis (PCA) to time-series data to differentiate arterial and venous flow patterns [44].

Data Interpretation

• Vascular Resolution: Higher quality NIR-IIb agents (e.g., PbS/CdS) enable visualization of ~36 μm wide tiny blood vessels, surpassing capabilities of NIR-I imaging [44] [45].
• Circulation Longevity: LZ-1105 provides vascular visualization for up to 4 hours post-injection (SBR > 5.0), enabling long-term monitoring of dynamic processes [45].
• Hemodynamic Assessment: Blood flow velocity can be quantified by tracking fluorescence front movement between two points in a vessel [45].

Protocol 2: Quantitative Tissue Perfusion Imaging in Peripheral Arterial Disease Models

This protocol describes the application of NIR-II imaging for monitoring tissue perfusion recovery in a murine model of hindlimb ischemia, relevant for studying peripheral arterial disease (PAD).

Materials and Reagents

• Disease Model: Mouse model of PAD (hindlimb ischemia induced by femoral artery ligation) [44]
• Fluorophore: PbS/CdS quantum dots (200 μL, 5 mg/mL) or LZ-1105 (5 mg/kg) [44] [45]
• Imaging System: NIR-IIb imaging setup (1500-1700 nm window) with InGaAs camera
• Analysis Software: ImageJ with Time Series Analyzer plugin

Step-by-Step Procedure

• Model Preparation: Surgically induce unilateral hindlimb ischemia following established surgical protocols. Allow 24 hours for recovery before initial imaging [44].
• Imaging Setup: Position anesthetized mouse ventral side up on warming stage. Align both hindlimbs symmetrically within imaging field.
• Contrast Administration: Inject PbS/CdS QDs or LZ-1105 via tail vein [44] [45].
• Image Acquisition: Capture fluorescence images of both ischemic and contralateral control limbs at designated time points post-surgery (e.g., days 0, 3, 7, 10, 14) [44].
• Perfusion Quantification:
  • Define regions of interest (ROIs) encompassing entire plantar surface of both hindlimbs.

• Measure mean fluorescence intensity in both ischemic (Iischemic) and control (Icontrol) limbs.
• Calculate perfusion ratio as: Perfusion Ratio = I_ischemic / I_control.
• Monitor changes in microvascular density by quantifying number of visible vessel branches in NIR-IIb images over time [44].

Data Interpretation

• Perfusion Recovery: Significant improvement in hindlimb blood perfusion can be detected over 10-day recovery period (p < 0.05) [44].
• Microvascular Density: NIR-IIb imaging reveals significant increase in microvascular density over first 7 days after PAD induction, indicating active angiogenesis [44].
• Validation: Compare perfusion measurements with laser Doppler imaging as reference standard.

Protocol 3: CNS Drug Discovery Applications – Blood-Brain Barrier Integrity Assessment

This protocol utilizes NIR-II fluorescence imaging to monitor blood-brain barrier (BBB) opening and recovery, a crucial application in CNS drug discovery for assessing delivery of therapeutic agents.

Materials and Reagents

• Fluorophore: LZ-1105 (5 mg/kg) or other long-circulating NIR-II probes [45]
• BBB Modulation: Mannitol (for osmotic BBB disruption) or focused ultrasound with microbubbles
• Imaging System: NIR-II imaging setup with high-sensitivity InGaAs camera
• Surgical Equipment: Stereotaxic frame for precise agent delivery (if required)

Step-by-Step Procedure

• Animal Preparation: Anesthetize mouse and secure in stereotaxic frame. Remove hair from scalp using depilatory cream.
• Baseline Imaging: Acquire pre-treatment NIR-II images of cerebral vasculature through intact skull [45].
• BBB Modulation: Apply chosen BBB opening technique (e.g., intracarotid mannitol infusion or focused ultrasound with microbubbles).
• Contrast Administration: Inject LZ-1105 (5 mg/kg) intravenously immediately after BBB modulation [45].
• Image Acquisition: Capture sequential NIR-II images of brain vasculature at 5, 15, 30, 60, 120, and 180 minutes post-injection.
• Data Analysis:
  • Quantify extravasation by measuring fluorescence signal in parenchymal regions outside visible vasculature.

• Normalize signal to baseline pre-treatment images.
• Calculate permeability coefficient based on fluorescence accumulation kinetics.

Data Interpretation

• BBB Integrity: Intact BBB shows minimal parenchymal fluorescence, while BBB disruption results in significant signal extravasation.
• Recovery Kinetics: Sequential imaging allows monitoring of BBB closure over time, with LZ-1105 enabling continuous assessment due to its long circulation half-life (3.2 h) [45].
• Therapeutic Assessment: Method enables evaluation of BBB-modifying agents for improved CNS drug delivery.

Signaling Pathways in CNS Drug Discovery

The following diagram illustrates key biological pathways and mechanisms relevant to CNS drug discovery that can be investigated using NIR-II fluorescence imaging.

Advanced Applications and Future Directions

The development of NIR fluorescence imaging continues to evolve with emerging capabilities that further enhance its utility in biomedical research. Multiplexed imaging approaches enable simultaneous visualization of multiple biological targets using fluorophores with non-overlapping emission bands, allowing researchers to detect different tumor subtypes or physiological processes in a single imaging session [43]. Furthermore, the exploration of extended NIR windows beyond 1880 nm, previously disregarded due to strong water absorption, now shows promise for high-contrast imaging as evidenced by recent work demonstrating exceptional performance in the 1880-2080 nm window when using sufficiently bright probes [16].

The clinical translation of NIR imaging continues to progress, with NIR-II fluorescence-guided surgery already demonstrated in patient studies for liver cancer [30]. For CNS applications, the combination of NIR imaging with other modalities such as MRI and PET in hybrid imaging systems offers complementary structural and functional information, presenting a powerful approach for advancing drug discovery research [42] [43]. These technological advances, coupled with the development of increasingly sophisticated molecular probes, promise to further expand the capabilities of in vivo fluorescence imaging for anatomical and functional analysis in preclinical research and clinical applications.

Sentinel lymph node (SLN) biopsy is a critical procedure for staging cancers, such as breast cancer, in patients with clinically negative lymph nodes. The current clinical gold standard often employs a combination of a radiotracer (e.g., Technetium-99m) and a blue dye (e.g., patent blue). However, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has emerged as a powerful adjunct, demonstrating superior identification rates and the potential to reveal metastatic nodes missed by conventional techniques [46]. This protocol details a clinical workflow for integrating NIR fluorescence with radiotracers to enhance the accuracy and efficiency of SLN mapping.

Quantitative Performance of SLN Mapping Tracers

The efficacy of SLN mapping hinges on the choice of tracer. A systematic review of 34 studies encompassing 12,157 identified SLNs revealed that combination tracers consistently outperform single agents. The table below summarizes the detection accuracy of various tracer combinations [47].

Table 1: Detection Accuracy of Tracer Combinations for SLN Mapping

Tracer Combination	Identification Rate (%)	Number of Studies
ICG + Tc-99 + Patent Blue	100%	4
Methylene/Patent Blue + ICG + Tc-99	100%	1
Isosulfan Blue + ICG	100%	1
Isosulfan Blue + ICG + Tc-99	100%	1
Vital Blue + Tc-99	100%	1
ICG + Tc-99	99.47%	9
ICG + Patent Blue	99.36%	5
ICG + Methylene Blue	99.0%	11
ICG alone	96.32%	16
Methylene Blue + Tc-99	96.79%	5

A separate multicenter clinical trial with 95 breast cancer patients further validated the integration of NIR fluorescence. The study reported a 99% successful SLN identification rate using a combination of NIR fluorescence and radioactive guidance. The procedure led to the resection of 177 SLNs, with the following ex vivo detection rates [46]:

• NIR Fluorescence: 100%
• Radioactive: 88%
• Blue Dye (in a subset of 40 nodes): 78%

Critically, in 2.1% of patients (2/95), SLNs containing macrometastases were identified only by NIR fluorescence, underscoring its value in reducing false negatives and improving cancer staging [46].

Integrated Clinical Workflow

The following diagram and protocol outline the integrated workflow for SLN mapping using NIR fluorescence and radiotracers.

Detailed Experimental Protocol

Objective: To intraoperatively identify and resect SLNs in breast cancer patients using a combination of NIR fluorescence and radiotracer guidance.

I. Materials and Reagent Preparation

Table 2: Research Reagent Solutions for Integrated SLN Mapping

Item	Function / Description	Preparation Notes
Indocyanine Green (ICG)	NIR fluorescent tracer for real-time visualization of lymphatics and SLNs [46].	Resuspend 25 mg vial in 10 mL sterile water to create 2.5 mg/mL (3.2 mM) stock. Dilute to 0.5 mM (0.39 mg/mL) working concentration.
99mTechnetium-colloid	Radioactive tracer for pre-operative lymphoscintigraphy and intraoperative gamma probe detection.	Prepared and administered per institutional nuclear medicine protocol.
Patent Blue or Isosulfan Blue (Optional)	Visual blue dye for adjunctive SLN identification.	Use per institutional guidelines; may be omitted when NIR/radioactive guidance is used [46].
NIR Fluorescence Imaging System	Enables real-time visualization of ICG fluorescence.	Systems like Mini-FLARE provide simultaneous display of color video and NIR fluorescence. Ensure sterile draping for intraoperative use [46].
Handheld Gamma Probe	Detects radioactivity from 99mTechnetium for SLN localization.	Standard equipment for SLN biopsy procedures.

II. Pre-operative Procedures (Day of/Defore Surgery)

• Radiotracer Injection: Administer 99mTechnetium-colloid (e.g., ~100 MBq for lymphoscintigraphy or ~0.8 mCi subareolarly 1-3 hours pre-op) as per standard institutional protocol [46].
• Lymphoscintigraphy: Perform imaging to map general drainage patterns, if part of the standard workflow.

III. Intraoperative Procedures

• ICG Injection: Immediately before surgery, inject a total of 1.6 mL of 0.5 mM ICG intradermally and periareolarly (or peritumorally) in multiple deposits [46]. Gently massage the injection site to facilitate lymphatic drainage.
• Equipment Setup: Position the sterile-draped NIR imaging system approximately 30 cm over the surgical field. Adjust camera exposure times between 5-500 ms for optimal signal [46].
• Percutaneous Mapping: Before incision, inspect the axilla with the NIR imaging system to identify the path of fluorescent lymphatic channels and the approximate location of SLNs.
• Incision and SLN Identification:
  • Make a standard axillary incision.
  • Use the NIR imaging system for real-time, visual guidance to dissect along the fluorescent lymphatic channels.
  • Simultaneously, use the handheld gamma probe to locate areas of elevated radioactivity.
• SLN Resection Criterion: Resect all lymph nodes that are either [46]:
  • NIR Fluorescent (in-situ Signal-to-Background Ratio, SBR ≥ 1.1), and/or
  • Radioactive (ex-vivo counts are more than 10% of the SLN with the highest radioactive count).
• Ex Vivo Confirmation: After resection, use the NIR imaging system and gamma probe to confirm the fluorescent and radioactive signatures of each resected SLN.

IV. Post-operative Analysis

• Submit all resected SLNs for routine histopathological analysis according to standard clinical guidelines.

Discussion and Clinical Impact

Integrating NIR fluorescence with the radiotracer-based gold standard creates a synergistic SLN mapping workflow. NIR fluorescence provides superior real-time visual guidance of lymphatic channels, which can facilitate smaller incisions and more precise dissection [46]. This is particularly valuable for surgeons early in their learning curve. The high sensitivity of ICG, as evidenced by its 100% ex vivo detection rate and ability to identify metastatic nodes missed by other modalities, can potentially reduce false-negative rates and improve patient staging [46] [47].

This protocol aligns with the 2025 SAGES guidelines, which recommend the use of fluorescence imaging with ICG for intra-operative lymph node identification in gastrointestinal cancers, highlighting its growing acceptance as a surgical adjunct [6]. For the broader thesis on in vivo NIR imaging, this clinical workflow exemplifies a successful translation where standardized protocols and tracer formulation are critical for reproducible and effective outcomes [19].

Multimodal phototheranostics represents a significant advancement in cancer treatment, integrating multiple diagnostic and therapeutic functions into a unified platform. This approach simultaneously employs optical imaging techniques—such as fluorescence imaging (FLI), photoacoustic imaging (PAI), and photothermal imaging (PTI)—with phototherapies, including photodynamic therapy (PDT) and photothermal therapy (PTT) [48] [49]. Compared to traditional cancer treatments like surgery, chemotherapy, and radiotherapy, multimodal phototheranostics offers substantial benefits: it is minimally invasive, provides precise spatiotemporal control, induces negligible drug resistance, and leverages synergistic effects between treatment modalities for outstanding diagnostic and therapeutic performance [49]. The second near-infrared window (NIR-II, 1000–1700 nm) is particularly advantageous for these applications. When compared to the visible spectrum and the first near-infrared window (NIR-I, 700–900 nm), NIR-II light experiences reduced scattering, diminished tissue autofluorescence, and deeper tissue penetration, leading to superior imaging contrast and more effective treatment of deep-seated tumors [50] [48]. The development of "one-for-all" organic molecules that combine all these functionalities within a single chemical entity is a key research focus, promising well-defined structures, tunable properties, and high reproducibility [48] [49].

Molecular Design of NIR-II Organic Agents

Fundamental Design Strategies and Engineering

The creation of high-performance NIR-II organic phototheranostic agents relies on strategic molecular engineering to optimize optical properties and balance excited-state energy dissipation.

• Donor-Acceptor-Donor (D-π-A-π-D) Architecture: A predominant design strategy involves constructing molecules with a strong electron-acceptor (A) core flanked by electron-donor (D) units, connected via π-bridges (π). This structure promotes intramolecular charge transfer, effectively narrowing the energy bandgap and resulting in redshifted absorption and emission into the NIR-II region [48] [49]. For instance, the molecule CTBA utilizes cyclopenta[2,1-b:3,4-b′]dithiophene (CPDT) as the donor and benzo[c][1,2,5]thiadiazole-5,6-diamine as the acceptor, forming a D–π–A–π–D system [50].

• Multi-dimensional Donor Engineering: This advanced protocol optimizes donor design at multiple levels. At the molecular level, it fine-tunes donor-acceptor strength to achieve an optimal balance between absorption/emission wavelengths and intrinsic non-radiative decay. At the aggregated state level, it controls molecular conformation to alter stacking modes and enhance fluorescence quantum yields. At the solvent-interaction level, it introduces bulky hydrophobic groups to minimize quenching interactions with water molecules, significantly boosting fluorescence brightness in aqueous environments [49]. An example is the AIEgen OPITBT, which incorporates a modified diphenylamine indeno[1,2-b]thiophene donor to achieve a 21-fold fluorescence enhancement in nanoparticles [49].

• Conformational Locking via Non-covalent Interactions: Incorporating intramolecular non-covalent interactions, such as S···N and S···O locks, enhances molecular planarity and rigidity. This strategy reduces energy loss through non-radiative pathways, extends π-conjugation, and can lead to bathochromic shifts and improved photothermal conversion efficiency (PCE) [51]. The molecule IR-FDHT employs this approach, achieving a high PCE of 52.5% [51].

• Aggregation-Induced Emission (AIE): AIE luminogens (AIEgens) are designed with twisted, propeller-like structures that exhibit weak emission in solution but brighten significantly in the aggregated state due to the restriction of intramolecular motions (RIM) [48]. This mechanism provides a versatile platform for balancing radiative (fluorescence) and non-radiative (heat/ROS) energy dissipation pathways, making AIEgens ideal for "one-for-all" multimodal phototheranostics [48] [49].

Activatable Probes for Enhanced Specificity

To overcome the limitations of "always-on" agents, which can cause off-target effects and high background signals, activatable probes are designed for tumor-specific activation. A prominent example is the probe CTBA, which is activated by nitric oxide (NO), a signaling molecule overexpressed in the tumor microenvironment [50]. Upon reaction with NO, the electron acceptor in CTBA is converted into a triazole derivative (CTBT) with stronger electron-withdrawing ability. This transformation induces a dramatic red-shift in both absorption and emission, "turning on" NIR-II fluorescence, photodynamic, and photothermal capabilities specifically at the tumor site, thereby improving diagnostic accuracy and treatment safety [50].

Table 1: Key NIR-II Organic Molecules and Their Optimized Properties

Molecule Name	Molecular Structure	Key Engineering Strategy	Emission (nm)	PCE (%)	ROS Generation
CTBT [50]	D–π–A–π–D	NO-activated conversion	800-1200	High	Yes (Type II)
OTTITQ [48]	D–π–A–π–D	AIE + ITQ Acceptor	NIR-II	High	Yes (Type I)
OPITBT [49]	D–A–D	Multi-dimensional Donor Engineering	NIR-II	Excellent	Yes (Type I)
IR-FDHT [51]	D–A–D	S···N/S···O Conformational Lock	NIR-II	52.5	N/A

Experimental Protocols for Nanoparticle Preparation and Characterization

Nanoparticle Formulation and Surface Functionalization

Most organic NIR-II molecules are hydrophobic and require nanoformulation for biological application. The standard method is nanoprecipitation or self-assembly with amphiphilic block copolymers.

Protocol: Preparation of Targeted Nanoparticles (NPs)

• Materials:
  • Organic NIR-II molecule (e.g., CTBA, OTTITQ, OPITBT, IR-FDHT).
  • Amphiphilic copolymer (e.g., PS1000–PEG2000, DSPE-PEG2000, DSPE-PEG2000-cRGDfk).
  • Organic solvent (e.g., Tetrahydrofuran, THF).
  • Deionized water.
  • Laboratory equipment: Ultrasonic bath, probe sonicator, magnetic stirrer, dialysis tubing.

• Method: a. Stock Solution Preparation: Dissolve the organic NIR-II molecule and the amphiphilic polymer in THF at a specific mass ratio (e.g., 1:5 for CTBA and PS1000–PEG2000 [50]). b. Nanoprecipitation: Rapidly inject the THF solution (e.g., 1 mL) into deionized water (e.g., 10 mL) under vigorous stirring or sonication. c. Solvent Removal: Stir the mixture for several hours to allow complete evaporation of THF, or remove the organic solvent via dialysis against deionized water for 12-24 hours. d. Purification: Filter the resulting nanoparticle suspension through a 0.22 µm filter to remove aggregates and obtain a clear colloid. e. Targeting Functionalization: For active tumor targeting, use PEG chains pre-conjugated with targeting ligands (e.g., cRGDfk peptides for αvβ3 integrin targeting [49] or SP94 peptides for targeting hepatocellular carcinoma [51]) during the self-assembly process.

Photophysical and Photothermal Characterization

Comprehensive characterization is essential to validate the performance of the developed NPs.

Protocol: Characterizing NIR-II Probes

• Spectroscopic Analysis:
  • UV-vis-NIR Absorption: Measure the absorption spectrum of the NP solution to determine the peak absorption wavelength and molar extinction coefficient.
  • NIR-II Fluorescence: Acquire fluorescence emission spectra under NIR excitation (e.g., 808 nm) using a spectrometer equipped with an InGaAs detector. Calculate the fluorescence quantum yield (QY) using a reference dye [49].

• Photothermal Performance Evaluation: a. Temperature Measurement: Irradiate an NP solution of a standard concentration (e.g., 100 µg/mL) with an NIR laser (808 nm or 1064 nm) at a specified power density (e.g., 0.5-1.0 W/cm²). Monitor the temperature change over time with a thermocouple or thermal camera [50] [51]. b. Photothermal Conversion Efficiency (PCE) Calculation: Calculate the PCE (η) using the established formula [52]: * η = (hS × ΔTmax - QDis)/(I × (1 - 10^(-Aλ))) * Where *h* is the heat transfer coefficient, *S* is the surface area of the container, *ΔTmax* is the maximum temperature change, Q_Dis is the heat dissipation from the solvent and container, I is the laser power, and A_λ is the absorbance at the laser wavelength.

• Reactive Oxygen Species (ROS) Detection:

  • Use commercial probe-based assays. For example, incubate NPs with Singlet Oxygen Green (SOSG) for Type II ROS or Dihydroethidium (DHE) for Type I ROS/superoxide generation.
  • Irradiate the solution with an NIR laser and monitor the fluorescence increase of the ROS-sensitive probe over time [48].

Diagram 1: Workflow for nanoparticle preparation and characterization.

In Vitro and In Vivo Application Protocols

Cell Culture and In Vitro Validation

Protocol: In Vitro Phototherapy and Imaging

• Cell Seeding: Seed cancer cells (e.g., 4T1, MCF-7) in culture plates and incubate until 70-80% confluency.
• NP Incubation: Replace the medium with a fresh one containing the NIR-II NPs at a predetermined concentration. Incubate for several hours (e.g., 4-6 h) to allow cellular uptake.
• NIR-II Fluorescence Imaging: Wash cells to remove excess NPs. Image using an NIR-II fluorescence microscope with an 808 nm laser excitation and an InGaAs camera to confirm cellular uptake and localization [48].
• In Vitro Phototherapy: a. Laser Irradiation: Irradiate cells with an NIR laser (808 nm) at a safe power density (e.g., 0.5-1.0 W/cm²) for 10 minutes. b. Viability Assessment: Post-irradiation, assess cell viability using standard assays like MTT or Calcein-AM/PI staining after a further 12-24 hour incubation. Compare viability between laser-treated groups (PTT/PDT) and control groups (no NPs, no laser, NPs only, laser only) [50] [51].

Animal Model and In Vivo Theranostics

Protocol: In Vivo Imaging-Guided Phototherapy

• Tumor Model: Subcutaneously inject cancer cells into the flank of mice (e.g., BALB/c mice) to establish a xenograft model.
• NP Administration: Intravenously inject the NP formulation (e.g., 100-200 µL of 1 mg/mL solution) via the tail vein when tumor volume reaches ~100 mm³.
• In Vivo Multimodal Imaging: a. NIR-II FLI: At various time points post-injection, anesthetize the mouse and acquire NIR-II fluorescence images using an in vivo imaging system. Monitor the accumulation of NPs in the tumor via the enhanced permeability and retention (EPR) effect or active targeting [49]. b. Photoacoustic Imaging (PAI): Use a PA imaging system to map the distribution of NPs within the tumor based on their optical absorption, providing complementary depth information [48] [49].
• Image-Guided Phototherapy: Once the NP signal in the tumor reaches its peak (e.g., 24 h post-injection), irradiate the tumor region with an NIR laser (808 nm, 0.5-1.0 W/cm²) for 10-15 minutes. Monitor the tumor surface temperature in real-time with a thermal camera to ensure it reaches the therapeutic range (e.g., 45-55°C) [50] [51].
• Efficacy and Biosafety Evaluation: a. Tumor Volume Monitoring: Measure tumor dimensions and body weight every 2-3 days post-treatment to evaluate therapeutic efficacy and systemic toxicity. b. Histological Analysis: At the endpoint, harvest major organs and tumors for histological staining (e.g., H&E, TUNEL) to assess tumor apoptosis and any potential organ damage [49].

Table 2: Summary of Key In Vivo Phototherapy Parameters from Literature

Molecule / NPs	Laser Parameters	Therapeutic Modality	In Vivo Model	Key Outcome
CTBA-NPs [50]	808 nm, 0.8 W/cm², 10 min	Synergistic PDT/PTT	4T1 tumor-bearing mice	Precise tumor ablation with minimal background damage
OTTITQ NPs [48]	808 nm laser	PDT/PTT Synergistic Therapy	Bladder cancer model	Effective tumor eradication via trimodal imaging guidance
OPITBT-R NPs [49]	808 nm laser	PDT/PTT Synergistic Therapy	Orthotopic breast cancer	High-resolution NIR-IIb vascular imaging & cancer elimination
FDHT-SP94-Fc NPs [51]	1064 nm laser	Mild HPTT/Enhanced CDT	Hepatocellular carcinoma (HCC)	Synergistic antitumor effect with high specificity and safety

Diagram 2: In vivo workflow for imaging-guided synergistic phototherapy.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents and Materials for NIR-II Theranostics Research

Item Category	Specific Examples	Function/Purpose
NIR-II Organic Molecules	CTBA [50], OTTITQ [48], OPITBT [49], IR-FDHT [51]	Core phototheranostic agents providing NIR-II fluorescence, photothermal, and photodynamic activities.
Amphiphilic Polymers for Nanoformulation	PS1000–PEG2000 [50], DSPE-PEG2000, DSPE-PEG2000-cRGDfk [49], SP94-PEG-Fc [51]	Enable nanoparticle self-assembly in water, improve biocompatibility, prolong circulation, and confer active tumor targeting.
Laser Systems	808 nm diode laser, 1064 nm NIR laser [51]	Light source for exciting NIR-II probes to induce fluorescence, generate heat for PTT, and produce ROS for PDT.
In Vivo Imaging Systems	NIR-II Fluorescence Imager (e.g., with InGaAs camera) [49], Photoacoustic Imaging System [48] [49], Thermal Camera [50]	For non-invasive, real-time monitoring of NP biodistribution, tumor accumulation, and temperature during PTT.
Cell Viability Assays	MTT, Calcein-AM/PI Staining [50]	To quantitatively and qualitatively assess phototherapeutic efficacy in vitro.
ROS Detection Kits	Singlet Oxygen Green (SOSG), Dihydroethidium (DHE) [48]	To detect and quantify the generation of reactive oxygen species during PDT.

Achieving High-Fidelity Data: A Practical Guide to Optimization and Problem-Solving

In the realm of in vivo near-infrared (NIR) fluorescence imaging, achieving a high signal-to-background ratio (SBR) is paramount for obtaining clear, interpretable data. The fundamental challenge lies in managing how light interacts with biological tissues—specifically through the processes of photon absorption and scattering. Strategic control of these phenomena enables researchers to significantly enhance image contrast, improve detection sensitivity, and obtain more accurate quantitative results in preclinical and drug development research.

The second near-infrared window (NIR-II, 900-1880 nm) and the newly proposed NIR-III window (2080-2340 nm) offer superior imaging performance compared to traditional NIR-I imaging. This is largely due to reduced photon scattering and the strategic utilization of light absorption by tissue components like water to suppress background signals [53]. This document provides detailed application notes and protocols, framed within a broader thesis on in vivo NIR fluorescence imaging, to guide researchers in maximizing SBR through advanced methods.

Theoretical Foundation: Light-Tissue Interaction and SBR

The quality of a fluorescence image is determined by the ballistic photons that travel directly from the emission source to the detector, carrying accurate spatial information, and is degraded by the multiply scattered photons that create a diffuse background [53]. The SBR and spatial resolution are thus directly influenced by the optical properties of the tissue.

The Dual Role of Light Absorption

While often viewed as a detrimental process that attenuates signal, light absorption can be harnessed to improve SBR. Monte Carlo simulations demonstrate that a moderate increase in the absorption coefficient (μa) can preferentially deplete the longer-path, multiply scattered photons, which contribute to background, while having a lesser impact on the shorter-path ballistic photons that constitute the signal [53]. This leads to a narrower point spread function and a significant increase in SBR, enhancing spatial resolution and image contrast.

The Advantage of Reduced Scattering

The reduced scattering coefficient (μs') of biological tissue generally decreases at longer NIR wavelengths. This reduction means photons are less likely to be deflected from their original path, allowing more ballistic photons to reach the detector and preserving the fidelity of the spatial information from the fluorescence source [53]. The combined effect of reduced scattering and strategic absorption defines the optimal imaging windows.

Table 1: Defined Near-Infrared Imaging Windows and Their Characteristics

Imaging Window	Wavelength Range (nm)	Key Characteristics	Impact on SBR
NIR-I	760 - 900	Traditional window; higher scattering & autofluorescence [54].	Lower SBR due to significant background.
NIR-II	900 - 1880	Less scattering; includes regions near water absorption peaks [53].	High SBR and spatial resolution.
⋯ NIR-IIa	900 - 1400	Encompasses the ~980 nm and ~1200 nm water absorption peaks.	Improved SBR via absorption-based background suppression.
⋯ NIR-IIb	1500 - 1700	Previously considered the "clear" window with low scattering [53].	High SBR, though potentially less than NIR-IIx.
⋯ NIR-IIx	1400 - 1500	Sits atop a strong water absorption peak at ~1450 nm [53].	Potentially superior SBR due to strong background photon rejection.
⋯ NIR-IIc	1700 - 1880	Similar properties to NIR-IIb, but with higher water absorption [53].	High SBR, comparable to NIR-IIb.
NIR-III	2080 - 2340	Very high water absorption; demands very bright fluorophores [53].	Theoretically the best performance, but technically challenging.

Diagram 1: Pathways to Maximize SBR in NIR Imaging. Strategic control (green arrow) enhances signal, while suppression strategies (red arrow) minimize background.

Practical Strategies and Protocols for SBR Enhancement

Protocol: Dual-Tracer Background Subtraction for Targeted Imaging

This protocol uses an untargeted tracer to model and subtract nonspecific background fluorescence, directly revealing bound, targeted signal [55].

Principle: The fluorescence distribution of a targeted tracer ((xT)) can be decomposed into bound ((x{bound})), unbound background ((x{bk})), and autofluorescence ((x{af})) components. An untargeted tracer ((xU)) with similar delivery kinetics exhibits only background ((x{bk,u})) and autofluorescence ((x{af,u})) components. Assuming the backgrounds are proportional ((x{bk} = c \cdot x{bk,u})) and autofluorescence is negligible, the bound signal can be isolated as: ( \bar{J} x{bound} = dT - c \cdot dU ), where (dT) and (dU) are the measured data for the targeted and untargeted tracers, respectively [55].

Materials:

• Targeted Tracer: e.g., anti-EGFR antibody-conjugated fluorescent nanoparticles [56].
• Untargeted Tracer: A fluorescent tracer with similar hydrodynamic size and surface chemistry but no targeting moiety.
• Imaging System: A fluorescence molecular tomography (FMT) or similar system capable of multi-wavelength detection [55] [56].

Procedure:

• Tracer Administration: Simultaneously inject a mixture of the targeted and untargeted tracers intravenously into the animal model. The injected doses should be calibrated based on the quantum yields and system sensitivity at each wavelength.
• Image Acquisition: At the desired time point post-injection, acquire fluorescence images at both the targeted and untargeted tracer emission wavelengths. Ensure identical animal positioning and imaging geometry.
• Scaling Factor Calculation: Identify a region in the acquired image where the bound targeted signal is expected to be negligible (e.g., muscle tissue). Calculate the scaling coefficient (c) such that (c \cdot dU \leq 0.1 \cdot dT) in this region [55].
• Background Subtraction: Perform the subtraction (d{corrected} = dT - c \cdot d_U) on a pixel-by-pixel or region-of-interest basis.
• Image Reconstruction: Use the corrected data vector (d{corrected}) for subsequent FMT reconstruction to generate a 3D map of the bound targeted tracer, (x{bound}).

Protocol: Adaptive Background Fluorescence Subtraction

This method estimates and subtracts heterogeneous background fluorescence from a single image, without a second tracer, by leveraging the distribution of excitation light [56].

Principle: The background fluorescence emanating from homogeneous baseline fluorophores is modelled as the product of a weighting coefficient and the distribution of excitation light transmitting through the tissue. The weighting coefficient is calculated using a linear minimum mean square error estimation, and an adaptive mask is applied to selectively refine the subtraction and avoid over-subtraction in target regions [56].

Materials:

• Fluorescent Nanoparticles (FNPs): e.g., PLGA-based nanoparticles, either passively or actively targeted [56].
• Multi-Modality Imaging System: e.g., a CT-FMT system where CT provides anatomical information for 3D mesh construction [56].

Procedure:

• Image Acquisition: Acquire the fluorescence image of the animal following FNP administration. Acquire a CT scan for anatomical context.
• Excitation Light Modelling: Using the anatomical data from CT and known optical properties, simulate the distribution of excitation light ((I_{ex})) within the tissue.
• Background Estimation: Model the background fluorescence as (F{bg} = \beta \cdot I{ex}), where the coefficient (\beta) is estimated to minimize the mean square error between the model and the measured fluorescence in regions known to contain only background.
• Adaptive Masking: Create a binary mask to exclude areas with high expected target fluorescence (e.g., the tumor region identified from CT) from the background estimation process to prevent signal corruption.
• Subtraction: Subtract the estimated background (F_{bg}) from the original fluorescence image to generate a background-corrected image with enhanced tumor contrast.

Strategic Wavelength Selection: NIR-IIx and Long-Pass Detection

Simulations and experiments confirm that imaging in specific wavelength regions near water absorption peaks (e.g., NIR-IIx, 1400-1500 nm) provides superior SBR and resolution compared to the NIR-IIb window [53]. Furthermore, for bright fluorophores with emission peaks below 1400 nm but a bright emission tail, using a 1400 nm long-pass (LP) filter can yield better performance than restricting collection to the NIR-IIb window (1500-1700 nm) [53].

Protocol for Window Optimization:

• Fluorophore Selection: Select a fluorophore with a tunable or tailing emission that extends into the NIR-IIx region (e.g., PbS/CdS core-shell quantum dots with emission at ~1450 nm) [53].
• Comparative Imaging: Image the same subject using different spectral filters (e.g., 1000 nm LP, 1400 nm LP, and 1500 nm LP).
• Quantitative Analysis: Calculate and compare the SBR and spatial resolution (e.g., Full Width at Half Maximum, FWHM) for each detection window. The 1400 nm LP detection is expected to outperform 1500 nm LP (NIR-IIb) due to the beneficial absorption effects in the NIR-IIx region [53].

Table 2: Comparison of Background Subtraction and Suppression Techniques

Technique	Underlying Principle	Key Advantage	Key Limitation
Dual-Tracer Subtraction [55]	Uses untargeted tracer to model & subtract nonspecific background.	Effective for heterogeneous background from nonspecific tracer uptake.	Requires administration of two tracers; assumes similar pharmacokinetics.
Adaptive Background Subtraction [56]	Estimates background from excitation light distribution in a single image.	No need for a second tracer; adapts to optical heterogeneity.	Relies on accurate modelling of excitation light and may be less effective if background is highly irregular.
NIR-II/x/c Window Imaging [53]	Uses tissue properties (reduced scattering, water absorption) to inherently suppress background.	Fundamental improvement; no complex processing; enhances resolution.	Requires specialized detectors and bright fluorophores for absorptive windows.
Homogeneous Background Subtraction [55]	Subtracts a simulated homogeneous fluorescence background.	Simple to implement; no extra data acquisition.	Fails if background is highly heterogeneous, leading to inaccurate subtraction.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Reagents and Materials for High-SBR NIR Imaging

Item	Function/Description	Application in SBR Maximization
Indocyanine Green (ICG) [54]	FDA-approved, non-targeted NIR fluorophore (Ex/Em ~805/830 nm).	Passive targeting via EPR effect; baseline for comparison and lymphatic mapping.
Targeted Nanoparticles (e.g., PLGA-anti-EGFR) [56]	Polymeric nanoparticles conjugated with targeting ligands (e.g., antibodies).	Active tumor targeting increases specific signal accumulation, enhancing SBR.
PbS/CdS Core-Shell QDs [53]	Quantum dots with tunable emission into NIR-IIx region.	Enables exploitation of low-scattering, high-absorption NIR-IIx window for superior SBR.
Ion Gel [57]	A polymer matrix confining a strongly conducting liquid.	Used in electrostatic doping devices to control Fermi energy in materials like graphene, useful for fundamental studies of scattering pathways.
Near-Infrared Fluorescence Microscopy [53]	Microscopy systems equipped with InGaAs detectors sensitive beyond 1000 nm.	Essential for capturing fluorescence in the NIR-II, NIR-IIx, and longer windows.
Multi-Modality Imaging Platform (e.g., CT-FMT) [56]	Integrated system combining computed tomography (CT) and fluorescence molecular tomography (FMT).	Provides anatomical context for accurate background modelling and image reconstruction.

Diagram 2: Integrated Workflow for a Targeted, High-SBR Imaging Experiment. This combines probe design, biological delivery, and data processing strategies.

In vivo near-infrared (NIR) fluorescence imaging represents a powerful tool for biomedical research and drug development, enabling non-invasive visualization of biological processes with high sensitivity and superior spatial resolution [58]. However, the illumination required to excite fluorophores can lead to phototoxicity and photobleaching, which adversely affect living samples and compromise data quality [59]. This application note provides a comprehensive framework for optimizing excitation power and exposure time to minimize these detrimental effects while maintaining high-quality imaging data. The protocols outlined herein are particularly crucial for longitudinal studies where maintaining cell viability and signal integrity over extended periods is paramount for generating reliable results in drug discovery applications.

Core Principles of Photodamage

Phototoxicity and Photobleaching Mechanisms

Photodamage in fluorescence microscopy manifests through two primary mechanisms: phototoxicity and photobleaching. Phototoxicity, which applies exclusively to live-cell imaging, occurs when cellular molecules or excited fluorophores react with oxygen to produce reactive oxygen species (ROS). These ROS subsequently oxidize biomolecules including DNA and proteins, causing irreparable cellular damage [60]. Photobleaching affects both fixed and live samples, resulting in gradual signal loss as fluorophores in the triplet excited state absorb sufficient energy to break covalent bonds, permanently damaging their chemical structure [60].

A fundamental relationship exists between excitation intensity and exposure time, creating a critical trade-off that researchers must navigate. While high laser powers can speed up data acquisition, they dramatically reduce image quality by decreasing both localization precision and effective labeling efficiency [61]. Evidence indicates that for single molecule localization microscopy (SMLM), fast imaging with high excitation intensity can decrease photon counts per localization by a factor of 10, resulting in three-fold deteriorated localization precision and 8-fold deteriorated resolution [61].

Quantitative Optimization Guidelines

Parameter Optimization Tables

Table 1: Impact of Excitation Intensity on SMLM Image Quality Parameters

Excitation Intensity	Photon Count per Localization	Localization Precision	Effective Labeling Efficiency	Recommended Application
Low	High (Reference)	Optimal (Reference)	High (65%)	High-resolution fixed cell imaging
Medium	Decreased by ~5x	Deteriorated by ~2x	Reduced by ~1.5x	Live-cell dynamic processes
High	Decreased by ~10x	Deteriorated by ~3x	Reduced by ~3x	High-throughput screening

Table 2: Optimized Imaging Conditions for Different Fluorophore Classes

Fluorophore Class	Optimal Excitation Intensity	Exposure Time Range	Special Considerations
Organic dyes (AF647)	Low (for highest quality)	Medium to long	Avoid high-power initial off-switching
CF660C	Low to high	Short to long	High photostability; suitable for 3D and whole-cell imaging
Green/Yellow FPs	≤100 W/cm²	Medium	Responsive to NIR co-illumination
Red FPs	Variable	Medium	Complex response to NIR co-illumination

Determining Optimal Exposure Time

The optimal exposure time should be determined based on specific experimental goals:

• For quantitative intensity comparisons: Set exposure time using the sample with brightest expected signal, utilizing the full dynamic range of the camera without saturating any pixels [62].
• For live-cell imaging: Sacrifice some signal intensity by using shorter exposure times to maintain cell health, setting exposure time just long enough to detect structures of interest [62].
• For dynamic processes: Determine the maximum acceptable exposure time based on the temporal dynamics of the biological process being studied [59].

Advanced Technical Strategies

Minimizing Illumination Overhead

"Illumination overhead" refers to the time when fluorescent samples are exposed to incident light but fluorescence emission is not being collected by the detector [59]. This unnecessary exposure contributes significantly to photodamage without generating useful data. To minimize illumination overhead:

• Implement fast-switching LED illumination systems with transistor-transistor logic (TTL) circuits to synchronize illumination with camera acquisition [59]
• Utilize global TTL-in features on LED systems for direct camera synchronization, achieving triggering speeds as fast as <7 μs [60]
• Avoid high-intensity initial off-switching in SMLM, which can bleach up to half of fluorophores before single-molecule detection begins [61]

Near-Infrared Co-illumination

A novel approach to reducing photobleaching and phototoxicity involves NIR co-illumination at approximately 900 nm during fluorophore excitation. This technique exploits a photophysical process called reverse intersystem crossing (RISC), where NIR light excites fluorophores from their lowest triplet state to a higher triplet state, from which they transition back to singlet excited states before relaxing to the ground state [63] [64].

Table 3: NIR Co-illumination Effectiveness Across Fluorophore Types

Fluorophore Type	RP Effect	Optimal NIR Wavelength	NIR Intensity
EGFP	3.5x	900 nm	2 kW/cm²
YPet	1.5-9.2x	885 nm	0.8 kW/cm²
Other green/yellow FPs	1.5-9.2x	800-1000 nm	0.5-2 kW/cm²
ECFP	No effect	N/A	N/A
Red FPs	Complex response	Variable	Variable

Implementation of NIR co-illumination can be achieved through modification of standard epifluorescence illuminators to integrate an 885-nm laser diode, achieving NIR co-illumination of 0.8 kW/cm² over the same field as visible excitation [64]. This approach substantially reduces phototoxicity, as demonstrated by restored normal growth rates in YPet-labeled bacteria and improved migration in primary mouse neutrophils expressing LifeAct-GFP [64].

Experimental Protocols

Workflow for Optimization of Live-Cell Imaging Conditions

Diagram Title: Live-Cell Imaging Optimization Workflow

Protocol 1: Systematic Optimization of Imaging Parameters

Purpose: To establish the optimal balance between excitation power and exposure time for specific experimental conditions.

Materials:

• Live cells expressing fluorescent reporter or stained with fluorescent dye
• Inverted fluorescence microscope with controllable illumination system
• Environmental chamber maintained at 37°C and 5% CO₂
• Culture medium appropriate for cell type (e.g., Brainphys Imaging medium for neurons [65])

Procedure:

• Determine maximum exposure time: Calculate based on the temporal dynamics of your biological process. For rapid processes, shorter exposure times are necessary [59].
• Set initial imaging parameters:
  • Begin with the lowest possible excitation intensity that yields detectable signal
  • Use exposure time that utilizes most of the camera's dynamic range without saturation [62]
• Implement illumination control:
  • Activate TTL synchronization between camera and illumination source
  • Ensure illumination is only active during camera exposure [60]
• Assess cell health:
  • Include mitochondrial markers or other viability indicators in assay [59]
  • Monitor cell behavior for signs of phototoxicity (e.g., altered migration [64])
• Iterative optimization:
  • If signal-to-noise ratio is insufficient, gradually increase exposure time before increasing excitation intensity
  • If phototoxicity is observed, reduce exposure time and/or excitation intensity
  • For green and yellow FPs, implement NIR co-illumination at 800-1000 nm [63]

Protocol 2: Whole-Cell 3D SMLM with Minimal Photodamage

Purpose: To acquire high-quality super-resolution data of entire cells while maintaining fluorophore integrity.

Materials:

• CF660C dye or similar photostable fluorophore [61]
• Glucose oxidase/catalase imaging buffer with MEA [61]
• Tightly sealed imaging chamber to prevent buffer acidification [61]
• Microscope capable of 3D SMLM with astigmatism

Procedure:

• Sample preparation:
  • Label cells with CF660C using appropriate tagging approach (SNAP-tag, nanobody, or antibody)
  • Mount samples in glucose oxidase/catalase blinking buffer
  • Seal chamber to exclude air bubbles, preserving buffer pH for >24 hours [61]
• Initial off-switching:
  • Use low-intensity illumination (not high power) to push fluorophores into dark state
  • High-power initial switching bleaches up to 50% of fluorophores [61]
• Image acquisition:
  • Use medium to low excitation intensity to maximize photon counts and localization precision
  • Step through multiple z-positions for 3D imaging
  • Acquire up to 1 million frames for complete cell coverage [61]
• Data analysis:
  • Merge localizations persistent over consecutive frames
  • Calculate photon counts per localization and effective labeling efficiency

Research Reagent Solutions

Table 4: Essential Reagents for Minimizing Photodamage

Reagent/Material	Function	Application Examples
CF660C dye	High-photostability fluorophore	Long-duration SMLM, whole-cell 3D imaging [61]
Brainphys Imaging medium	Rich antioxidant profile, omits reactive components	Long-term neuronal imaging, reduces ROS [65]
Glucose oxidase/catalase buffer	Oxygen-depleting blinking buffer	dSTORM, single-molecule imaging [61]
Human-derived laminin	Extracellular matrix supporting neuronal health	Improves neuron viability under phototoxic stress [65]
MEA/BME reducing agents	Triplet state quenchers	Blinking buffers for SMLM [61]

Optimizing the balance between excitation power and exposure time requires a systematic approach that considers the specific requirements of each experiment. The protocols outlined in this application note provide a roadmap for minimizing phototoxicity and photobleaching while maintaining data quality, particularly for in vivo NIR fluorescence imaging applications in drug development research. By implementing these strategies—including careful parameter optimization, minimization of illumination overhead, utilization of NIR co-illumination where appropriate, and selection of optimal reagents—researchers can significantly extend the viability of live samples and the quality of acquired data, leading to more reliable and reproducible results in preclinical studies.

In vivo near-infrared (NIR) fluorescence imaging enables researchers to visualize molecular processes, track cellular activity, and monitor disease progression in live subjects. The quality of this data hinges on effectively capturing the full spectrum of fluorescence signals, which often exceeds the native dynamic range of conventional imaging detectors. Biological samples frequently exhibit fluorescence intensity variations that span several orders of magnitude due to fluctuating protein expression or heterogeneous probe distribution, often resulting in regions of signal that are either saturated or obscured by background noise during single-exposure acquisitions [66]. High dynamic range (HDR) imaging techniques address this limitation by combining multiple exposures to preserve quantitative data across both bright and dim regions, thereby ensuring accurate cellular segmentation and quantification essential for rigorous preclinical research [66].

Fundamental Concepts and Terminology

Understanding Dynamic Range and Histograms

In fluorescence imaging, dynamic range refers to the ratio between the maximum and minimum detectable fluorescence intensities within a single acquisition. This range is ultimately constrained by the photodetector's physical limits, typically spanning several orders of magnitude [66]. While modern scientific cameras offer substantial bit depth (8-16 bits), the effective dynamic range available for accurate signal quantification is often reduced by background noise and signal saturation near the detector's maximum threshold [66].

The histogram provides a critical visual representation of pixel intensity distribution within an image. For NIR fluorescence data, histogram analysis enables researchers to:

• Identify the distribution of fluorescence signals across the field of view
• Detect saturation (intensities clustered at maximum value) or excessive noise (intensities clustered at minimum value)
• Determine optimal exposure settings and HDR fusion parameters
• Guide post-acquisition tone mapping to preserve quantitative information

Table 1: Key Terminology for HDR Fluorescence Imaging

Term	Definition	Importance in NIR Imaging
Dynamic Range	Ratio between maximum nonsaturated signal and minimum detectable signal above noise [66]	Determines the maximum range of detectable input fluorescence signal
Bit Depth	Number of bits used to represent pixel intensity (e.g., 12-bit = 4,096 intensity levels) [66]	Defines the maximum number of discrete intensity values that can be captured
Signal Saturation	When fluorescence intensity exceeds the detector's maximum recordable value	Causes information loss in bright regions; indicates need for reduced exposure or HDR
Noise Floor	The baseline signal level created by detector noise and background fluorescence	Sets the lower limit of detection; signals near this floor have poor signal-to-noise ratio
Tone Mapping	Transformation of HDR data to lower dynamic range for display [66]	Enables visualization of extended dynamic range data on standard monitors

The HDR Imaging Workflow

The process of capturing high dynamic range fluorescence images follows a structured pipeline that transforms multiple low dynamic range acquisitions into a single, quantitatively superior image. This workflow ensures that the final reconstructed image preserves information across the entire intensity spectrum present in biological samples.

Experimental Protocols for HDR NIR Imaging

Multi-Exposure HDR Acquisition Protocol

This protocol describes a standardized approach for acquiring HDR fluorescence image data through sequential exposure bracketing, suitable for both confocal and two-photon microscopy systems [66].

Materials and Equipment:

• NIR fluorescence imaging system (confocal, two-photon, or wide-field)
• Fluorescent phantom or labeled biological specimen
• Data acquisition software with manual control of exposure parameters

Procedure:

• System Calibration
  • Characterize the detector's response function prior to experimentation using a reference standard [66]
  • Ensure stable excitation power output throughout the acquisition sequence
  • Set the detector to its maximum bit depth (e.g., 16-bit) to preserve intensity resolution

• Exposure Parameter Determination

  • Acquire a test image at intermediate exposure to assess the approximate signal range
  • Analyze the image histogram to identify saturation points and noise levels
  • Define an exposure sequence that brackets the full signal dynamic range: Minimum exposure: No pixels should be saturated Maximum exposure: Dimmest features should be detectable above noise floor Intermediate exposures: 2-3 additional exposures spaced exponentially between extremes

• Multi-Exposure Acquisition

  • Acquire the sequence of N low dynamic range (LDR) images Iₙ with identical spatial registration
  • Maintain constant excitation wavelength and optical settings throughout
  • Vary only the integration time or laser power between acquisitions
  • For biological imaging, acquire sequences rapidly to minimize motion artifacts

• Data Storage

  • Save all LDR images in a raw, uncompressed format (e.g., TIFF)
  • Record all acquisition parameters (exposure times, laser powers, timestamps)
  • Document detector response characteristics for subsequent processing

Table 2: Example Multi-Exposure Sequence for HDR Fluorescence Imaging

Acquisition	Exposure Time	Laser Power (%)	Target Signal Characteristics	Primary Purpose
LDR₁	50 ms	10%	No saturation in brightest regions	Capture highlight detail
LDR₂	200 ms	30%	Optimal mid-range intensities	Preserve mid-tone data
LDR₃	800 ms	60%	Detectable signal in dimmest regions	Capture shadow detail
LDR₄	1500 ms	80%	Maximum signal in dim regions	Resolve faint features

HDR Image Fusion and Reconstruction Algorithm

The fusion process computationally combines the multi-exposure sequence into a single HDR image with extended dynamic range, following the acquisition phase.

Processing Workflow:

• Image Registration
  • Align all LDR images to correct for potential sample movement during sequential acquisition
  • Use sub-pixel registration algorithms for maximum precision

• Detector Response Correction

  • Apply the predetermined detector response function to linearize intensity values
  • Correct for any nonlinearities in the detector's response across its dynamic range [66]

• HDR Fusion Calculation

  • For each pixel position (i,j), compute the HDR value using a weighted average:
    • pHDR = Σₖ[Tₖ × w(pₖ)] / Σₖ[w(pₖ)]
    • where Tₖ represents the transformed pixel value from the k-th LDR image
    • and w(pₖ) is a weighting function that minimizes contribution from saturated or noisy pixels [66]

• HDR Image Generation

  • Iterate the fusion process across all pixel positions
  • Store the resulting HDR image in a 32-bit floating-point format to preserve extended dynamic range

Tone Mapping and Visualization Protocol

Following HDR reconstruction, this protocol enables effective visualization of the extended dynamic range data while preserving quantitative relationships.

Procedure:

• Global Tone Mapping
  • Apply a nonlinear transformation to compress the dynamic range for display
  • Use logarithmic or gamma correction functions:
    • IrHDR = Zmax × (IHDR/IHDRmax)γ
    • where Zmax is a rescaling factor, and γ is the compression parameter [66]

• Adaptive Histogram Equalization

  • Implement Contrast Limited Adaptive Histogram Equalization (CLAHE) to enhance local contrast
  • Divide the image into tiles and apply histogram equalization to each region
  • Use histogram clipping to prevent noise amplification [66]

• Validation and Quality Control

  • Compare tone-mapped images with original LDR acquisitions to verify information preservation
  • Ensure intensity relationships remain quantitatively valid for subsequent analysis
  • Document all tone mapping parameters for reproducibility

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Research Reagent Solutions for HDR NIR Fluorescence Imaging

Reagent/Material	Function	Example Applications	Notes
Indocyanine Green (ICG)	Non-targeted NIR fluorophore [67]	Vascular imaging, perfusion assessment [67]	FDA-approved; peak excitation ~780 nm, emission ~800 nm [68]
Targeted Molecular Probes	Agent binding to specific biomarkers [19]	Tumor margin detection, receptor visualization [67]	e.g., Panitumumab-IRDye800 (EGFR-targeted) [67]
ZW800-1C	Zwitterionic heptamethine fluorophore [69]	Imaging of amyloid-β aggregates and tau fibrils [69]	Binds protein aggregates with fluorescence lifetime shift [69]
NIR-II Fluorophores	Emission in 1000-1700 nm range [67]	Deep-tissue vascular imaging, tumor detection [67]	Superior penetration depth vs. NIR-I [67]
Tissue-Simulating Phantoms	System calibration and validation [68]	Performance testing, quantification standardization [68]	Fluorophore-doped phantoms with calibrated optical properties [68]

Implementation and Quality Control

System Performance Validation

Regular performance validation ensures consistent HDR imaging quality. Implement a standardized testing protocol using fluorescent phantoms to assess:

• Uniformity: Measure fluorescence intensity variation across the field of view
• Sensitivity: Determine the minimum detectable fluorophore concentration
• Linearity: Verify the relationship between fluorophore concentration and detected signal
• Spatial Resolution: Quantify the smallest resolvable features using resolution targets [68]

Integration with Fluorescence Lifetime Imaging

Combine HDR intensity imaging with fluorescence lifetime (FLT) measurements for enhanced molecular specificity. NIR FLT imaging can distinguish bound versus unbound states of targeted agents through lifetime shifts rather than intensity changes alone [69]. This combination is particularly valuable for:

• Differentiating specific binding from nonspecific accumulation
• Resolving multiple fluorophores with overlapping spectra but distinct lifetimes
• Quantifying microenvironmental parameters (pH, viscosity) that affect fluorescence decay

The relationship between image quality and quantitative accuracy demonstrates why proper camera settings and HDR techniques are essential for robust NIR fluorescence imaging. Following these standardized protocols enables researchers to capture the full dynamic range of fluorescence signals, minimize information loss, and generate quantitatively reliable data for preclinical studies and drug development applications.

Mitigating Noise and Enhancing Quantum Efficiency in Low-Light Conditions

In vivo near-infrared (NIR) fluorescence imaging represents a powerful modality for preclinical research, enabling non-invasive visualization of biological processes with high spatial and temporal resolution. However, its efficacy is fundamentally constrained by two interconnected challenges in low-light conditions: the pervasive influence of noise and the limited quantum efficiency of fluorophores and detection systems. Noise, originating from both biological tissues and instrumentation, obscures weak signals, while low fluorescence quantum efficiency (FQE) restricts available photon budgets. This Application Note details validated protocols for mitigating noise through quantum-inspired imaging techniques and enhancing signal acquisition via molecular engineering of NIR-II fluorophores, providing a framework for achieving high-fidelity imaging in demanding in vivo contexts.

Theoretical Foundations

In fluorescence microscopy, the imperfection of an image is characterized by the discrepancy between the true photon flux and the measured pixel value. The dominant noise sources are shot noise and detector noise [70]. Shot noise arises from the quantum nature of light, where the number of photons detected at a pixel follows a Poisson distribution, with a standard deviation equal to the square root of the signal. Detector noise, often modeled as additive Gaussian noise, is introduced by the camera electronics and is independent of the signal level [70]. In scientific CMOS (sCMOS) cameras, this is compounded by fixed-pattern noise, where each pixel possesses unique offset (βp) and gain (γp) characteristics, leading to pixel-to-pixel variability even under uniform illumination [71]. The resulting image (Zp) can be modeled as: ( Zp = \gamma _p{Pois}{ Sp( \tau ) } + N(0,\sigmaR) + \betap ) where Sp(τ) is the underlying signal, τ is exposure time, and N(0, σR) is the readout noise [71].

Fundamentals of Quantum Efficiency

The term "quantum efficiency" pertains to two distinct components in an imaging system:

• Detector Quantum Efficiency (QE): The ratio of detected photoelectrons to incident photons, determining the sensor's sensitivity.
• Fluorophore Fluorescence Quantum Efficiency (FQE): The ratio of photons emitted to photons absorbed by a fluorophore. In the NIR-II window (1000-1700 nm), achieving high FQE is particularly challenging because molecular engineering strategies that redshift emission often intensify non-radiative decay pathways, quenching fluorescence [72] [73].

Protocols for Noise Mitigation

Quantum Illumination for Background and Sensor Noise Rejection

This protocol leverages spatial correlations between entangled photon pairs to distinguish a true signal from background light and sensor noise, even under conditions of high loss and noise [74].

• Principle: A probe photon beam illuminates the object, while its entangled reference beam bypasses the object. Detection of a photon in the reference beam heralds the arrival of its correlated probe photon, allowing genuine correlation events to be distinguished from accidental noise correlations through a coincidence-counting algorithm [74].
• Workflow: The detailed experimental workflow is illustrated below.

• Key Materials:
  • Photon Source: A β-barium borate (BBO) non-linear crystal cut for type-II phase-matching, pumped by a 355 nm laser to generate spatially correlated photon pairs via spontaneous parametric down-conversion (SPDC) at 710 nm [74].
  • Filters: Interference filters (center 710 nm, 10 nm bandpass) to select degenerate photon pairs [74].
  • Detector: An Electron Multiplying CCD (EMCCD) array detector in the far-field image plane of the crystal, operated in a sparse-photon regime [74].
• Procedure:
  • Align the optical path so the probe and reference beams are relayed onto neighboring regions of the EMCCD.
  • Set the illumination level and EMCCD threshold such that each acquired frame contains sparsely populated single-photon detection events.
  • For each frame, perform a pixel-by-pixel AND-operation between the probe and reference beam regions to identify spatially correlated photon-pair events.
  • Sum all AND-events over a large number of frames (e.g., thousands) to construct the quantum illumination image.
  • Enhanced Protocol: To reject accidental correlations, use information from the classically acquired image (sum of all events) and the reference beam to subtract accidental AND-events from the quantum AND-image. This requires no prior information about the scene or noise statistics [74].
• Performance: This improved protocol can reject >99.9% of background light and sensor noise, improving the distinguishability ratio by up to a factor of 27 compared to the classical image [74].

Content-Adaptive sCMOS Noise Correction (ACsN)

This algorithmic protocol corrects for sCMOS-specific noise, enabling fast, low-light, quantitative microscopy [71].

• Principle: ACsN combines a physics-based camera model with layered sparse filtering. It first corrects fixed-pattern noise using calibration maps, then estimates the combined readout and shot noise variance, and finally applies collaborative filtering in space and time to denoise image sequences while preserving signal [71].
• Workflow:

• Key Materials:
  • Microscope System: A fluorescence microscope equipped with a modern sCMOS camera.
  • Software: Implementation of the ACsN algorithm [71].
  • Calibration Data: Pre-acquired maps of per-pixel offset (βp) and gain (γp) for the specific sCMOS camera and gain setting.
• Procedure:
  • Camera Calibration: Acquire offset and gain maps for your sCMOS camera. This is typically done by capturing multiple dark frames (for offset) and flat-field images at different illumination levels (for gain) [71].
  • Fixed-Pattern Correction: For each raw input image (Zp), apply the correction using the calibrated parameters to obtain a pattern-corrected image.
  • Noise Estimation: The algorithm automatically estimates the total noise variance (σN² = σR² + σG²) by analyzing the frequency content of the image outside the optical transfer function (OTF), where only noise is present [71].
  • Collaborative Filtering: The algorithm performs a two-stage spatial filter using the estimated σN:
    • First Pass: Groups similar 2D image patches into 3D stacks and applies a 3D transform with hard-thresholding.
    • Second Pass: Uses the result from the first pass to guide a Wiener filter on the same patch groups.
  • Temporal Filtering: For video data, a final collaborative filter groups similar patches across neighboring frames in time to further suppress lingering noise [71].
• Performance: ACsN provides robust noise correction down to 5–10 photons per pixel, reduces temporal noise fluctuations by approximately an order of magnitude, and maintains high performance across a range of sampling rates [71].

Protocols for Enhancing Quantum Efficiency

Molecular Engineering of NIR-II Organic Fluorophores

This protocol outlines the design and evaluation of small-molecule fluorophores with enhanced FQE for the NIR-II window, which is critical for deep-tissue imaging with high signal-to-background ratio (SBR) [30].

• Principle: The Donor-Acceptor-Donor (D-A-D) molecular architecture is a predominant design, where a strong electron-accepting (A) core is bridged by π-conjugated linkers to two electron-donating (D) units. This facilitates intramolecular charge transfer (ICT), narrowing the energy gap to produce NIR emission. The FQE is optimized by balancing the ICT strength to suppress non-radiative decay via molecular vibration [72] [73].
• Design Strategies for Enhanced FQE: The following table summarizes key molecular engineering strategies.

Table 1: Molecular Engineering Strategies for Enhancing NIR-II Fluorophore FQE

Strategy	Mechanism	Exemplary Implementation	Impact on Properties
Asymmetric D-A-D' Design [72]	Uses two different donors (D and D') to create two independent ICT pathways, balancing spectral shift and FQE.	Unilateral heteroatom substitution at the ortho-position in a D-A-D scaffold (e.g., Fluo 2').	Suppresses non-radiative decay rates, achieving optimal NIR-II emission and enhanced FQE [72].
Naphthyl-Substitution [73]	Replacing phenyl rings with larger, rigid naphthalene groups in the molecular skeleton.	β-position naphthalene substitution in a BBTD-based fluorophore (e.g., C1-βNaphth).	Increases adiabatic excitation energy and reduces vibration coupling, leading to a 4.2-fold FQE enhancement with efficient NIR-II emission [73].
Steric Shielding [30]	Incorporating bulky side groups to restrict molecular motion and inhibit twisted ICT (TICT).	Attachment of bulky substituents like cyclohexane or adamantane.	Suppresses non-radiative decay pathways, thereby increasing FQE and photostability [30].
Aggregation-Induced Emission (AIE) [30]	Designing molecules that are non-emissive in solution but highly emissive in aggregate state.	Utilizing tetraphenylethylene (TPE) as a donor unit.	Restricts intramolecular rotation in aggregates, turning on fluorescence and boosting FQE for nanoparticle-based imaging [30].

• Key Materials for Fluorophore Synthesis:
  • Common Acceptors: Benzobisthiadiazole (BBTD), [1,2,5]thiadiazolo[3,4-g]quinoxaline (TQ), thienothiadiazole (TTD) [30].
  • Common Donors: Triphenylamine (TPA), alkylfluorenes, tetraphenylethylene (TPE) [30].
  • Solvents & Reagents: Standard organic synthesis reagents and solvents for Suzuki or Stille coupling reactions, which are commonly used to construct D-A-D frameworks.
• Evaluation Protocol:
  • Photophysical Characterization: Measure absorption and emission spectra in the target solvent. Determine the fluorescence quantum yield (FQE) using a reference dye with a known quantum yield (e.g., IR-26 for NIR-II) [30].
  • Theoretical Validation: Use Density Functional Theory (DFT) and thermal vibration correlation function (TVCF) methods to calculate key parameters like HOMO-LUMO energy gap, adiabatic excitation energy, and internal conversion rates (kIC) to rationalize the enhanced FQE [73].
  • In Vivo Validation: Conjugate the fluorophore with a biocompatible polymer (e.g., PEGylation) and administer it to animal models. Use a NIR-II imaging system (e.g., with an InGaAs camera) to quantify performance metrics such as signal-to-background ratio (SBR) and penetration depth [53] [30].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 2: Key Reagents and Materials for Low-Light NIR Imaging

Item	Function/Description	Application Context
BBO Crystal (Type-II)	Non-linear crystal for generating entangled photon pairs via Spontaneous Parametric Down-Conversion (SPDC).	Quantum Illumination imaging [74].
NIR-II Organic Fluorophores (D-A-D)	Small-molecule dyes (e.g., CH1055 derivatives) with emission in 1000-1700 nm range.	In vivo bioimaging in the NIR-II window [30] [73].
EMCCD Camera	Detector with on-chip electron multiplication, enabling single-photon detection under low-light conditions.	Quantum imaging; ultra-low-light fluorescence microscopy [74].
sCMOS Camera	Scientific-grade CMOS camera offering high speed, large field of view, and low readout noise.	General fluorescence microscopy; requires algorithms like ACsN for noise correction [71].
IR-780 Dye	Lipophilic cationic heptamethine dye with peak emission ~800 nm; targets mitochondria in tumor cells.	NIR-I fluorescence imaging; tumor-targeting agent [33].
ESS65-Cl Dye	Phenoxazine derivative that targets gastric tissue, potentially via H+/K+ ATPase activation.	Dual-channel NIR imaging for visualizing normal gastric structures [33].
Lead Sulfide Quantum Dots (PbS QDs)	Inorganic nanoparticles with tunable NIR-II emission and high brightness.	NIR-IIb (1500-1700 nm) deep-tissue imaging [53].

For a typical in vivo study aiming for deep-tissue imaging with high contrast, an integrated workflow is recommended. Begin by selecting or synthesizing a high-FQE NIR-II fluorophore, such as an asymmetric D-A-D' or naphthyl-substituted dye, based on the target optical window (e.g., 1000-1350 nm for optimal depth) [53]. Upon administering the probe, employ a cooled sCMOS camera for acquisition and process the data stream with the ACsN algorithm to minimize instrumental noise. For the most challenging low-light scenarios, such as detecting sparse molecular targets or operating under ultra-low illumination to minimize phototoxicity, quantum illumination protocols can provide the ultimate sensitivity by fundamentally rejecting Poissonian noise [74].

The synergistic application of these protocols—leveraging advances in molecular engineering for brighter probes and in computational and quantum optics for cleaner detection—provides a comprehensive strategy to overcome the core challenges of low-light in vivo imaging. This multi-faceted approach enables researchers and drug development professionals to extract maximal information from precious biological samples, pushing the boundaries of observation in live subjects.

Fluorescence imaging in the near-infrared (NIR) windows, particularly the second NIR window (NIR-II, 900-1700 nm), has emerged as a powerful modality for preclinical research and drug development due to its superior tissue penetration, high spatial resolution, and reduced autofluorescence [75] [37] [36]. However, the accuracy and quantitative potential of this technology are frequently compromised by two pervasive classes of artifacts: probe aggregation and non-specific background signals. Aggregation-caused quenching (ACQ) can drastically reduce fluorescence brightness, while background signals diminish the signal-to-background ratio (SBR), ultimately limiting imaging sensitivity and reliability [76] [77] [78]. This Application Note delineates these common pitfalls and provides validated experimental protocols and solutions to mitigate them, ensuring the generation of robust, interpretable, and high-fidelity imaging data.

Understanding and Mitigating Probe Aggregation

The Molecular Basis of Aggregation-Caused Quenching (ACQ)

Probe aggregation is a fundamental challenge, particularly for fluorophores with extensive planar π-conjugated structures designed for long-wavelength emission. In aggregated states, such as in nanoparticle formulations for in vivo delivery, close intermolecular proximity facilitates non-radiative energy decay pathways. Recent research has elucidated that dimeric aggregates (dimers) play a critical role in this quenching process. For instance, in the ring-fused fluorophore 4F, spectral decomposition revealed that dimer populations constituted 64.3% of the aggregates and were responsible for the severe emission quenching observed, as dimers exhibit significantly weaker emission and more intense intermolecular non-radiative decay compared to monomers [76].

Table 1: Characterization of ACQ in a Model Fluorophore (4F)

State	Absorption Max (nm)	Emission Max (nm)	Quantum Yield (ΦPL)	Primary Species
Unimolecular (in THF)	~808	~940	17.1%	Monomer
Aggregated (Nanoparticle)	~850	~1050	2.6%	Dimer (64.3%)

Protocol: Alleviating ACQ via Aggregation Control

This protocol outlines a strategy to mitigate ACQ by manipulating the population of dimeric aggregates within nanoparticles, based on the work with the 4F fluorophore [76].

• Principle: By controlling the aggregation process during nanoparticle formulation, the ratio of weakly emissive dimers to highly emissive monomers can be reduced, leading to a significant boost in overall nanoparticle brightness.

• Materials:

  • Hydrophobic NIR fluorophore (e.g., 4F).
  • Amphiphilic copolymer (e.g., Pluronic F-127).
  • Tetrahydrofuran (THF), anhydrous.
  • Deionized water.
  • Probe sonicator.
  • Dynamic Light Scattering (DLS) instrument.
  • Spectrofluorometer.

• Procedure:

  • Dissolution: Dissolve the hydrophobic fluorophore and the amphiphilic polymer in a suitable organic solvent (e.g., THF) to form a homogeneous solution.
  • Nanoprecipitation: Introduce the organic solution into a vigorously stirred aqueous phase using a controlled method. A coaxial microfluidic mixer is recommended for superior reproducibility and control over the mixing process, which directly influences aggregation kinetics [78].
  • Solvent Removal: Remove the organic solvent under reduced pressure or via dialysis to form aqueous dispersions of fluorophore-loaded nanoparticles.
  • Purification: Purify the nanoparticles via centrifugation or filtration to remove large aggregates or unencapsulated dye.
  • Characterization:
    • Size and Morphology: Determine the hydrodynamic diameter and polydispersity index (PDI) using DLS. Confirm morphology using Transmission Electron Microscopy (TEM).
    • Optical Properties: Measure the absorption and emission spectra. Calculate the photoluminescence quantum yield (ΦPL) using a reference dye (e.g., IR-26 for NIR-II).
    • Brightness: Calculate the fluorescence brightness as the product of extinction coefficient (ε) and ΦPL.

• Expected Outcome: Successful implementation of this protocol should yield nanoparticles (e.g., 4F NP3s) with a higher monomer-to-dimer ratio and significantly enhanced brightness (e.g., 5-fold greater than indocyanine green) compared to nanoparticles formed by standard methods [76].

Alternative Strategy: Exploiting Assembly/Aggregation-Induced Retention (AIR)

Contrary to mitigating aggregation, certain probe designs can leverage controlled self-assembly at the target site to improve performance. For example, a probe targeting integrin αvβ3 (1FCG-FFGRGD) incorporates a self-assembling peptide sequence (FFG). Upon binding to overexpressed receptors on cancer cells, the probes assemble into nanofibers, resulting in an Assembly/Aggregation-Induced Retention (AIR) effect. This strategy significantly prolongs retention at the tumor site and can even enhance fluorescence intensity, improving the signal for image-guided surgery [79].

Minimizing Non-Specific Background

Non-specific background signals arise from multiple sources, including probe accumulation in non-target tissues, tissue autofluorescence, and scattered light. This is a critical limitation for sensitivity, especially in deep tissues or for detecting small lesions. The liver, for instance, presents a significant challenge due to its inherent role in sequestering exogenous nanoprobes, leading to high background [78]. Furthermore, quantitative studies are often invalidated by overlooked pitfalls such as fluorophore dissociation from nanoparticle carriers or interactions with the biological environment that alter fluorescence yield, leading to erroneous conclusions about targeting efficacy [77].

Protocol: Implementing "Off-On-Off" Molecular Probes

This protocol describes the use of advanced activatable probes, specifically the NIR-II-excited "off-on-off" probe NDP, designed to minimize background through a multi-step activation/deactivation process [78].

• Principle: The probe is initially "off" (no fluorescence) upon injection. It activates ("on") only upon encountering a specific biomarker (e.g., H2S in liver tumors) and subsequently deactivates ("off") when it migrates back to normal tissue, drastically reducing background signal from non-target areas.

• Materials:

  • "Off-on-off" probe (e.g., NDP based on a naphthalene diimide derivative).
  • Amphiphilic polymer for encapsulation (e.g., F-127-D-Gal for galactose-targeting).
  • Coaxial microfluidic mixer for nanoparticle preparation.
  • NIR-II fluorescence imaging system with 1064 nm excitation capability.

• Procedure:

  • Probe Synthesis and Formulation:
    • Synthesize the activatable small molecule fluorophore (e.g., ND).
    • Encapsulate the fluorophore into a targeting nanoparticle (e.g., NDP) using a controlled nanoprecipitation method with a microfluidic mixer.
  • In Vitro Validation:
    • Specificity: Confirm the fluorescence turn-on response to the target biomarker (e.g., H2S) in buffer solutions. The turn-on ratio should be very high (e.g., ~12,000-fold for NDP).
    • Selectivity: Verify that the probe does not activate in the presence of other biologically relevant analytes.
    • Sensitivity: Determine the limit of detection (e.g., 5 nM for H2S with NDP).
  • In Vivo Imaging:
    • Administer the probe intravenously to the animal model.
    • Acquire longitudinal NIR-II fluorescence images over time using 1064 nm excitation.
    • Key Observation: Fluorescence should be confined primarily to the disease tissue (e.g., liver tumor), with minimal persistent signal in the surrounding normal tissue, even as the probe clears from the body.

• Expected Outcome: The use of such probes enables high-contrast imaging, allowing for the sensitive identification of small lesions (e.g., ~4 mm liver tumors) that would be obscured by background signals when using "always-on" or standard "off-on" probes [78].

Strategy: Leveraging Long-Wavelength Imaging Windows

Imaging in the NIR-II window, particularly in its longer sub-windows (e.g., NIR-IIb: 1500-1700 nm, NIR-IIc: 1700-1880 nm), inherently reduces scattering and autofluorescence [37] [36]. Counter-intuitively, regions with higher water absorption (e.g., ~1930 nm) can be exploited for superior contrast. While absorption attenuates the total signal, it preferentially depletes multiply scattered photons (which contribute to background blur) over ballistic signal photons. This physical principle results in a higher Signal-to-Background Ratio (SBR) [37].

Table 2: Comparison of NIR Fluorescence Imaging Windows

Imaging Window	Wavelength Range (nm)	Key Advantages	Primary Challenges
NIR-I	650 - 900	Established dyes, commercial systems	Significant tissue scattering & autofluorescence
NIR-II	1000 - 1700	Reduced scattering, low autofluorescence	Requires bright probes and sensitive detectors
NIR-IIa	1300 - 1400	Lower scattering than NIR-I
NIR-IIb	1500 - 1700	Very low scattering and autofluorescence	Water absorption increases
NIR-IIx / 1880-2080 nm	1400-1500 / 1880-2080	High contrast due to water absorption	Requires very bright probes to overcome strong absorption

The Scientist's Toolkit: Essential Reagents and Materials

Table 3: Key Research Reagent Solutions

Reagent/Material	Function	Example Use Case
Pluronic F-127	Amphiphilic copolymer	Encapsulates hydrophobic fluorophores to form water-soluble nanoparticles for in vivo delivery [76] [78].
RGD Peptide	Targeting ligand	Binds to integrin αvβ3 overexpressed on cancer cells, conferring specificity to fluorescent probes [79].
Indocyanine Green (ICG)	Clinical NIR-I dye	Benchmark fluorophore; can be repurposed for NIR-II "tail" imaging [75] [80].
PbS/CdS Quantum Dots	Inorganic NIR-II fluorophore	Bright, photostable probes with tunable emission into long-wavelength windows (>1500 nm) for deep-tissue imaging [37].
Coaxial Microfluidic Mixer	Nanoparticle formulation device	Provides precise control over mixing during nanoprecipitation, enabling reproducible synthesis of nanoparticles with optimized aggregation states [78].
D-Galactose (D-Gal)	Targeting moiety	Conjugated to polymers or probes to target the asialoglycoprotein receptor on liver cells [78].

Integrated Workflow for Probe Validation

The following diagram and protocol outline a comprehensive workflow for developing and validating a NIR fluorescent probe, integrating the solutions to aggregation and background artifacts.

Integrated Validation Protocol:

• Probe Design and Formulation:

  • Design probes with structures that minimize ACQ (e.g., incorporating bulky substituents) or leverage activatable mechanisms ("off-on-off").
  • Formulate into nanoparticles using a controlled microfluidic process to optimize aggregation state and brightness [76] [78].

• In Vitro Characterization:

  • Spectroscopic Analysis: Measure absorption/emission spectra and ΦPL in both dispersed and aggregated states to quantify ACQ.
  • Activation Specificity: Confirm the probe's response is specific to the target biomarker (e.g., enzyme, H2S) and not other interfering species.
  • Cell Studies: Test binding, uptake, and activation in target vs. non-target cell lines.

• In Vivo Imaging and Validation:

  • Imaging Parameters: Select the appropriate NIR sub-window (NIR-I, NIR-IIb, etc.) and camera system filters to match the probe's emission and maximize SBR [37] [81].
  • Longitudinal Imaging: Acquire time-lapsed images to monitor probe kinetics, activation at the target site, and clearance from background tissues.
  • Ex Vivo Validation: After imaging, harvest tissues for ex vivo fluorescence analysis and correlate with histological findings (e.g., immunohistochemistry for target expression) to confirm specificity.

• Data Analysis and Quantification:

  • Quantitative Metrics: Calculate SBR, target-to-background ratio (TBR), and contrast-to-noise ratio (CNR). Be cautious of interpreting fluorescence intensity alone, as it can be influenced by factors other than probe concentration [77] [81].
  • Statistical Analysis: Perform blinded studies where applicable to objectively assess the probe's ability to identify disease states, for example, distinguishing between healthy and tumor-bearing subjects [78].

By systematically addressing probe aggregation through controlled nanoformulation and combating non-specific background via smart molecular design and optimal window selection, researchers can significantly enhance the reliability and translational potential of in vivo NIR fluorescence imaging.

Benchmarking Performance: Validation Frameworks and Comparative Analysis with Other Modalities

The standardization of quantitative metrics is paramount for ensuring the reproducibility, accuracy, and clinical translation of in vivo near-infrared (NIR) fluorescence imaging. This document provides detailed Application Notes and Protocols for establishing robust standards for two fundamental metrics: the Signal-to-Noise Ratio (SNR) and Contrast. Framed within the broader thesis of advancing NIR fluorescence imaging protocols, this guide is intended for researchers, scientists, and drug development professionals. We summarize quantitative data into structured tables, delineate step-by-step experimental methodologies for system benchmarking, and visualize key workflows and relationships. Furthermore, we present a curated toolkit of essential research reagents and materials to facilitate the implementation of standardized practices in both preclinical and clinical settings.

Fluorescence molecular imaging (FMI) has solidified its role as a fundamental modality for visualizing anatomical, functional, and molecular information in living subjects [19]. Its utility in intraoperative guidance, particularly with near-infrared (NIR) agents like Indocyanine Green (ICG), is expanding rapidly [82] [81]. However, the field faces a critical challenge: the lack of consensus on how to compute key performance metrics, specifically the Signal-to-Noise Ratio (SNR) and Contrast [83].

The accurate quantification of fluorescent signals is complicated by the complex interactions among the imaging device, the fluorescent contrast agent, the imaging protocol, and the optical properties of tissue [19]. Without standardized definitions, the performance assessment of an FMI system can vary dramatically. Recent studies show that depending on the chosen background region and calculation formula, SNR values for a single system can fluctuate by up to ~35 dB, and contrast values by ~8.65 arbitrary units [83]. This level of inconsistency jeopardizes the comparison of results across different studies and institutions, hinders technology validation, and ultimately impedes clinical translation. Therefore, establishing precise guidelines for these metrics is imperative for quality control, reliable data interpretation, and the successful integration of FMI into the standard of care [83] [19].

Defining Core Quantitative Metrics

Signal-to-Noise Ratio (SNR)

The SNR is a measure of how much a signal of interest stands above the statistical fluctuations of the background. In quantitative fluorescence microscopy, it is defined as the ratio of the electronic signal from the desired source to the total background noise [84]. The total noise (( \sigma_{total} )) is the square root of the sum of variances from several independent sources, leading to the fundamental equation:

[ SNR = \frac{Ne}{\sigma{total}} = \frac{Ne}{\sqrt{\sigma{photon}^2 + \sigma{dark}^2 + \sigma{CIC}^2 + \sigma_{read}^2}} ]

Table 1: Components of Signal and Noise in Fluorescence Imaging

Component	Symbol	Description	Origin
Electronic Signal	( N_e )	Signal from target fluorescence	( \bar{N}_{photon} \times QE ) [84]
Photon Shot Noise	( \sigma_{photon} )	Statistical fluctuation of incoming photons	Poisson statistics of light emission [84]
Dark Current Noise	( \sigma_{dark} )	Electrons generated by heat, not light	Poisson statistics of heat-generated electrons [84]
Clock-Induced Charge	( \sigma_{CIC} )	Extra electrons from electron shuffling (EMCCD cameras)	Probabilistic electron amplification [84]
Readout Noise	( \sigma_{read} )	Noise from electron-to-voltage conversion	Gaussian distribution; independent of signal [84]

Contrast and Signal-to-Background Ratio (SBR)

The terms "contrast" and "Signal-to-Background Ratio" (SBR) are often used to describe the relative difference in intensity between a target (signal) and the surrounding tissue (background). A high SBR is crucial for clear delineation of structures like tumors. It is important to note that multiple, non-standardized formulas exist for calculating "contrast," which is a primary source of variability in performance assessment [83]. For the purpose of this protocol, we define SBR as:

[ SBR = \frac{\text{Mean Signal}{Target} - \text{Mean Signal}{Background}}{\text{Mean Signal}_{Background}} ]

Alternatively, Contrast-to-Noise Ratio (CNR) incorporates the background noise and is defined as:

[ CNR = \frac{|\text{Mean Signal}{Target} - \text{Mean Signal}{Background}|}{\sigma_{Background}} ]

where ( \sigma_{Background} ) is the standard deviation of the background signal.

Experimental Protocols for System Benchmarking

Protocol: Benchmarking FMI System Performance Using a Multi-Parametric Phantom

This protocol, adapted from Kriukova et al. (2025), outlines a standardized method to assess the sensitivity and performance of FMI systems by quantifying SNR and contrast using a calibrated phantom [83].

I. Materials and Equipment

• FMI System: Near-infrared fluorescence imaging system to be evaluated.
• Multi-Parametric Phantom: A phantom with embedded fluorescent targets of known concentrations and a homogeneous background material with well-characterized optical properties.
• Fluorescent Solution: A standardized solution of a NIR fluorophore (e.g., ICG or IR-780 [33]).
• Data Analysis Software: Software capable of quantifying mean pixel intensity and standard deviation in user-defined regions of interest (ROI) (e.g., ImageJ [33]).

II. Procedure

• System Preparation: Power on the FMI system and allow it to warm up for the manufacturer-specified time. Set the imaging parameters (exposure time, gain, lamp intensity) to predetermined baseline values and keep them constant throughout the experiment.
• Phantom Imaging: Place the multi-parametric phantom in the field of view. Acquire a fluorescence image. Ensure the phantom fills a significant portion of the field of view to assess illumination homogeneity [81].
• Background Region Selection: Define multiple background ROIs in the homogeneous area of the phantom. It is critical to document the size and location of these ROIs, as the choice of background significantly impacts the calculated metrics [83].
• Signal Region Selection: Define ROIs over the fluorescent targets within the phantom.
• Data Collection: Record the mean pixel intensity and the standard deviation of the pixel intensity for each signal and background ROI.
• Replication: Repeat steps 2-5 at least three times to ensure statistical robustness.

III. Data Analysis and Interpretation

• Calculate Metrics: For each image, calculate the SNR, SBR, and CNR for every target using the formulas defined in Section 2 and the data collected from the ROIs.
• Report Methodology Explicitly: When reporting results, explicitly state:
  • The formulas used for SNR and contrast.
  • The exact location and size of the background ROIs.
  • The specific fluorescent agent and its concentration in the phantom.
• Benchmarking Score: Calculate a benchmarking score for the system based on the achieved metrics. The rank of a system can change depending on the metric used, highlighting the need for a standardized approach [83].

Protocol: Camera Parameter Verification for SNR Optimization

This protocol provides a framework to verify a camera's marketed noise parameters (read noise, dark current, clock-induced charge), as discrepancies can compromise sensitivity and quantitative accuracy [84].

Table 2: Protocol for Camera Noise Parameter Verification

Step	Parameter	Procedure	Measurement
1	Readout Noise (( \sigma_{read} ))	Acquire an image with zero exposure time in a dark environment.	The standard deviation of the pixel values in the resulting image is a direct measure of the readout noise.
2	Dark Current (( \sigma_{dark} ))	Acquire multiple images with the sensor capped, using a long exposure time. Calculate the mean signal and its standard deviation over time.	The increase in signal and noise over the exposure time, after subtracting read noise, characterizes the dark current.
3	Clock-Induced Charge (( \sigma_{CIC} ))	For EMCCD cameras, acquire images at a high gain setting with zero exposure.	The variance of the signal under these conditions, after accounting for read noise, provides the CIC.
4	SNR Enhancement	Add secondary emission and excitation filters to the optical path. Introduce a wait time in the dark before acquisition to reduce background.	This can reduce excess background noise and improve the experimental SNR by up to 3-fold [84].

Advanced Considerations: From NIR-I to NIR-II

The pursuit of deeper tissue penetration and higher image quality is driving the development of fluorescence imaging in the second near-infrared window (NIR-II, 1000-1700 nm). Compared to the conventional NIR-I window (700-900 nm), NIR-II imaging benefits from significantly reduced photon scattering and minimal tissue autofluorescence [85] [30]. This results in superior penetration depth (up to several centimeters) and a higher signal-to-background ratio, enabling micrometer-level resolution in deep tissues [85].

However, NIR-II fluorophores face two major bottlenecks: relatively low fluorescence quantum yield (QY) and the challenge of achieving long-wavelength emission without further sacrificing QY [85]. Enhancing fluorescence brightness is therefore a critical research focus. Key strategies include:

• Reducing defect states and limiting intramolecular motion in the fluorophore structure to minimize non-radiative energy decay.
• Extending π-conjugated systems to redshift the emission wavelength.
• Utilizing aggregation-induced emission (AIE) scaffolds to create bright nanoparticles [85].

Furthermore, dual-channel imaging strategies using two fluorophores with distinct emissions (e.g., 700 nm and 800 nm) are being developed to simultaneously visualize different biological targets, such as tumors and normal tissues, thereby improving surgical precision [33].

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 3: Key Reagents and Materials for Standardized Fluorescence Imaging

Item	Function / Role	Examples & Notes
Clinical NIR-I Agents	Non-targeted perfusion and lymph node imaging; an established surgical adjunct.	Indocyanine Green (ICG): FDA-approved; used for angiography, lymphography, and perfusion assessment [82]. Methylene Blue: Used for parathyroid identification and other applications [81].
Targeted/Activatable Agents	Molecular imaging of specific biomarkers (e.g., tumor receptors, enzyme activity).	Cytalux (Pafolacianine): FDA-approved, targets folate receptor in ovarian and lung cancer [19]. LUMISIGHT (Pegulicianine): Activatable agent for detecting residual breast cancer [19].
NIR-II Organic Fluorophores	Deep-tissue imaging with high spatial resolution and low background.	D-A-D Fluorophores: e.g., BBTD-based molecules; tunable properties [30]. Cyanine Derivatives: e.g., IR-780; used in research for tumor targeting [33] [30].
Multi-Parametric Phantom	System calibration, performance benchmarking, and quality control.	Should contain fluorescent targets of varying concentrations and a homogeneous background with known optical properties [83].
Dual-Channel Imaging System	Simultaneous visualization of two distinct biological processes.	Requires a system capable of independent excitation and detection at two wavelengths (e.g., 700 nm and 800 nm) [33].

The establishment of standardized, universally accepted metrics for SNR and contrast is not merely an academic exercise but a foundational requirement for the future of quantitative fluorescence molecular imaging. To translate these protocols from theory to practice, we recommend the following actions:

• Adopt Reporting Guidelines: Utilize community-driven checklists, such as the REFLECT guidelines, to ensure all essential details of the fluorescent agent, imaging device, protocol, and analysis methods are reported [19].
• Implement Routine Phantom Testing: Integrate the system benchmarking protocol described in Section 3.1 as a routine quality control measure before initiating any new preclinical or clinical imaging study.
• Characterize Camera Performance: Verify camera noise parameters to ensure the system operates at its maximum specified sensitivity and to identify any hardware degradation over time.
• Contextualize Metric Selection: Choose the primary quantitative metric (SNR, SBR, or CNR) based on the specific clinical or research question, as outlined in Figure 1.

By adhering to these standardized protocols and reporting frameworks, the research community can overcome the current challenges of reproducibility and comparability, thereby accelerating the clinical translation of novel fluorescence imaging agents and technologies.

In vivo molecular imaging is a critical discipline for preclinical research and drug development, providing non-invasive visualization and quantification of biological processes. Each imaging modality presents a unique profile of capabilities and constraints, influencing its suitability for specific research applications. This application note provides a structured, evidence-based comparison of Near-Infrared (NIR) Fluorescence imaging against three established clinical and preclinical modalities: Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The content is framed within the context of developing robust in vivo NIR fluorescence imaging protocols, detailing experimental methodologies, and providing a clear resource for researchers selecting the optimal imaging strategy for their specific investigative needs in oncology, cardiovascular disease, and neurology.

Quantitative Modality Comparison

The selection of an imaging modality requires balancing key performance parameters with experimental goals. The following table summarizes the quantitative and qualitative characteristics of NIR Fluorescence, PET, SPECT, and MRI.

Table 1: Technical and Operational Specifications of Preclinical Imaging Modalities

Feature	NIR Fluorescence	PET	SPECT	MRI
Sensitivity	High (pico- to femto-molar) [86]	High (nano- to picogram tracer amounts) [86]	High [87]	Low (millimolar) [86]
Spatial Resolution	Sub-mm to a few mm (depth-dependent) [86]	1-2 mm [87] [88]	~7 mm (clinical) [89] [90]	Sub-mm to 1 mm [91]
Penetration Depth	Limited (up to a few cm) [86]	Unlimited	Unlimited	Unlimited
Temporal Resolution	Seconds to minutes (Real-time capability) [86]	Minutes to hours	Minutes to hours [89]	Minutes to hours
Multiplexing Capability	Excellent (via multiple fluorophores) [86]	Poor (limited by radiotracer isotopes)	Moderate (with different energy isotopes)	Poor
Quantitative Accuracy	Moderate (affected by tissue optics)	High	Moderate (affected by attenuation) [89]	High
Cost	Relatively low cost [86]	Very high (cyclotron, hot lab) [90]	High [90]	High
Ionizing Radiation	No [86]	Yes [92] [93]	Yes [89]	No [91] [94]
Primary Applications	Image-guided surgery, lymphatic mapping, preclinical tumor studies [86]	Cancer detection, brain and heart metabolism [92] [93]	Myocardial perfusion, bone scintigraphy, functional brain imaging [90]	Soft tissue, CNS, musculoskeletal, and cardiovascular imaging [91] [94]

Experimental Protocols for Modality Comparison

A direct, head-to-head comparison of imaging modalities requires a standardized experimental setup. The following protocol outlines a methodology for evaluating tumor targeting of a novel agent, such as a labeled antibody, using all four modalities in a preclinical murine model.

Animal Model and Tracer Administration

• Animal Model: Use immunocompromised mice (e.g., nude or NSG) subcutaneously implanted with human cancer cells (e.g., HT-29 colorectal carcinoma) on both flanks. Allow tumors to grow to a target volume of 200-500 mm³.
• Tracer/Agent Preparation:
  • NIR Fluorescence: Conjugate the targeting antibody (e.g., anti-CEA) with a NIR fluorophore such as IRDye 800CW or a NIR-II dye (e.g., IR-1061). Purify the conjugate via dialysis or size-exclusion chromatography [86].
  • PET: Label the same antibody with a suitable positron-emitting isotope (e.g., Zirconium-89, ^89^Zr).
  • SPECT: Label the same antibody with a gamma-emitting isotope (e.g., Indium-111, ^111^In) [87] [88].
  • MRI: Conjugate the antibody to a superparamagnetic iron oxide (SPIO) nanoparticle [87] [91].
• Dosing and Administration: Calculate doses based on the molecular weight of the conjugate and standard preclinical dosing guidelines. Administer via tail vein injection. For a fair comparison, the number of targeting molecules should be equivalent across all groups. Include a control group injected with a non-targeted/isotype control conjugate for each modality.

Image Acquisition Workflow

Imaging should be performed at multiple time points post-injection (e.g., 4, 24, 48, and 72 hours) to assess biodistribution and pharmacokinetics. The following acquisition parameters are recommended:

• NIR Fluorescence Imaging: Anesthetize mice with isoflurane. Acquire images using a pre-clinical NIR fluorescence imager. For NIR-I, use excitation 745-785 nm and emission filter 800-850 nm. For NIR-II, use excitation and emission settings appropriate for the specific dye (e.g., 1064 nm excitation, 1500 nm long-pass emission). Acquire a white light image for anatomical overlay. Maintain consistent imaging settings (exposure time, f-stop, binning) across all animals [86].
• PET/CT Imaging: Following NIR imaging, acquire PET data for 10-15 minutes using a preclinical PET scanner. This should be immediately followed by a low-dose CT scan (e.g., 50 kVp, 0.5 mA) for anatomical coregistration and attenuation correction [93].
• SPECT/CT Imaging: If using a separate cohort for SPECT, acquire SPECT projections using a high-resolution collimator. A 360-degree rotation with 32-64 projections is typical. Reconstruct using an iterative algorithm. Follow with a CT scan as with PET/CT [89] [90].
• MRI: Anesthetize mice and place in a dedicated rodent radiofrequency coil. Use a high-field preclinical scanner (e.g., 7T or higher). Acquire high-resolution T2-weighted anatomical scans. For SPIO-labeled agents, acquire T2*-weighted or T2-weighted fast spin-echo sequences to detect signal voids (dark contrast) [87] [91] [94].

Data Analysis and Interpretation

• Co-registration: Use software to co-register functional images (NIR, PET, SPECT) with their corresponding anatomical datasets (CT, MRI).
• Region of Interest (ROI) Analysis: Draw ROIs around the tumor, major organs (liver, heart, kidneys, muscle), and background. For NIR fluorescence, also measure fluorescence intensity in an area adjacent to the tumor for background subtraction.
• Quantification:
  • NIR Fluorescence: Calculate the mean fluorescence intensity in each ROI. Express tumor targeting as the Tumor-to-Background Ratio (TBR).
  • PET/SPECT: Calculate the percentage of the injected dose per gram of tissue (%ID/g) using calibration standards.
  • MRI: For T2-weighted contrast agents, quantify the change in signal intensity (SI) in the tumor over time, expressed as percentage signal enhancement or reduction.
• Statistical Analysis: Compare TBR, %ID/g, and signal changes between targeted and control groups at each time point using an appropriate statistical test (e.g., two-way ANOVA). Generate biodistribution plots and representative maximum intensity projections (MIPs) for each modality.

Fundamental Imaging Mechanisms

The underlying physical principles of each imaging modality dictate its capabilities and the nature of its signal. The following diagram illustrates the core mechanisms of signal generation for NIR Fluorescence, PET, SPECT, and MRI.

The Scientist's Toolkit: Research Reagent Solutions

The following table catalogs essential reagents and materials required for executing the experiments described in the protocols above.

Table 2: Key Research Reagents and Materials for In Vivo Imaging

Reagent/Material	Function	Example Products / Notes
NIR Fluorophores	Exogenous contrast agent that emits light upon NIR excitation for detection.	IRDye 800CW, Cy7, ICG (FDA-approved); NIR-II dyes (e.g., IR-1061) [86].
Radionuclides (PET)	Positron-emitting isotopes for tracer labeling; decay produces detectable gamma pairs.	Fluorine-18 (¹⁸F-FDG), Zirconium-89 (⁸⁹Zr), Copper-64 (⁶⁴Cu) [92] [93].
Radionuclides (SPECT)	Gamma-emitting isotopes for tracer labeling; single gamma rays are detected.	Technetium-99m (⁹⁹mTc), Indium-111 (¹¹¹In) [89] [90].
MRI Contrast Agents	Modifies local magnetic properties to enhance tissue contrast in images.	Gadolinium-based (e.g., Gd-DTPA) for T1-weighting; Superparamagnetic Iron Oxide (SPIO) for T2-weighting [87] [91] [94].
Targeting Ligands	Provides molecular specificity to the imaging agent by binding to a biological target.	Monoclonal Antibodies (mAbs), peptides, affibodies, small molecules.
Preclinical Imaging Systems	Integrated instruments for data acquisition in live animal models.	NIR: LI-COR Pearl, PerkinElmer FMI; PET/CT: Siemens Inveon, Mediso NanoScan; SPECT/CT: Mediso NanoScan, Bruker Albira; MRI: Bruker BioSpec, Agilent MRI Systems.
Image Analysis Software	For image reconstruction, visualization, co-registration, and quantitative region-of-interest (ROI) analysis.	OsiriX, Horos, PMOD, VivoQuant, AnalyzeNN, ImageJ.

Near-infrared (NIR) fluorescence imaging has emerged as a powerful tool for enhancing surgical precision in oncology, providing real-time visual guidance for critical procedures such as sentinel lymph node (SLN) mapping and tumour visualization [95]. This document frames the clinical validation of these techniques within the broader context of a thesis on in vivo NIR fluorescence imaging protocols, providing detailed application notes and experimental methodologies. The content is structured to serve researchers, scientists, and drug development professionals by summarizing quantitative evidence from randomized trials, providing detailed experimental protocols, and cataloguing essential research reagents. While robust evidence exists for applications in breast cancer surgery, as detailed herein, it is important to note that a parallel literature search conducted for this article did not identify specific randomized trial data for adrenal surgery, indicating a significant gap and opportunity for future research in that particular field.

The validation of NIR fluorescence imaging in breast cancer has been significantly advanced by well-designed randomized controlled trials (RCTs). A seminal study by van der Vorst et al. directly compared the performance of NIR fluorescence using indocyanine green (ICG) against the established combination of radiotracer (99m-nanocolloid) and patent blue dye [96] [97].

The table below summarizes the key quantitative findings from this randomized comparison:

Table 1: Key Outcomes from a Randomized Trial of NIR Fluorescence for SLN Mapping in Breast Cancer

Metric	NIR Fluorescence (ICG) + Radiotracer	Patent Blue + Radiotracer	P-value
Successful SLN Mapping	23 out of 24 patients	23 out of 24 patients	N/A
Signal-to-Background Ratio (SBR)	10.3 ± 5.7	8.3 ± 3.8	0.32
Detection Rate of SLNs	100%	84%	N/A
Cases Requiring Gamma Probe	25% of patients	25% of patients	N/A

This trial demonstrated non-inferiority of the NIR fluorescence approach and, importantly, highlighted that the addition of patent blue dye provided no significant benefit to the SBR when NIR fluorescence and a radiotracer were already employed [96]. The consistent 100% detection rate of SLNs with fluorescence, compared to 84% with blue dye, underscores its superior reliability [96] [97]. Furthermore, the trial preliminarily explored the potential for omitting radiotracers altogether, though the need to use the gamma probe in a quarter of patients suggests this may be reserved for selected cases, such as those with a lower body mass index (BMI) [96].

Detailed Experimental Protocol for SLN Mapping

The following protocol is adapted from the methods section of the randomized trial by van der Vorst et al. and is presented as a standardized workflow for research and clinical validation [96].

Reagent Preparation

• Indocyanine Green (ICG) Solution: Resuspend a 25 mg vial of ICG in 10 mL of sterile water for injection to create a 2.5 mg/mL (3.2 mM) stock solution. To achieve the optimal 500 μM working concentration, dilute 7.8 mL of the stock solution in 42.8 mL of sterile water [96].
• Radiotracer: Prepare and administer approximately 100 MBq of 99m-nanocolloid to the patient per institutional standards, typically on the day before surgery [96].
• Control Agent (if applicable): For the patent blue control arm, 1 mL of patent blue (Bleu Patenté V) is used [96].

Patient Preparation and Dosing

• Patient Population: The study enrolled consecutive breast cancer patients with clinically negative axillary lymph nodes scheduled for SLN biopsy [96].
• Injection Protocol: All patients receive a periareolar intradermal injection of the prepared 1.6 mL total volume of 500 μM ICG at four sites. For patients randomized to the control arm, 1 mL of patent blue is similarly injected periareolarly immediately before surgery [96].
• Massage: Apply gentle pumping pressure to the injection site for 1 minute to facilitate lymphatic uptake [96].

Image Acquisition and Intraoperative Procedure

• Imaging System: The procedure utilizes a dedicated NIR imaging system, such as the Mini-FLARE (Fluorescence-Assisted Resection and Exploration). The system should be equipped with a white light source (400–650 nm) and a NIR laser source (760 nm). The imaging head is positioned approximately 30 cm from the surgical field under sterile conditions [96].
• Initial Incision and Imaging: After making the axillary skin incision, the operating room lights are dimmed. The surgical field is illuminated using the system's white light, and NIR fluorescence imaging is initiated. For the first 15 minutes, the surgeon should rely solely on the fluorescent and visual (blue dye) signals to locate the SLN(s) [96].
• Gamma Probe Use: If the SLN is not localized within the first 15 minutes using optical guidance alone, the surgeon may then use the handheld gamma probe to assist in localization [96].
• Signal Interpretation: A lymph node exhibiting a signal-to-background ratio (SBR) of ≥ 1.1 in situ is considered a positive SLN [96].

Data Analysis and Validation

• Ex Vivo Analysis: All resected SLNs are subjected to standard histopathological analysis, including frozen section analysis, followed by formalin fixation and paraffin embedding for hematoxylin and eosin staining and immunohistochemical staining [96].
• Outcome Measures: The primary outcomes are the success rate of SLN mapping, the SBR for each modality, and the concordance between the fluorescent, radioactive, and blue-dye-stained nodes [96].

The logical flow of this protocol and the decision-making process during surgery can be visualized in the following workflow:

Diagram 1: Experimental workflow for SLN mapping using NIR fluorescence.

The Scientist's Toolkit: Essential Research Reagents & Materials

Successful execution and validation of NIR fluorescence-guided surgery protocols depend on a core set of reagents and instruments. The table below details these essential components and their functions within the experimental workflow.

Table 2: Key Research Reagent Solutions for NIR Fluorescence-Guided Surgery

Item	Function/Description	Example/Specification
Fluorophore	The imaging agent that emits NIR light upon excitation.	Indocyanine Green (ICG); optimal dose at 500 μM for SLN mapping [96].
NIR Imaging System	Dedicated camera system for visualizing fluorescence.	Must include a NIR light source (~760 nm) and a sensitive CCD camera; e.g., Mini-FLARE system [96].
Co-registration Agent (Control)	Established standard for performance comparison.	99m-nanocolloid (radiotracer) and/or patent blue dye [96] [97].
Targeted Tracers (Emerging)	Fluorophores conjugated to target-specific biomolecules.	Antibodies or small molecules (e.g., folate receptor-targeted agents) for specific tumour visualization [95] [19].
Sterile Water for Injection	Solvent for reconstituting fluorophore powders.	Essential for preparing the correct concentration of ICG solution [96].

For novel fluorescent agents, comprehensive characterization is crucial. This includes reporting the chemical structure, excitation/emission spectra, molecular extinction coefficient, quantum yield, and Degree of Labeling (DoL) for conjugated agents, as these factors critically impact performance and detectability [19].

Signaling Pathways and Mechanism of Action

The effectiveness of NIR fluorescence imaging, particularly for applications like lymphatic mapping, relies on the physiological trafficking of fluorophores rather than a classic biochemical signaling pathway. ICG, when used for SLN mapping, functions as a non-targeted lymphatic tracer. The following diagram illustrates this mechanistic journey from injection to surgical visualization.

Diagram 2: Mechanism of ICG transport and detection in SLN mapping.

Upon intradermal injection, ICG passively drains into the initial lymphatic capillaries [95]. It is then actively transported through afferent lymphatic vessels towards the regional lymph node basin. The SLN, being the first node in the drainage pathway, traps the ICG molecules, which are often bound to albumin in the interstitial fluid, leading to significant accumulation [96] [95]. During surgery, the SLN is located by illuminating the surgical field with NIR light (~760 nm). The accumulated ICG in the node absorbs this light and emits fluorescence at a longer wavelength (~830 nm), which is detected by the specialized camera system and overlaid in pseudo-color onto the white-light image for the surgeon [95]. For tumour-targeted agents, the mechanism involves specific binding to biomarkers on the tumour cell surface (e.g., folate receptor), leading to a higher concentration of the fluorophore in malignant tissue compared to healthy tissue [19].

Within the framework of thesis research on in vivo near-infrared (NIR) fluorescence imaging protocols, the evaluation of probe safety and pharmacokinetics (PK) is a critical cornerstone. The advancement of these imaging modalities hinges on the development and validation of molecular probes that are not only optically sensitive but also biologically safe and predictably distributed within a living organism. This document provides detailed application notes and protocols for rigorously assessing the toxicity, biodistribution, and clearance profiles of NIR fluorescent probes, providing researchers and drug development professionals with standardized methodologies to accelerate preclinical development.

The core advantage of NIR optical imaging, particularly in the 700-900 nm (NIR-I) and 1000-1700 nm (NIR-II) windows, lies in the low absorption of biological molecules in these regions, which allows for deeper tissue penetration and higher signal-to-background ratios compared to visible light imaging [98] [99]. However, the translational potential of any NIR probe is ultimately governed by its biocompatibility and its in vivo pharmacokinetic behavior, which must be thoroughly characterized through disciplined experimental workflows.

Safety and Toxicity Evaluation of NIR Probes

The safety profile of a NIR fluorescent probe is paramount. A comprehensive assessment should investigate both acute and chronic toxicity.

Key Toxicity Endpoints

The following table summarizes the core endpoints that must be evaluated in a standard toxicity assessment protocol.

Table 1: Key Endpoints for Probe Toxicity Evaluation

Endpoint Category	Specific Metrics	Common Assay/Method
Cellular Toxicity	Cell viability, proliferation, membrane integrity, oxidative stress	MTT/XTT assay, LDH release, glutathione levels
Hemocompatibility	Hemolysis, platelet activation	Hemolysis assay, flow cytometry
Histopathology	Tissue architecture, necrosis, inflammatory infiltrate	H&E staining of major organs
Systemic Toxicity	Body weight, organ weight, serum biochemistry, behavioral changes	Daily monitoring, clinical chemistry analyzers

Protocol: In Vitro Cytotoxicity Assessment (MTT Assay)

This protocol provides a standardized method for an initial screening of probe toxicity.

• Materials:

  • Cell line relevant to the intended application (e.g., HepG2 for liver toxicity)
  • NIR fluorescent probe at various concentrations
  • MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
  • Dimethyl sulfoxide (DMSO)
  • Cell culture plate (96-well)
  • Microplate reader

• Procedure:

  • Seed cells in a 96-well plate at a density of 5,000-10,000 cells per well and culture for 24 hours.
  • Expose cells to a series of concentrations of the NIR probe (e.g., 0, 1, 10, 50, 100 µM) for a predetermined period (e.g., 24 and 48 hours). Include a negative control (media only) and a positive control (e.g., a cytotoxic agent like doxorubicin).
  • Carefully remove the media and add fresh media containing MTT reagent (0.5 mg/mL final concentration). Incubate for 2-4 hours at 37°C.
  • Remove the MTT-containing media and solubilize the formed formazan crystals with DMSO.
  • Measure the absorbance of each well at 570 nm using a microplate reader. The percentage of cell viability is calculated as (Absorbance of treated sample / Absorbance of untreated control) × 100%.

• Data Analysis: Plot cell viability (%) against probe concentration to determine the half-maximal inhibitory concentration (IC₅₀). A probe is generally considered to have low cytotoxicity if viability remains >80% at the intended working concentration.

Pharmacokinetics and Biodistribution Profiling

Pharmacokinetic (PK) studies reveal the temporal dynamics of a probe's absorption, distribution, metabolism, and excretion (ADME), which are critical for determining optimal imaging time windows and understanding potential off-target effects.

Non-Invasive In Vivo Imaging for PK Analysis

Fluorescence reflectance imaging (FRI) allows for the longitudinal, non-invasive tracking of a probe's whole-body distribution in live small animals [98] [100].

• Materials:

  • Anesthetized mice (e.g., using 2% isoflurane)
  • NIR fluorescent probe (e.g., IRDye 800CW 2-DG)
  • Preclinical FRI system (e.g., Carestream In-Vivo MS FX PRO) with appropriate excitation/emission filters (e.g., 760±10 nm ex / 830±15 nm em for Cypate) [98]
  • Warming pad for animal recovery

• Procedure:

  • Anesthetize the animal and place it in the light-tight imaging chamber on the imaging platform.
  • Administer the probe via the intended route (e.g., intravenous injection).
  • Acquire serial images over time (e.g., from 5 minutes to 24-48 hours post-injection). Acquisition times are typically 10-60 seconds, depending on probe brightness [98].
  • Maintain anesthesia throughout imaging and place the animal on a warming pad until awake post-procedure.

• Data Analysis: Using analysis software (e.g., Carestream Molecular Imaging or ImageJ), draw regions of interest (ROIs) over target tissues (e.g., tumor) and a reference background area. Calculate the mean fluorescence intensity for each ROI per time point. This data is used to generate time-activity curves for each tissue.

Diagram 1: PK and Biodistribution Workflow

Ex Vivo Biodistribution Quantification

To obtain quantitative, tissue-specific data, ex vivo analysis of excised organs is required, often expressed as the percentage of injected dose per gram of tissue (%ID/g) [101].

• Procedure:

  • At selected time points post-injection (e.g., 1, 4, 24, 48 hours), euthanize animals (n=3-5 per group).
  • Excise all organs of interest (e.g., heart, liver, spleen, lungs, kidneys, tumor, muscle).
  • Rinse tissues in saline, blot dry, and weigh them.
  • Place tissues in a pre-defined order on a petri dish and image them using the same FRI system.
  • Perform ROI analysis on each tissue to measure fluorescence intensity.

• Data Analysis: To convert fluorescence intensity to %ID/g, a standard curve must be prepared by serially diluting a known amount of the probe and imaging it alongside the tissues. The fluorescence intensity of each tissue is then interpolated from the standard curve, and the %ID/g is calculated using the formula: (Amount in tissue (μg) / Injected dose (μg)) / Tissue weight (g) * 100.

Impact of Probe Design on Pharmacokinetics

The physicochemical properties and structure of a probe fundamentally dictate its PK profile. Research shows that even a small modification, like conjugating the IRDye800 to a monoclonal antibody (mAb), can significantly alter its disposition compared to the unlabeled mAb, leading to discrepancies in calculated plasma clearance and increased liver uptake [101]. Furthermore, the size and valency of the probe are major determinants.

Table 2: Pharmacokinetic Properties of Different Antibody Fragment Probes [102]

Probe Type	Molecular Weight	Key PK Characteristics	Optimal for
scFv, Diabody	26-52 kDa	Rapid accumulation in tumor (peak 2-4 h), fast renal clearance	Same-day imaging, high contrast
Fab	~50 kDa	Faster blood clearance than IgG, renal clearance	Imaging within hours
scFv-Fc, IgG	105-150 kDa	Long circulation (days), high tumor signal, liver distribution	Long-term tracking, therapy

Case Study: Evaluating an IRDye800-mAb Conjugate

A study highlights the critical importance of validating that the fluorescent label does not alter the native molecule's behavior. When a model monoclonal antibody (8C2) was labeled with IRDye800 (≤1.5 dye/mAb), its PK profile changed significantly [101].

• Findings: The plasma clearance (CL) calculated via NIR fluorescence was 8.4 mL/day/kg, which was over 3 times faster than the CL of 2.5 mL/day/kg measured by ELISA for the unlabeled antibody. Furthermore, biodistribution analysis showed a over 4-fold increase in liver concentration for the IR800-8C2 conjugate compared to a prior study using a radioiodinated ([¹²⁵I]) version of the same antibody [101].

• Interpretation: This discrepancy suggests that IR800 conjugation can alter mAb disposition, potentially through increased hepatic uptake or altered interaction with the neonatal Fc receptor (FcRn). It underscores the necessity of using multiple analytical methods (e.g., fluorescence detection paired with a functional assay like ELISA) to cross-verify PK parameters.

The Scientist's Toolkit: Key Research Reagent Solutions

The following table lists essential reagents and tools for conducting the experiments described in this protocol.

Table 3: Essential Research Reagents and Materials

Reagent/Material	Function/Application	Example Products / Notes
IRDye 800CW	Widely used NIR-I fluorophore for labeling biomolecules	LI-COR Biosciences
Cy-based Dyes (e.g., Cy5.5, Cy7)	Common organic fluorophores for NIR-I imaging	GE Healthcare
ICG (Indocyanine Green)	FDA-approved NIR-I dye; also emits in NIR-II	Diagnostic Green Inc.
cRGD Peptide	Targeting motif for integrin αvβ3, used in tumor-targeting probes	Custom synthesis
MMP2/9 Cleavable Peptide Linker	Enzyme-responsive element for activatable probes	Sequence: Pro-Leu-Gly-Val-Arg-Gly [103]
SP94 Peptide	Targeting peptide for Hepatocellular Carcinoma (HCC)	Targets Glucose-Regulated Protein 78 (GRP78) [104]
Preclinical FRI System	For non-invasive, in vivo fluorescence imaging	Carestream In-Vivo MS FX PRO [98]
Time-Domain Imaging System	For fluorescence lifetime imaging (FLIM)	ART Optix MX2 [98]

Robust evaluation of safety and pharmacokinetics is non-negotiable for the development of reliable NIR fluorescent probes. The protocols outlined herein—from standardized cytotoxicity assays and longitudinal in vivo imaging to quantitative ex vivo biodistribution—provide a foundational framework for researchers. Adhering to these detailed application notes ensures the generation of high-quality, reproducible data that is critical for validating probe performance, understanding its in vivo behavior, and ultimately, translating novel NIR imaging agents from the bench to the bedside.

Near-infrared (NIR) fluorescence imaging has emerged as a powerful modality for biomedical research, particularly in the realms of surgical guidance and preclinical studies. This technology leverages light in the near-infrared spectrum (700-900 nm for NIR-I; 1000-1700 nm for NIR-II) to visualize biological processes with high sensitivity and specificity [105] [106]. The core principle involves administering fluorescent agents that accumulate in target tissues, which upon excitation with NIR light, emit fluorescence captured by specialized imaging systems [107] [108]. This application note provides a structured analysis of the strengths and limitations of NIR fluorescence imaging, supported by quantitative data and detailed protocols, to define its ideal use cases within biomedical research and drug development.

Fundamental Principles and Performance Characteristics

The Optical Window of Biological Tissues

The efficacy of NIR fluorescence imaging stems from the unique interaction between NIR light and biological tissues. Within the NIR spectrum, the absorption by endogenous chromophores like hemoglobin, water, and lipids is significantly reduced compared to visible light [109]. This reduction, coupled with decreased photon scattering and minimal tissue autofluorescence, creates an "optical window" that allows NIR light to penetrate deeper into tissues with a higher signal-to-background ratio (SBR) [85] [106]. The transition from the first near-infrared window (NIR-I, 700-900 nm) to the second (NIR-II, 1000-1700 nm) offers further improvements. Table 1 summarizes the performance characteristics of fluorescence imaging across different spectral windows.

Table 1: Characteristics of Different Fluorescence Imaging Spectral Windows

Parameter	Visible Light (400-700 nm)	NIR-I (700-900 nm)	NIR-II (1000-1700 nm)
Tissue Penetration Depth	Shallow (sub-millimeter)	1-2 cm [105] [109]	Several centimeters [85]
Tissue Scattering	High	Moderate	Significantly Reduced [2] [106]
Autofluorescence	High	Low	Very Low / Negligible [2] [109]
Spatial Resolution	Low at depth	Moderate at depth	High at depth (micrometer resolution) [85]
Signal-to-Background Ratio	Low	Good	Superior [85] [106]

Key Performance Metrics of NIR Fluorescence Imaging

The performance of NIR fluorescence imaging is quantified by several key metrics, which vary depending on the specific imaging device and fluorophore used. Sensitivity refers to the lowest detectable concentration of a fluorophore, while dynamic range defines the span of concentrations over which the signal can be linearly detected [110]. The tumor-to-background ratio (TBR) is a critical parameter in oncology applications, indicating the contrast between target and surrounding tissues [2]. Table 2 compares the in vitro and in vivo performance of two representative imaging systems.

Table 2: Performance Comparison of Representative NIR Imaging Systems

Performance Metric	Conventional Microscope with NIR Module (System 1)	Dedicated NIR Imaging Platform (System 2)
In Vitro Sensitivity (ICG detection range)	1.5 – 251 μg/L [110]	0.99 – 503 μg/L [110]
In Vitro Peak SBR	~3.25 [110]	~12 (camera maximum) [110]
In Vivo SBR (Pre-dura opening)	1.2 ± 0.15 [110]	2.6 ± 0.63 [110]
In Vivo SBR (Post-tumor exposure)	1.8 ± 0.26 [110]	6.1 ± 1.9 [110]

Diagram 1: Logical flow from fundamental principles to defined use cases of NIR fluorescence imaging, highlighting key strengths and limitations.

The Scientist's Toolkit: Essential Reagents and Materials

Successful implementation of NIR fluorescence imaging relies on a suite of specialized reagents and equipment. Table 3 lists key components essential for conducting in vivo NIR fluorescence imaging experiments.

Table 3: Essential Research Reagent Solutions for In Vivo NIR Fluorescence Imaging

Item Category	Specific Examples	Function & Application Notes
Clinical Fluorophores	Indocyanine Green (ICG), Methylene Blue (MB) [106]	FDA-approved, non-targeted agents for perfusion, lymphatic, and vascular imaging [107].
Targeted Molecular Agents	Cetuximab-IRDye800CW, ABY-029 (anti-EGFR) [106], PARPi-FL [106]	Antibody- or affibody-dye conjugates that bind specific cellular targets (e.g., EGFR) for enhanced tumor contrast.
Activatable Probes	ONM-100 [106]	"Smart" probes activated by specific tumor microenvironment (TME) conditions (e.g., low pH).
NIR-II Fluorophores	Silver Chalcogenide QDs, SWCNTs, Rare Earth Nanoparticles [109]	Emerging materials for NIR-II imaging offering deeper penetration and higher resolution; mostly preclinical [85] [109].
Imaging Systems	Photodynamic Eye (PDE), SPY, FLARE, VisionSense Iridium [107] [110]	Devices comprising NIR light sources, sensitive cameras (e.g., CCD), and filters for excitation/emission [107].
In Vivo Model	Mouse, Rat, etc.	Appropriate animal models for the disease under investigation.
Analysis Software	ImageJ, MATLAB [108] [110]	For quantitative analysis of fluorescence intensity, TBR, and SBR.

Experimental Protocol: In Vivo Tumor Imaging with a Targeted NIR Agent

This protocol outlines a standard procedure for fluorescence-guided surgery in a preclinical murine model using a targeted NIR imaging agent, such as cetuximab-IRDye800CW, which binds to the Epidermal Growth Factor Receptor (EGFR) commonly overexpressed in many cancers [2] [106].

Pre-Imaging Procedures

• Agent Preparation: Reconstitute the targeted fluorescent agent (e.g., cetuximab-IRDye800CW) according to the manufacturer's instructions. Determine the appropriate dose based on prior pharmacokinetic studies (e.g., 2 mg/kg for cetuximab-IRDye800CW [2]). Protect from light using aluminum foil.
• Animal Preparation: Anesthetize the tumor-bearing mouse (e.g., with isoflurane). Ensure the animal is securely positioned on a heated stage to maintain body temperature during imaging. Remove hair from the surgical and imaging site to minimize light scattering and absorption.
• System Calibration: Power on the NIR fluorescence imaging system (e.g., a dedicated platform like mini-FLARE or VisionSense Iridium). Set the appropriate excitation and emission filters (e.g., excitation 760-785 nm, emission 800-850 nm for IRDye800CW). Capture a pre-injection background image of the animal under both white light and NIR fluorescence to establish baseline autofluorescence.

Agent Administration and Image Acquisition

• Systemic Administration: Administer the prepared dose of the fluorescent agent via a tail vein injection using an insulin syringe. Record the time of injection as time zero.
• Longitudinal In Vivo Imaging: At predetermined time points post-injection (e.g., 1, 24, 48, and 72 hours), place the anesthetized animal in the imaging chamber. Acquire co-registered white light and NIR fluorescence images using identical exposure times, fields of view, and camera settings for all animals in the study. Ensure all ambient lights are turned off during fluorescence acquisition to maximize signal detection [110].
• Intraoperative Imaging (Terminal Procedure):
  • After the optimal imaging time point has been reached (e.g., 24-48 hours for many targeted agents), perform a surgical exposure of the tumor.
  • First, image the tumor in situ through the skin and then after making an incision. This wide-field imaging helps delineate the primary tumor and identify potential satellite lesions [106].
  • Surgically resect the primary tumor. Following resection, image the surgical cavity (wound bed) to check for residual fluorescent signal indicating positive margins.
  • Finally, place the excised tumor specimen on a black background and perform ex vivo close-field fluorescence imaging to confirm agent accumulation and assess margin status with higher sensitivity [106].

Post-Imaging and Data Analysis

• Image Processing: Use image analysis software like ImageJ (NIH) for all quantitative analyses [110].
• Quantitative Analysis: For each image, draw regions of interest (ROIs) over the tumor (or highest signal area) and adjacent normal background tissue. Calculate the mean fluorescence intensity for each ROI.
  • Key Metric Calculation: Compute the Tumor-to-Background Ratio (TBR) using the formula: TBR = Mean Fluorescence Intensity (Tumor) / Mean Fluorescence Intensity (Background).
  • Statistical Analysis: Report TBR values as mean ± standard deviation. Perform appropriate statistical tests (e.g., t-tests) to compare TBRs between different groups or time points [110].
• Validation: After imaging, fix the resected tumor and relevant tissues in formalin and process for standard histopathology (e.g., H&E staining). Correlate the fluorescence images with the histological findings to validate the specificity and accuracy of the imaging agent.

Diagram 2: Experimental workflow for in vivo tumor imaging and image-guided surgery using a targeted NIR fluorescent agent.

Analysis of Strengths and Limitations

Core Strengths

• High Sensitivity and Real-Time Capability: NIR fluorescence imaging can detect fluorophores at extremely low concentrations (in the μg/L range), enabling visualization of subtle molecular targets [110]. Furthermore, it provides real-time video rate imaging, which is indispensable for guiding dynamic surgical procedures, such as identifying critical structures or ensuring complete tumor resection [108] [106].
• Superior Contrast and Resolution in Deeper Tissues: Compared to visible light imaging, NIR light, especially in the NIR-II window, offers significantly reduced scattering. This results in higher resolution images at greater tissue depths (up to several centimeters) and a superior signal-to-background ratio, which is critical for accurately defining tumor margins [85] [106].
• Non-Ionizing Radiation and Safety Profile: Unlike CT or PET, NIR fluorescence imaging uses non-ionizing radiation, allowing for repeated and prolonged imaging sessions without cumulative radiation exposure risks for patients or researchers [85]. Fluorophores like ICG have a long-standing and excellent safety record in clinical use [107].

Inherent Limitations

• Limited Tissue Penetration Depth: Despite advantages over visible light, the penetration depth of NIR fluorescence remains a fundamental constraint. The estimated maximum depth for detecting NIR-I agents is typically 1-4 cm beneath the tissue surface, which restricts its application to superficial tissues, open surgical settings, or small animal imaging [107] [105]. This makes it unsuitable for deep-seated human tumors without surgical exposure.
• Background Signal and Quantification Challenges: While autofluorescence is reduced, it is not entirely eliminated in the NIR-I window [2]. Furthermore, factors such as tissue absorption (e.g., by blood), variable ambient light, and the orientation/distance of the camera can lead to heterogeneous signal fluctuation and complicate accurate quantification of fluorophore concentration in vivo [106].
• Dependence on Fluorophore Performance: The effectiveness of the imaging strategy is heavily reliant on the photophysical properties of the fluorophore. Many agents face challenges such as relatively low quantum yield, poor photostability, and limited aqueous solubility. Furthermore, achieving specific and high-affinity targeting while maintaining favorable pharmacokinetics (rapid clearance from background tissues) remains a significant hurdle in probe design [108] [106].

The analysis of strengths and limitations clearly delineates the scenarios where NIR fluorescence imaging provides the most value.

• Intraoperative Guidance for Superficial and Accessible Tumors: It is ideally suited for real-time visualization of tumor margins during surgery for cancers such as head and neck, breast, and brain tumors, where achieving complete resection is critical for patient prognosis [106]. The ability to identify satellite lesions and check the wound bed for residual disease intraoperatively is a transformative application.
• Lymphatic Mapping and Vascular Perfusion Studies: The rapid uptake and vascular confinement of non-targeted agents like ICG make this technology a gold standard for sentinel lymph node biopsy and for assessing tissue perfusion in reconstructive and vascular surgery [107].
• Preclinical Drug Development and Molecular Imaging: In animal models, NIR fluorescence is a powerful tool for non-invasively studying disease progression, target engagement, and the biodistribution of novel therapeutic compounds, thereby accelerating the drug discovery pipeline [108].

In conclusion, NIR fluorescence imaging is a highly sensitive, real-time modality that excels in providing optical contrast for superficial tissues and in surgical settings. Its limitations in penetration depth and quantification are being actively addressed through the development of NIR-II agents, improved imaging systems, and the integration of complementary technologies like artificial intelligence for enhanced image analysis [85] [106]. Understanding these parameters allows researchers and clinicians to deploy this powerful technology in its most effective context.

Conclusion

In vivo NIR fluorescence imaging has matured into an indispensable tool for biomedical research, propelled by a deeper understanding of light-tissue interactions and the continuous development of brighter, more biocompatible probes operating in extended NIR windows. The exploration of high-absorption regions like 1880-2080 nm demonstrates that contrast can be dramatically improved by strategically leveraging, rather than avoiding, tissue properties. For drug development, the ability to perform real-time, high-resolution molecular imaging offers unparalleled insights into drug pharmacokinetics, target engagement, and therapeutic efficacy in live subjects. Future progress hinges on the clinical translation of novel NIR-II probes, the deeper integration of fluorescence into multimodal imaging systems, and the refinement of theranostic platforms that combine diagnosis with therapy. By adhering to the rigorous protocols and validation frameworks outlined herein, researchers can fully harness the potential of this technology to accelerate the journey from preclinical discovery to clinical application.

References

• 1. In vivo near-infrared fluorescence imaging [https://www.sciencedirect.com/science/article/abs/pii/S1367593103001091]
• 2. Systematic comparison of fluorescence imaging in the near ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11566260/]
• 3. Near-Infrared-II Bioimaging for in Vivo Quantitative Analysis [https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2021.763495/full]
• 4. Near-infrared fluorescence imaging in the largely ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6096386/]
• 5. Comparison of NIR versus SWIR fluorescence imaging ... [https://www.nist.gov/publications/comparison-nir-versus-swir-fluorescence-imaging-indocyanine-green-using-si-derived]
• 6. 2025 Guidelines for Fluorescence Image-guided Surgery ... [https://www.sages.org/publications/guidelines/figs-with-icg-guideline/%22]
• 7. Construction and optimization of organic fluorophores in ... [https://pubs.rsc.org/en/content/articlelanding/2025/cs/d5cs00063g]
• 8. Visible-Light and Near-Infrared Fluorescence and Surface ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9135580/]
• 9. 《德国应用化学》报道我校有机近红外发光材料研究新进展 [https://chem.ecust.edu.cn/2025/1117/c6623a184726/page.htm]
• 10. 近红外二区b窗口（NIR-Ⅱb）激发/发射的稀土发光纳米晶应用于生物 ... [https://cjl.lightpublishing.cn/zh/article/doi/10.37188/CJL.20250139/]
• 11. A Fluorinated Conjugated Polymer Allows for Enhanced ... [https://pubmed.ncbi.nlm.nih.gov/40817580/]
• 12. 2.5. In Vivo NIR Fluorescence Imaging [https://bio-protocol.org/exchange/minidetail?id=16777850&type=30]
• 13. 基于咔唑骨架的近红外荧光探针在生物成像领域的研究进展 [https://www.ebiotrade.com/newsf/2025-10/20251002004444741.htm]
• 14. 综述：光学技术在监测药物及代谢剂迁移与递送中的应用 [https://www.ebiotrade.com/newsf/2025-9/20250928082526929.htm]
• 15. 2025年第二届化学与生物成像材料与技术创新发展大会 [https://www.huiyi-123.com/article/4g4h0m6e-179.html]
• 16. High-contrast in vivo fluorescence imaging exploiting ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12075662/]
• 17. Optimization of near-infrared fluorescent sentinel lymph ... [https://www.sciencedirect.com/science/article/pii/S0002937811009562]
• 18. Design and characterization of an optimized simultaneous ... [https://www.spiedigitallibrary.org/journals/journal-of-biomedical-optics/volume-18/issue-12/126018/Design-and-characterization-of-an-optimized-simultaneous-color-and-near/10.1117/1.JBO.18.12.126018.full]
• 19. Reflect: reporting guidelines for preclinical, translational ... [https://www.nature.com/articles/s44303-025-00125-8]
• 20. The Application of Heptamethine Cyanine Dye DZ-1 and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5486152/]
• 21. In Vivo Tumor-Targeted Fluorescence Imaging Using Near- ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3617504/]
• 22. NIR-quantum dots in biomedical imaging and their future [https://pmc.ncbi.nlm.nih.gov/articles/PMC7921844/]
• 23. Aggregation control of anionic pentamethine cyanine ... [https://www.nature.com/articles/s41467-024-55429-x]
• 24. Design of NIR-II high performance organic small molecule ... [https://www.sciencedirect.com/science/article/abs/pii/S0010854522002041]
• 25. Comparison of Five Near-Infrared Fluorescent Folate ... [https://link.springer.com/article/10.1007/s11307-021-01685-y]
• 26. Near-infrared fluorescent probes: a next-generation tool for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8179524/]
• 27. New Strategies for Fluorescent Probe Design in Medical ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3241938/]
• 28. Biocompatible Quantum Dots for Biological Applications [https://pmc.ncbi.nlm.nih.gov/articles/PMC3752999/]
• 29. Rhodamine vs Other Fluorophores: How to Choose the Best Dye? [https://probes.bocsci.com/resources/rhodamine-vs-other-fluorophores-how-to-choose-the-best-dye.html]
• 30. Near-Infrared-II Fluorescence Imaging of Tumors with ... [https://www.mdpi.com/1424-8220/25/22/7080]
• 31. Seven steps to designing an effective in vivo fluorescence ... [https://www.revvity.com/blog/seven-steps-designing-effective-vivo-fluorescence-imaging-study]
• 32. Clinical Integration of NIR-II Fluorescence Imaging for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12384335/]
• 33. Dual-Channel NIR Fluorescence Imaging for Precise ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12559798/]
• 34. Matrix-designed bright near-infrared fluorophores for ... [https://www.sciencedirect.com/science/article/pii/S0142961225001097]
• 35. Near-infrared fluorescent probes in cancer imaging and therapy [https://pmc.ncbi.nlm.nih.gov/articles/PMC3956734/]
• 36. Advances in the near-infrared Ⅱ for in vivo fluorescence ... [https://www.sciencedirect.com/science/article/abs/pii/S003991402501121X]
• 37. High-contrast in vivo fluorescence imaging exploiting ... [https://www.nature.com/articles/s41467-025-59630-4]
• 38. Imaging of proteases using activity-based probes [https://www.sciencedirect.com/science/article/abs/pii/S1367593123000376]
• 39. Molecular Imaging of Proteases in Cancer - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC2838618/]
• 40. Detection of Hydroxyapatite in Calcified Cardiovascular Tissues [https://pmc.ncbi.nlm.nih.gov/articles/PMC3459140/]
• 41. Advancing breast cancer diagnosis with a near-infrared ... [https://www.nature.com/articles/s41598-023-48556-w]
• 42. In vivo near-infrared fluorescent optical imaging for CNS ... [https://pubmed.ncbi.nlm.nih.gov/32396023/]
• 43. In vivo fluorescence imaging: success in preclinical imaging ... [https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-022-01648-7]
• 44. Near-Infrared IIb Fluorescence Imaging of Vascular ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6640151/]
• 45. Organic NIR-II molecule with long blood half-life for in vivo ... [https://www.nature.com/articles/s41467-020-16924-z]
• 46. Near-infrared fluorescence sentinel lymph node mapping in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3899688/]
• 47. Determining Accurate Dye Combinations for Sentinel ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10852373/]
• 48. Unveiling photophysical mechanisms of NIR-II AIE ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12409622/]
• 49. Multi-dimensional donor engineering of NIR-II AIEgens for ... [https://www.sciencedirect.com/science/article/abs/pii/S0142961225001127]
• 50. Nitric oxide-activatable NIR-II organic small molecule for ... [https://pubs.rsc.org/en/content/articlehtml/2025/sc/d5sc03636d]
• 51. Rational design of ultrabright NIR-II nanofluorophores with ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12547213/]
• 52. Advances in Second Near-Infrared Window Photothermal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12473562/]
• 53. Perfecting and extending the near-infrared imaging window [https://www.nature.com/articles/s41377-021-00628-0]
• 54. Near-infrared fluorescence guided surgery: State of the ... [https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.919739/full]
• 55. Dual-tracer background subtraction approach for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3537325/]
• 56. In vivo active-targeting fluorescence molecular imaging ... [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1130155/full]
• 57. Berkeley Lab Scientists Control Light Scattering in Graphene [https://newscenter.lbl.gov/2011/03/16/control-scattering-graphene/]
• 58. Organic probes for NO-activatable biomedical imaging: NIR ... [https://pubs.rsc.org/en/content/articlehtml/2025/sc/d5sc03611a?page=search]
• 59. Optimizing live-cell fluorescence imaging conditions to ... [https://pubmed.ncbi.nlm.nih.gov/31988150/]
• 60. Minimising photodamage during fluorescence microscopy ... [https://www.coolled.com/whitepapers/minimising-photodamage-during-fluorescence-microscopy-with-led-illumination/]
• 61. Optimizing imaging speed and excitation intensity for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7610360/]
• 62. Exposure Times | Thermo Fisher Scientific - ES [https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-analysis-learning-center/molecular-probes-school-of-fluorescence/imaging-basics/capturing-analyzing-your-samples/exposure-times.html]
• 63. Near-infrared co-illumination of fluorescent proteins ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11180605/]
• 64. Near-infrared co-illumination of fluorescent proteins ... [https://www.nature.com/articles/s41587-023-01893-7]
• 65. Optimizing the in vitro neuronal microenvironment to mitigate ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04591-0]
• 66. High dynamic range fluorescence imaging - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC6785194/]
• 67. Near-Infrared Fluorescence Imaging in General Surgery [https://pmc.ncbi.nlm.nih.gov/articles/PMC12516436/]
• 68. Performance test methods for near‐infrared fluorescence ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7496362/]
• 69. Near-infrared fluorescence lifetime imaging of amyloid-β ... [https://www.nature.com/articles/s41551-023-01003-7]
• 70. Imaging in focus: An introduction to denoising bioimages ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8552122/]
• 71. Fast and accurate sCMOS noise correction for ... [https://www.nature.com/articles/s41467-019-13841-8]
• 72. Constructing NIR-II Fluorophores with Enhanced ... [https://pubmed.ncbi.nlm.nih.gov/40857653/]
• 73. Naphthyl-substitution strategy for enhancing luminescence ... [https://www.sciencedirect.com/science/article/abs/pii/S1386142525014830]
• 74. Noise rejection through an improved quantum illumination ... [https://www.nature.com/articles/s41598-021-01122-8]
• 75. NIR fluorescence imaging and treatment for cancer ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9305898/]
• 76. Alleviating NIR-II emission quenching in ring-fused ... [https://www.nature.com/articles/s41377-025-01787-0]
• 77. Pitfalls and opportunities in quantitative fluorescence ... [https://www.sciencedirect.com/science/article/pii/S0168365921002753]
• 78. NIR-II-excited off-on-off fluorescent nanoprobes for ... [https://www.nature.com/articles/s41467-024-55096-y]
• 79. A near-infrared fluorescent probe with assembly ... [https://www.sciencedirect.com/science/article/abs/pii/S0956566324008078]
• 80. Recent Progresses in NIR-I/II Fluorescence Imaging for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8591038/]
• 81. A Guideline for Clinicians Performing Clinical Studies with ... [https://jnm.snmjournals.org/content/63/5/640]
• 82. 2025 Guidelines for Fluorescence Image-guided Surgery ... [https://www.sages.org/publications/guidelines/figs-with-icg-guidelines/]
• 83. Impact of signal-to-noise ratio and contrast definition on the ... [https://pubmed.ncbi.nlm.nih.gov/39034959/]
• 84. A framework to enhance the signal-to-noise ratio for ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0330718]
• 85. Enhancing the fluorescence emission of the NIR-II ... [https://www.sciencedirect.com/science/article/abs/pii/S0010854525000815]
• 86. In vivo fluorescence imaging: success in preclinical imaging ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9571426/]
• 87. Comparison of Different Imaging Techniques for Tracking ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3638042/]
• 88. Comparison of Imaging Techniques for Tracking Cardiac ... [https://jnm.snmjournals.org/content/48/12/1916]
• 89. Single Photon Emission Computed Tomography - NCBI - NIH [https://www.ncbi.nlm.nih.gov/books/NBK232492/]
• 90. Single-photon emission computed tomography [https://en.wikipedia.org/wiki/Single-photon_emission_computed_tomography]
• 91. Magnetic Resonance Imaging (MRI) [https://www.nibib.nih.gov/science-education/science-topics/magnetic-resonance-imaging-mri]
• 92. Positron emission tomography scan [https://www.mayoclinic.org/tests-procedures/pet-scan/about/pac-20385078]
• 93. PET/CT - Positron Emission Tomography/Computed ... [https://www.radiologyinfo.org/en/info/pet]
• 94. MRI (Magnetic Resonance Imaging): What It Is & Results [https://my.clevelandclinic.org/health/diagnostics/4876-magnetic-resonance-imaging-mri]
• 95. Fluorescence-guided surgery: comprehensive review - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10183714/]
• 96. Randomized Comparison of Near-infrared Fluorescence ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3465510/]
• 97. Randomized Comparison of Near-Infrared Fluorescence ... [https://pubmed.ncbi.nlm.nih.gov/22752379/]
• 98. Near-infrared Molecular Probes for In Vivo Imaging - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC3334312/]
• 99. Recent advances in NIR small molecule activable probes ... [https://www.sciencedirect.com/science/article/abs/pii/S0010854525004746]
• 100. 小动物活体成像技术：揭秘药物在体内的“生命轨迹” [https://dmpkservice.wuxiapptec.com/cn/blogs/474-id/]
• 101. Evaluation of Near Infrared Fluorescent Labeling ... [https://www.sciencedirect.com/science/article/abs/pii/S0090955624115176]
• 102. Evaluation of antibody fragment properties for near-infrared ... [https://www.thno.org/v08p4856.htm]
• 103. Recent Progress in Peptide-Based Fluorescent Probes ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12414470/]
• 104. 肝癌靶向诊疗新策略：基于理性分子工程设计的超亮NIR-II纳米荧光 ... [https://www.ebiotrade.com/newsf/2025-10/20251002004741058.htm]
• 105. Research progress of near-infrared fluorescence imaging ... [https://www.sciencedirect.com/science/article/pii/S1572100025000109]
• 106. Illuminating the future of precision cancer surgery with ... [https://www.nature.com/articles/s41698-024-00699-3]
• 107. A review of performance of near-infrared fluorescence ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4277384/]
• 108. An update on recent advances in fluorescent materials for ... [https://pubs.rsc.org/en/content/articlehtml/2025/ra/d5ra03102h]
• 109. NIR-II Probes for In vivo Imaging [https://www.teledynevisionsolutions.com/learn/learning-center/scientific-imaging/nir-ii-probes-for-in-vivo-imaging/]
• 110. Comparison of Near-Infrared Imaging Camera Systems for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11145178/]